<SEC-DOCUMENT>0001104659-21-149412.txt : 20211214
<SEC-HEADER>0001104659-21-149412.hdr.sgml : 20211214
<ACCEPTANCE-DATETIME>20211214080534
ACCESSION NUMBER:		0001104659-21-149412
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211214
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211214
DATE AS OF CHANGE:		20211214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		211489730

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2135322d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20211214">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_syn_syntheticbiologics.com_20211214 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20211214_20211214_zohOTX85l8c1 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20211214.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-12-14to2021-12-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-14</xbrli:startDate>
        <xbrli:endDate>2021-12-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20211214__20211214_zltZkk3z3nth"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_908_edei--DocumentPeriodEndDate_c20211214__20211214_zfPZEjDnWnQl"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 14, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityRegistrantName_c20211214__20211214_z4ZWUeb3Mn72"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityRegistrantName">SYNTHETIC BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20211214__20211214_zrICv3SjpSQc"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20211214__20211214_zgdfYvteKyTk"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20211214__20211214_zElMPOQvDOTk"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20211214__20211214_zjhRtGFW64Q1"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20211214__20211214_ziDALkepNk6i"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20211214__20211214_zq2fkA0vVyKc"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20211214__20211214_zRkdjKZsM063"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20211214__20211214_zTLwact7PZw6"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_903_edei--CityAreaCode_c20211214__20211214_zG9CA9ZngRGf"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20211214__20211214_z33HnVdFshS3"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90E_edei--WrittenCommunications_c20211214__20211214_zLIWhuJETHTj"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90A_edei--SolicitingMaterial_c20211214__20211214_zJGOxOKoiY8l"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_907_edei--PreCommencementTenderOffer_c20211214__20211214_zsRxhOFo53A8"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20211214__20211214_zeLR6CWRDl7a"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20211214__20211214_zBsxCnxcoXMk"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20211214__20211214_z2N8XFVCilz7"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" name="dei:TradingSymbol">SYN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--SecurityExchangeName_c20211214__20211214_zODYpn9sThoi"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20211214__20211214_zKyjEk9OyQz8"><ix:nonNumeric contextRef="From2021-12-14to2021-12-14" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 &#160;&#160;Entry into a Material
Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 14, 2021, Synthetic Biologics, Inc.
(&#8220;Synthetic&#8221;) entered into a Share Purchase Agreement (&#8220;Purchase Agreement&#8221;) with VCN Biosciences, S.L., a corporation
organized under the laws of Spain (&#8220;VCN&#8221;) and the shareholders of VCN (the &#8220;Sellers&#8221;), which provides for the
acquisition by SYN (the &#8220;Acquisition&#8221;) of all the outstanding shares of VCN (the &#8220;VCN Shares&#8221;) from the shareholders
of VCN. VCN is a private, clinical-stage biopharmaceutical company which is developing new agents for the treatment of certain cancers
based on oncolytic adenoviruses with high potency and selectivity. VCN&#8217;s lead product candidate, VCN-01, is an oncolytic adenovirus
being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. Oncolytic
viruses have a unique mechanism of action as compared to other cancer drugs and can detect cancer mutations, replicate or self-amply within
cancer cells, break down (i.e., lyse) the membranes of the cells thereby killing them and then propagate the oncolytic effect to neighboring
cancer cells. The therapeutic effect is therefore amplified within tumors reducing the viral dose needed to reach tumors. Currently VCN
has four exclusive patent licenses in independent technologies developed internally and in collaboration with the Virotherapy Group of
the Catalan Institute of Oncology (ICO-IDIBELL) that result in enhanced antitumoral potency of oncolytic adenoviruses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Material Terms of the Purchase Agreement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreement, as consideration
for the purchase of the VCN Shares, Synthetic has agreed at the closing of the transactions contemplated by the Purchase Agreement (the
 &#8220;Closing&#8221;) to pay $4,700,000 (the &#8220;Closing Cash Consideration&#8221;) to Grifols Innovation and New Technologies Limited
(&#8220;Grifols&#8221;), the owner of approximately 86% of the equity of VCN, and to issue to the remaining Sellers 26,395,303 shares
of common stock, $.001 par value, of Synthetic (the &#8220;Closing Shares&#8221;), representing 19.99% of the outstanding shares of Synthetic&#8217;s
common stock on December 14, 2021, the date of the Purchase Agreement. As additional consideration for the purchase of the VCN Shares
held by Grifols, Synthetic has also agreed to make the following milestone payments to Grifols:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><b>Milestone Payments</b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0.5in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$3MM upon VCN-01 US IND Safe to Proceed &#8211;
    PDAC (or other <i>first</i> indication)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$2.75MM upon VCN-01 US IND Safe to Proceed &#8211;
    RB (or other <i>second </i>indication)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$3.25MM upon VCN-01 US first patient dosed&#8211;
    PDAC (or other <i>first</i> indication) after receipt of VCN-01 US IND Safe to Proceed for PDAC being informed</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$3.25MM upon VCN-01 US first patient dosed &#8211;
    RB (or other <i>second </i>indication) after receipt of VCN-01 US IND Safe to Proceed for RB being informed</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$6MM upon VCN-01 US Phase 2 trial meets the primary
    endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being initiated &#8211; PDAC
    (or other <i>first</i> indication)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$8MM upon VCN-01 Pivotal Trial meeting the primary
    endpoint or upon BLA Submission &#8211; RB (or other <i>second </i>indication)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$12MM upon VCN-01 US Phase 3 trial meeting the
    primary endpoint or upon BLA Submission &#8211; PDAC (or other <i>first</i> indication)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$16MM upon VCN-01 BLA Approval &#8211; PDAC (or
    other <i>first</i> indication)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">US$16MM upon VCN-01 BLA Approval &#8211; RB (or
    other <i>second </i>indication)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement provides that at the Closing
VCN shall have no liabilities of any nature outstanding other than up to $2,400,000 of liabilities (the &#8220;Specified Indebtedness&#8221;)
which Synthetic will assume, which include certain loans from the Spanish Government and the Catalan Government Agency. In the event VCN&#8217;s
liabilities at Closing exceed the amount of the Specified Indebtedness, the Closing Cash Consideration will be reduced by the amount of
such excess liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement contains customary representations,
warranties and covenants of the Sellers and Synthetic. Subject to certain customary limitations, the Sellers have agreed to indemnify
Synthetic and its officers and directors against certain losses related to, among other things, breaches of their representations and
warranties, certain specified liabilities and the failure to perform covenants or obligations under the Purchase Agreement. The Closing
of the transaction is subject to the approval by the Spanish government of Synthetic&#8217;s acquisition of VCN under Spain&#8217;s Foreign
Investment Act and other customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement further provides that
prior to Closing Synthetic will loan to VCN up to $425,000 to help finance the costs of certain of VCN&#8217;s research and development
activities. In the event that Closing does not take place under certain circumstances, the loan will become due and payable to Synthetic.
In addition, at Closing VCN and Grifols will enter into a sublease agreement for the sublease by VCN of the laboratory and office space
currently occupied by it as well as a transitional services agreement. Synthetic agreed as a post- Closing covenant &#160;to commit to
fund VCN&#8217;s research and development programs, including but not limited to VCN01 PDAC phase 2 trial, VCN01 RB pivotal trial and
necessary G&amp;A within a budgetary plan of approximately 27.81 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A.G.P/Alliance Global Partners and Griffin Securities,
Inc. served as financial advisors to Synthetic&#8217;s board of directors and Tungsten Partners LLC served as financial advisor to VCN.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary of the Purchase Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement that is filed
herewith as Exhibit 2.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representations, warranties and
covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely
for the benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties.
Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the
terms of the Purchase Agreement, and not to provide investors with any other factual information regarding Synthetic, VCN or either
of their businesses, and should be read in conjunction with the disclosures in Synthetic&#8217;s periodic reports and other filings
with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Forward-Looking Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Report contains forward-looking
statements (including within the meaning of Section&#160;21E of the United States Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;), and Section&#160;27A of the United States Securities Act of 1933, as amended) concerning Synthetic, VCN, the
Purchase Agreement and other matters. These statements are based upon management&#8217;s current beliefs, expectations and
assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements
regarding the proposed Acquisition of VCN by Synthetic, the timing of such acquisition and the various timelines for development of
VCN&#8217;s product candidates. The forward-looking statements are subject to risks and uncertainties that could cause actual
results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in Synthetic&#8217;s forward-looking statements include, among others, the
risk a<span style="background-color: white">ssociated with </span>Synthetic&#8217;s <span style="background-color: white">and
VCN&#8217;s ability to satisfy the conditions to consummate the proposed Acquisition, including obtaining necessary governmental
approvals, the timing of the closing of the proposed Acquisition,&#160;the occurrence of any event, change or other circumstance or
condition that could give rise to the termination of the Purchase Agreement between the Sellers and </span>Synthetic, <span style="background-color: white">unanticipated
difficulties or expenditures relating to the proposed Acquisition</span> or development of VCN&#8217;s drug candidates<span style="background-color: white">,
the response of business partners and competitors to the announcement of the proposed Acquisition, and/or potential difficulties in
employee retention as a result of the announcement and pendency of the proposed Acquisition, whether the combined business of
Synthetic and VCN will be successful,&#160;</span> Synthetic&#8217;s and VCN&#8217;s product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior results, the ability to initiate clinical trials and if initiated,
the ability to complete them on time and achieve the desired results and benefits continuing enrollment as expected, the ability to
obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory
limitations relating to <span style="background-color: white">Synthetic&#8217;s and VCN&#8217;s </span>ability to promote or
commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the
successful development, marketing or sale of <span style="background-color: white">Synthetics&#8217; and VCN&#8217;s</span>
products, developments by competitors that render such products obsolete or non-competitive, <span style="background-color: white">Synthetic&#8217;s
and VCN&#8217;s</span> ability to maintain license agreements, the continued maintenance and growth of <span style="background-color: white">Synthetics&#8217;
and VCN&#8217;s </span>patent estate, and other factors described in Synthetics&#8217; annual report on Form 10-K for the year ended
December 31, 2020, subsequent quarterly reports on Form 10-Qs and any other filings we make with the SEC. <span style="background-color: white">Synthetic
can give no assurance that the conditions to the acquisition will be satisfied. </span>The information in this presentation is
provided only as of the date presented, and Synthetic undertakes no obligation to update any forward-looking statements contained in
this presentation on account of new information, future events, or otherwise, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2.03 &#160;&#160;Creation of a Direct
Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of the Purchase Agreement in &#8220;Item
1.01 Entry into a Material Definitive Agreement&#8221; of this Current Report on Form 8-K is incorporated by reference in its entirety
into this Item 2.03.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;3.02.&#160;&#160;&#160;Unregistered
Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item&#160;1.01 of
this Current Report on Form 8-K is incorporated herein by reference into this Item&#160;3.02 in its entirety. The Closing Shares will
be issued in a transaction exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) thereof. The Sellers
receiving the shares of Synthetic common stock represented that they each were an &#8220;accredited investor,&#8221; as defined in Regulation
D, and were acquiring the securities described herein for investment only and not with a view towards, or for resale in connection with,
the public sale or distribution thereof or are exempt from registration under exemption afforded by Regulation S. Accordingly, the Closing
Shares will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an exemption
from registration under the Securities Act and any applicable state securities laws.</p>

<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01. &#8211; Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 14, 2021, Synthetic
Biologics issued the press release attached hereto as Exhibit 99.1 announcing entering into the Share Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">The
press release is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the  Exchange
Act, or otherwise subject to the liabilities of that section, nor shall such information
be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes
 &#8220;safe harbor&#8221; language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain
statements contained therein are &#8220;forward-looking&#8221; rather than historical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. &#8211; Financial Statements and Exhibits.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 3%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(d)</b></span></td>
    <td style="width: 96%; padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><b>Exhibit<br />Number</b></td>
<td style="vertical-align: top; padding-right: 0.8pt">&#160;</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 0.8pt"><b>Description</b></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><a href="tm2135322d2_ex2-1.htm">2.1*</a></td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt"><a href="tm2135322d2_ex2-1.htm">Share Purchase Agreement, by and among Synthetic Biologics, Inc., VCN Biosciences, S.L. and the shareholders of VCN Biosciences, S.L., dated December 14, 2021</a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><a href="tm2135322d2_ex99-1.htm">99.1</a></td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt"><a href="tm2135322d2_ex99-1.htm">Press Release issued by Synthetic Biologics, Inc., dated December 14, 2021</a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left">104</td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td>
<td style="padding-right: 0.8pt">&#160;</td></tr>
<tr>
<td colspan="3" style="vertical-align: top; background-color: white"><i>*The schedules to the Share Purchase Agreement have been omitted pursuant to Item 601(b)(2) of Regulation&#160;S-K.&#160;Certain portions of the exhibits to the Share purchase Agreement have been omitted in accordance with Item 601(b)(10) of Regulation S-K</i>.&#160;<i>A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</i>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Dated: December 14, 2021</span></td>
    <td colspan="3" style="padding-right: 2.8pt"><span style="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 5%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 5%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 39%; padding-right: 0.8pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">and Chief Financial Officer</p></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4d6GSXDhVxyhgi3hYXpbg1I60/eyTf0m5DDIGQnPPlCDERG1rrGhnOyzKHIzZtrRxCiVdkNBf0jmy7S8HPEm/aOlbGDesPzMgz6JnZdKH8fXA+tcUqhWgeyiSMJURJKhMo9iLo9YzMVVdonFY1KFNBwdSyRqe4Gz8c1ZsMNd2QdEK2mkwKchqN8gfiSMZwoKd6Ed8t5HkmgslQgdgwPdo+5mEdNbCqsfFZdkT/HXwB5GpJJA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2135322d2_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT
BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION
HAS BEEN REDACTED.</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 90%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHARE PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY AND AMONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>VCN BIOSCIENCES, S.L. AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SHAREHOLDERS OF VCN BIOSCIENCES, S.L.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated as of December 14, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 90%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article I </B></TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">DESCRIPTION OF TRANSACTION </TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%">1.1</TD><TD STYLE="width: 88%"><U>Agreement to Purchase and Sell the Shares</U>. </TD>
    <TD STYLE="text-align: right; width: 4%">1</TD></TR>
<TR STYLE="vertical-align: top">
<TD>1.2</TD><TD><U>Payment of Closing Consideration</U>. </TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top">
<TD>1.3</TD><TD><U>Milestone Payments</U>. </TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top">
<TD>1.4</TD><TD><U>Administrative and Operational Activities of Company after the Closing</U>. </TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top">
<TD>1.5</TD><TD><U>Definitions</U>. </TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article II </B></TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDERS </TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.1</TD><TD><U>Organization and Good Standing</U>. </TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.2</TD><TD><U>Capitalization</U>. </TD>
    <TD STYLE="text-align: right">4</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.3</TD><TD><U>Subsidiaries</U>. </TD>
    <TD STYLE="text-align: right">5</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.4</TD><TD><U>Authority; No Conflict; Required Filings and Consents</U>. </TD>
    <TD STYLE="text-align: right">5</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.5</TD><TD><U>Company Financial Statements; Books and Records</U>. </TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.6</TD><TD><U>No Undisclosed Liabilities; Indebtedness</U>. </TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.7</TD><TD><U>No Company Material Adverse Effect</U>. </TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.8</TD><TD><U>Absence of Certain Changes or Events</U>. </TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.9</TD><TD><U>Taxes</U>. </TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.10</TD><TD><U>Real Property</U>. </TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.11</TD><TD><U>Personal Property</U>.</TD>
    <TD STYLE="text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.12</TD><TD><U>Intellectual Property</U>.</TD>
    <TD STYLE="text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.13</TD><TD><U>Agreements</U>. </TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.14</TD><TD><U>Litigation</U>. </TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.15</TD><TD><U>Environmental Matters</U>. </TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.16</TD><TD><U>Employee Matters</U>. </TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.17</TD><TD><U>Employee Benefit Plans</U>.</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.18</TD><TD><U>Compliance With Laws; Governmental Authorizations</U>. </TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.19</TD><TD><U>Insurance</U>. </TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.20</TD><TD><U>Brokerage and Transaction Bonuses</U>. </TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.21</TD><TD><U>Title to and Sufficiency of Assets</U>. </TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.22</TD><TD><U>Inventory</U>. </TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.23</TD><TD><U>Bank Accounts</U>. </TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.24</TD><TD><U>Accounts Payable</U>. </TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.25</TD><TD><U>Related Party Transactions</U>. </TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.26</TD><TD><U>Customers and Suppliers</U>. </TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.27</TD><TD><U>Certain Payments</U>. </TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.28</TD><TD><U>Personal Information and Privacy</U>. </TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.29</TD><TD><U>Regulatory Filings</U>. </TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.30</TD><TD><U>Company Products and Product Candidates</U>. </TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.31</TD><TD><U>OFAC</U>. </TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.32</TD><TD><U>Anti-Bribery and Anti-Money Laundering Laws</U>. </TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.33</TD><TD><U>Related Party Transactions</U>. </TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD>2.34</TD><TD><U>Notices To Third Parties</U>. </TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article III </B></TD>
    <TD STYLE="text-align: right"> 30</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">REPRESENTATIONS AND WARRANTIES OF EACH SHAREHOLDER</TD>
    <TD STYLE="text-align: right"> 30</TD></TR>
<TR STYLE="vertical-align: top">
<TD>3.1</TD><TD><U>Authority, No Conflict; Required Filings and Consents</U>. </TD>
    <TD STYLE="text-align: right"> 30</TD></TR>
<TR STYLE="vertical-align: top">
<TD>3.2</TD><TD><U>Ownership; Title to Company Shares</U>.</TD>
    <TD STYLE="text-align: right"> 31</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%">3.3</TD><TD STYLE="width: 88%"><U>Litigation</U>. </TD>
    <TD STYLE="text-align: right; width: 4%">31</TD></TR>
<TR STYLE="vertical-align: top">
<TD>3.4</TD><TD><U>Brokerage and Transaction Bonuses</U>. </TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article IV </B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">REPRESENTATIONS AND WARRANTIES OF REMAINING SHAREHOLDERS</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.1</TD><TD><U>Restricted Securities</U>. </TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.2</TD><TD><U>Accredited Investor</U>. </TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.3</TD><TD><U>No Bad Actor Disqualification Events</U>. </TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.4</TD><TD><U>Investment Experience</U>. </TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.5</TD><TD><U>Foreign Investors</U>. </TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.6</TD><TD><U>No General Solicitation</U>. </TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.7</TD><TD><U>Residence</U>. </TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.8</TD><TD><U>Legends</U>. </TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD>4.9</TD><TD><U>Investment Purpose; Disclosure of Information</U>. </TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article V</B></TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">REPRESENTATIONS AND WARRANTIES OF THE PURCHASER</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD>5.1</TD><TD><U>Organization and Good Sttanding</U>. </TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD>5.2</TD><TD><U>Authority, No Conflict; Required Filings and Consents</U>. </TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD>5.3</TD><TD><U>SEC Filings; Financial Statements</U>. </TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD>5.4</TD><TD><U>Purchaser Stock Consideration</U>. </TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD>5.5</TD><TD><U>Sufficiency of Funds</U> </TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article VI</B></TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">CERTAIN COVENANTS AND AGREEMENTS</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.1</TD><TD><U>Due Diligence Access and Investigation</U>. </TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.2</TD><TD><U>Operation of the Company&rsquo;s Business</U>. </TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.3</TD><TD><U>Contract Manufacturing and Regulatory Services Agreements</U>. </TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.4</TD><TD><U>Notification</U>. During the Pre-Closing Period, the Company and each Shareholder shall immediately notify the Purchaser in writing
of: </TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.5</TD><TD><U>Interim Financials</U>. </TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.6</TD><TD><U>Release of Grifols' Guarantees</U>. </TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.7</TD><TD><U>Public Announcements</U>. </TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.8</TD><TD><U>Reasonable Efforts; Further Assurances; Cooperation</U>. </TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.9</TD><TD><U>Tax Matters</U>. </TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.10</TD><TD><U>Cooperation with Financial Reporting</U>. </TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top">
<TD>6.11</TD><TD><U>Release</U>. </TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article VII</B></TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE PURCHASER</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.1</TD><TD><U>Accuracy of Representations</U>. </TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.2</TD><TD><U>Performance of Covenants</U>. </TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.3</TD><TD><U>Company Compliance Certificate</U>. </TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.4</TD><TD><U>Consents</U>. </TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.5</TD><TD><U>Secretary&rsquo;s Certificate</U>. </TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.6</TD><TD><U>Ancillary Agreements and Deliveries</U>. </TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.7</TD><TD><U>Release of Liens</U>. </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.8</TD><TD><U>No Material Adverse Effect</U>. </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.9</TD><TD><U>No Restraints</U>. </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.10</TD><TD><U>No Negative Regulatory Correspondence</U>. </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.11</TD><TD><U>Company Financial Statements</U> </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.12</TD><TD><U>NYSE Matters.</U> </TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.13</TD><TD><U>Laboratory Sublease</U>. </TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.14</TD><TD><U>Accredited Investor; Non-U.S. Person and Bad Actor Questionnaire</U>. </TD>
    <TD STYLE="text-align: right">45</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%">7.15</TD><TD STYLE="width: 88%"><U>Transition Services Agreement</U> </TD>
    <TD STYLE="text-align: right; width: 4%">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>7.16</TD><TD><U>Termination of the Pooling Agreement</U></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article VIII</B></TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY AND THE SHAREHOLDERS</TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.1</TD><TD><U>Accuracy of Representations</U>. </TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.2</TD><TD><U>Performance of Covenants</U>. </TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.3</TD><TD><U>Purchaser Compliance Certificate</U>. </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.4</TD><TD><U>Ancillary Agreements and Deliveries</U>. </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.5</TD><TD><U>No Restraints</U>. </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.6</TD><TD><U>Consents</U>. </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.7</TD><TD><U>NYSE Matters.</U> </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.8</TD><TD><U>No Material Adverse Effect</U>. </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD>8.9</TD><TD><U>Release of Guaranty</U>. </TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article IX</B></TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">CLOSING </TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD>9.1</TD><TD><U>Closing</U>. </TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD>9.2</TD><TD><U>Shareholder and Company Closing Deliveries</U>. </TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD>9.3</TD><TD><U>Purchaser Closing Deliveries</U>. </TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD>9.4</TD><TD><U>Closing Actions</U>. </TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD>9.5</TD><TD><U>Protocolization of this Agreement before a Spanish notary public</U>. </TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article X</B></TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">TERMINATION</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top">
<TD>10.1</TD><TD><U>Termination Events</U>. </TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top">
<TD>10.2</TD><TD><U>Expenses</U>. </TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article XI</B></TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">INDEMNIFICATION</TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.1</TD><TD>[I<U>ntentionnally Omitted</U>] </TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.2</TD><TD><U>Indemnification of the Purchaser Indemnified Parties</U> </TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.3</TD><TD><U>Indemnification of the Shareholder Indemnified Parties</U> </TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.4</TD><TD><U>Indemnification Procedure</U>. </TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.5</TD><TD> <U>Survival Period</U>. </TD>
    <TD STYLE="text-align: right">51</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.6</TD><TD><U>Investigations.</U> </TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.7</TD><TD><U>Offset Against Milestone Payments</U>. </TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.8</TD><TD><U>Indemnity Cap</U>. </TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.9</TD><TD><U>No Double Recovery and no Double Counting</U> </TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.10</TD><TD><U>Mitigation of Damages</U> </TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.11</TD><TD><U>Insurance</U>. </TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.12</TD><TD><U>Net Financial Benefit</U> </TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD>11.13</TD><TD><U>Characterization of Indemnification Payments</U>. </TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article XII</B></TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD>12.1</TD><TD><U>Research Funding</U>. </TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD>12.2</TD><TD><U>Project Commitment</U>. </TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top">
<TD>12.3</TD><TD><U>Bhatavia</U> Litigation. </TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top">
<TD>12.4</TD><TD><U>Non-Competition</U>. </TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><B>Article XIII</B></TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">MISCELLANEOUS PROVISIONS</TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.1</TD><TD><U>Further Assurances</U>. </TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.2</TD><TD><U>Fees and Expenses</U>. </TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.3</TD><TD><U>Waiver; Amendment</U>. </TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.4</TD><TD><U>Entire Agreement</U>. </TD>
    <TD STYLE="text-align: right">56</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.5</TD><TD><U>Execution of Agreement; Counterparts; Electronic Signatures</U>. </TD>
    <TD STYLE="text-align: right">56</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.6</TD><TD><U>Governing Law; Exclusive Jurisdiction</U>. </TD>
    <TD STYLE="text-align: right">56</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%">13.7</TD><TD STYLE="width: 88%"><U>WAIVER OF JURY TRIAL</U>. </TD>
    <TD STYLE="text-align: right; width: 4%">56</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.8</TD><TD><U>Assignment and Successors</U>. </TD>
    <TD STYLE="text-align: right">57</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.9</TD><TD><U>Parties in Interest</U>. </TD>
    <TD STYLE="text-align: right">57</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.10</TD><TD><U>Notices</U>. </TD>
    <TD STYLE="text-align: right">57</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.11</TD><TD><U>Construction; Usage</U>. </TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.12</TD><TD><U>Enforcement of Agreement</U>. </TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.13</TD><TD><U>Severability</U>. </TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.14</TD><TD><U>Time of Essence</U>. </TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.15</TD><TD><U>Disclosure Schedule</U>. </TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD>13.16</TD><TD><U>Schedules and Exhibits</U>. </TD>
    <TD STYLE="text-align: right">59</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-variant: small-caps"><B>Exhibit A &#9;--&#9;Schedule
of Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-variant: small-caps"><B>Exhibit B &#9;--&#9;Definitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-variant: small-caps"><B>Exhibit C &#9;--&#9;Spousal
Consent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-variant: small-caps"><B>Exhibit D &#9;--&#9;Accredited
Investor and Bad Actor Questionnaire </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-variant: small-caps"><B>Exhibit E &#9;--&#9;Budgetary
Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHARE PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS SHARE PURCHASE AGREEMENT</B>
is made and entered into as of December 14, 2021, by and among Synthetic Biologics, Inc., a Nevada corporation (the &ldquo;<B><I>Purchaser</I></B>&rdquo;),
VCN Biosciences, S.L., a corporation organized under the laws of Spain (the &ldquo;<B><I>Company</I></B>&rdquo;), and each of the shareholders
of the Company set forth on the signature pages to this Agreement (collectively, the &ldquo;<B><I>Shareholders</I></B>&rdquo; and each,
individually, a &ldquo;<B><I>Shareholder</I></B>&rdquo;). Purchaser, Company and Shareholders are sometimes referred to herein individually
as a &ldquo;<B><I>Party</I></B>&rdquo; and collectively as the &ldquo;<B><I>Parties</I></B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Shareholders
collectively own and desire to sell to the Purchaser one hundred percent (100%) of the issued and outstanding Company shares <I>(participaciones
sociales)</I> (the &ldquo;<B><I>Shares</I></B>&rdquo;), and the Purchaser desires to purchase and acquire the Shares from the Shareholders,
on and subject to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the respective covenants, agreements and representations and warranties set forth in this Agreement, the parties to this
Agreement, intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
I</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">DESCRIPTION
OF TRANSACTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agreement to Purchase and Sell the Shares</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to the terms
and conditions in this Agreement, at the Closing, the Shareholders shall sell, assign, transfer and deliver to the Purchaser free and
clear of all Liens, and the Purchaser shall purchase and acquire from such Shareholders, all such Shareholders&rsquo; right, title and
interest in and to the Shares as set forth on EXHIBIT A hereto, which the Company and the Shareholders represent and warrant are the Company&rsquo;s
total share capital. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Closing Consideration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#9;At the Closing, the Purchaser shall deliver to (i) Grifols Innovation and New Technologies Limited (&ldquo;<B><I>Grifols</I></B>&rdquo;)
the Closing Cash Consideration by means of wire transfer of immediately available funds to an account or accounts designated by Grifols;
and (ii) the Remaining Shareholders evidence of registration with the Purchaser&rsquo;s transfer agent of shares of Purchaser Common Stock
in the name of each Remaining Shareholder, in each case for such number of shares of Purchaser Common Stock (rounded down to the nearest
whole share of Purchaser Common Stock) as is equal to the product of (A) the total number of Closing Shares to be issued by the Purchaser
<I>multiplied by</I> (B) each remaining Shareholder&rsquo;s Consideration Percentage<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT>
(collectively, the &ldquo;<B><I>Closing Consideration</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#9;At the Closing, the Shareholders shall transfer, grant, convey, sell and assign to the Purchaser or its designee all of the
Shares, free and clear of all liens, claims or encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Milestone Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#9;<U>Milestone Payments</U>. As additional consideration for the purchase of the Shares held by Grifols, the Purchaser shall
provide Grifols with written notice of the first occurrence of each milestone event set forth below with respect to a Product within
forty- five (45) days after such occurrence. Within sixty (60) days of the first occurrence of each of the milestone events set forth
below with respect to the applicable Product, the Purchaser shall make the following payments to Grifols, whether such milestone is achieved
by the Company, its Affiliates or any of their respective sublicensees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in;"><B>Milestone
Payments</B></P></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: left; text-indent: 0.5in; layout-grid-mode: line">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$3MM upon VCN01 US IND Safe
to Proceed &ndash; PDAC (or other <I>first</I> indication)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$2.75MM upon VCN01 US IND
Safe to Proceed &ndash; RB (or other <I>second </I>indication)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$3.25MM upon VCN01 US first
patient dosed&ndash; PDAC (or other <I>first</I> indication) after VCN01 US IND Safe to Proceed for PDAC</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$3.25MM upon VCN01 US first
patient dosed &ndash; RB (or other <I>second </I>indication) after VCN01 US IND Safe to Proceed for RB</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$6MM upon VCN01 US Phase
2 trial meets the primary endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being
initiated &ndash; PDAC (or other <I>first</I> indication)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$8MM upon VCN01 Pivotal
Trial meeting the primary endpoint or upon BLA Submission &ndash; RB (or other <I>second </I>indication)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$12MM upon VCN01
US Phase 3 trial meeting the primary endpoint or upon BLA Submission &ndash; PDAC (or other <I>first</I> indication)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$16MM upon VCN01
BLA Approval &ndash; PDAC (or other <I>first</I> indication)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">US$16MM upon VCN01 BLA Approval
 &ndash; RB (or other <I>second </I>indication)</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the payments set forth above in this
Section 1.3(a) (collectively, the &ldquo;<B><I>Milestone Payments</I></B>&rdquo; and each, a &ldquo;<B><I>Milestone
Payment</I></B>&rdquo;) shall be paid only once for the applicable Product regardless of: (i) the number of Indications for which
the Product is developed or approved, and (ii) the number of Products developed, so that the aggregate maximum Milestone Payments
that may be made to Grifols is $70,250,000. If VCN-11 should achieve any of the above milestones before VCN-01 should achieve such
milestone then VCN-01 in the chart above shall be replaced by VCN-11 with respect to such milestone payment and future milestone
payments, so that no further Milestone Payments whatsoever are made with respect to VCN-01. For clarity, any milestone paid with
respect to VCN-01 shall not be paid with respect to VCN-11. For example, if Purchaser has been paid US $6.25 MM upon achievement of
the initial two milestones for VCN-01 PDAC (US $3MM uponVCNC01 US IND Safe to Proceed-PDAC and US$3.25MM upon VCN01 US first patient
dosed&ndash; PDAC) and thereafter VCN-01 is no longer used in trials but instead VCN-11 is used then no further payments will be
made to Grifols upon VCN-11 filing an IND and dosing patients in its first US trial for PDAC, however, payments will be made with
respect to VCN-11 for use to treat PDAC only after a VCN-11 US Phase 2 trial meets the primary endpoint or if a Phase 2 trial is not
conducted and only a Phase 3 trial is conducted then upon a Phase 3 being initiated &ndash; PDAC. Likewise, if &nbsp;Purchaser has
paid US $6.0 MM upon achievement of the initial two milestones for VCN-01 RB (US $2.75 MM uponVCNC01 US IND Safe to Proceed-RB and
US$3.25MM upon VCN01 US first patient dosed&ndash; RB) and thereafter VCN-01 is no longer used in trials for PDAC but instead VCN-11
is used then no further payments will be made to Grifols upon VCN-11 filing an IND and dosing patients in its first US trial for RB,
however, payments will be made with respect to VCN-11 for use to treat RB only after a&nbsp; VCN-11 US Phase 2 trial meets the
primary endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being
initiated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the Closing Date, the Company shall have no liabilities of any nature outstanding other than up to the $2,400,000 of liabilities set forth
on <U>Section 2.6(c)</U> of the Disclosure Schedule (the &ldquo;<B><I>Specified Indebtedness</I></B>&rdquo;) which the Purchaser shall
assume. In the event the Company&rsquo;s liabilities exceed the amount of the Specified Indebtedness, the Closing Cash Consideration shall
be reduced by the amount of such excess liabilities. In the event it is discovered after the Closing that the Company&rsquo;s liabilities
exceeded the amount of the Specified Indebtedness, upon written notice thereof to Grifols by Purchaser, Grifols shall pay to Purchaser
within ten days of such discovery and notice thereof being provided to Grifols, the amount by which on the Closing Date the Company&rsquo;s
liabilities exceeded the amount of the Specified Indebtedness. In addition, the Closing Cash Consideration shall be reduced by any liabilities
or penalties incurred by the Company prior to Closing for the failure to have its own separate environmental license issued by the municipality
council of Sant Cugat del Valles, in accordance with the provisions set forth in Article XI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Administrative and Operational Activities of Company after the Closing</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">After
the Closing, the Company shall continue its current legal structure as a limited liability company (<I>sociedad limitada</I>) formed under
the laws of Spain and become a wholly owned subsidiary of Purchaser. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Capitalized terms used in this Agreement but not otherwise
defined in this Agreement shall have the meanings set forth in <B>EXHIBIT B</B> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
II</B></FONT><B><FONT STYLE="text-transform: none">.&#9;</FONT></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">REPRESENTATIONS
AND WARRANTIES OF THE SHAREHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">Except as set forth on the
Disclosure Schedule, the Shareholders hereby, jointly and severally, represent and warrant to the Purchaser and for the benefit of the
Indemnified Parties, as of the date of this Agreement and as of the Closing Date, as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization and Good Standing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is a limited liability company (<I>sociedad limitada</I>) incorporated, validly existing and in good standing under
the laws of the country of Spain, has all requisite and necessary power and authority to own, lease, use and operate its properties and
assets, to carry on and conduct its business as now being conducted and as proposed to be conducted by the Company as of the Closing Date
and to perform its obligations under all Material Contracts, and is duly qualified or registered to do business and is in good standing
in Spain, which jurisdiction constitutes as of the date of this Agreement the only jurisdiction in which the character of the properties
it owns, operates or leases or the nature of its activities makes such qualification necessary or advisable. The Company has full corporate
power and authority to do and perform all acts and things to be done by it under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not conducted any business under or otherwise used, for any purpose or in any jurisdiction, any fictitious name,
assumed name, trade name or other name other than the corporate name currently registered in the Commercial Registry of Barcelona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has provided to the Purchaser accurate and complete copies of: (i) the bylaws and other Organizational Documents of
the Company, as in effect on the date of this Agreement, and such copies reflect all amendments made thereto at any time prior to the
date of this Agreement, (ii) the Shareholders Registry Book (<I>Libro Registro de Socios</I>) of the Company, (iii) the minutes and other
records of the meetings and other proceedings (including any actions taken by written consent or otherwise without a meeting) of the
shareholders of the Company, the board of directors of the Company and all committees of the board of directors of the Company (clauses
(i), (ii) and (iii), collectively, the &ldquo;<B><I>Company Constituent Documents</I></B>&rdquo;). There have been no formal meetings
or other proceedings of the shareholders of the Company, the board of directors of the Company or any committee of the board of directors
of the Company that are not fully reflected in the Company Constituent Documents. There has not been any violation of or default under
the Company Constituent Documents, and the Company has not taken any action that is inconsistent with the Company Constituent Documents.
The books and records of the Company are up to date, true, correct and complete in all material respects. All the records of the Company
have been maintained in accordance with applicable Laws and are in the actual possession and direct control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capitalization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The share capital of the Company consists of 215,930 Company Shares. All of the Company Shares have been validly issued, and are
fully assumed and paid and non-assessable and have been issued and granted in compliance with (i) the Spanish Companies Act (<I>Ley de
Sociedades de Capital</I>) and other applicable Laws; and (ii) all requirements set forth in the Company Constituent Documents and applicable
Contracts. Section 2.2(a) of the Disclosure Schedule accurately sets forth with respect to each Company Share as of the date of this Agreement,
the name of the registered holder of such Company Shares. The Shareholders are the owners of the Shares registered in the Company&rsquo;s
Shareholders Registry Book (<I>Libro Registro de Socios</I>) which represent 100% of the Company&rsquo;s share capital. None of the Shares
were issued in violation of any preemptive rights or other rights to subscribe or purchase Shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of (i) this Agreement other than as provided pursuant to the relevant Existing Shareholders Agreement and (ii) the Closing Date
there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) or any purchase rights,
subscription rights, conversion rights, exchange rights to acquire, or that relates to, any of the Company Shares; (ii) outstanding instrument
or obligation that is or may become convertible into or exchangeable for any of the Company Shares; (iii) Contract or commitment under
which the Company is or may become obligated to sell or otherwise issue any of its Company Shares or that otherwise could affect rights
or obligations of the holders of the Company Shares; or (iv) condition or circumstance that may give rise to or provide a basis for the
assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any Company Shares (clauses (i) through
(iv), collectively, &ldquo;<B><I>Company Rights</I></B>&rdquo;). The Company does not have any outstanding share appreciation rights,
phantom shares, performance based shares or equity rights or similar share or equity rights or obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of the issued Company Shares constitute restricted shares or are otherwise subject to a repurchase or redemption right or
right of first refusal in favor of the Company or any other party, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not a party to or bound by any, and to the Knowledge of the Shareholders, there are no agreements or understandings
with respect to the voting (including pooling agreements, voting trusts and proxies) or sale or transfer (including agreements imposing
transfer restrictions) of any Company Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of (i) this Agreement other than as provided pursuant to the relevant Existing Shareholders Agreement and (ii) the Closing
Date, none of the Company Shares are subject to any purchase option, call option, right of first refusal, preemptive right, right of
participation, subscription right or any similar right (whether pursuant to the Company Constituent Documents or any Contract or any
statute to which the Company is subject, except for Article 108 of the Spanish Companies Act) and there is no Contract relating to information
rights, financial statement requirements, the voting or registration of, or restricting any Person from purchasing, selling, pledging,
transferring or otherwise disposing of (or granting any option or similar right with respect to), any of the Company Shares. The Company
is not under any obligation, or bound by any Contract pursuant to which it may become obligated (i) to repurchase, redeem or otherwise
acquire any of the Company Shares; or (ii) make any investment (in the form of a loan or capital contribution) in any other Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has never repurchased, redeemed or otherwise reacquired any of its Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company has no Subsidiaries and has never had
any Subsidiaries. The Company does not own, and has never owned, beneficially or otherwise, any shares or other securities of, or any
direct or indirect equity or other financial interest in, any other Entity. The Company has not agreed and is not obligated to make any
future investment in or capital contribution to any Entity. The Company has not guaranteed any obligations of any other Entity other than
in the ordinary course of business. Neither the Company nor any of its shareholders has ever approved or commenced any proceeding, or
made any election contemplating, the dissolution or liquidation of the business or affairs of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority; No Conflict; Required Filings and Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has all requisite corporate power and authority to enter into this Agreement and any Shareholder Related Agreement
to which it is a party, perform its obligations under this Agreement and any Shareholder Related Agreement to which it is a party and
to consummate the transactions contemplated by this Agreement and any Shareholder Related Agreement to which it is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution, delivery and performance of this Agreement and any Shareholder Related Agreement to which it is a party and the
consummation of the transactions contemplated by this Agreement and any Shareholder Related Agreement to which it is a party by the Company
have been duly authorized by all necessary corporate action on the part of the Company, no other corporate action or proceeding on the
part of the Company or its board of directors is necessary to authorize the execution, delivery or performance of this Agreement, any
Shareholder Related Agreement or the consummation of the transactions contemplated by this Agreement or any Shareholder Related Agreement.
This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting or relating to creditors&rsquo; rights generally; and (ii) the availability
of injunctive relief and other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Other than as provided under this Agreement, neither the execution, delivery or performance by the Company of this Agreement,
or any Shareholder Related Agreement nor the consummation of the transactions contemplated by this Agreement or any Shareholder Related
Agreement, will directly or indirectly (with or without notice or lapse of time, or both): (i) contravene, conflict with, or result in
any violation or breach of, any Company Constituent Document; (ii) contravene, conflict with, or result in any violation or breach of,
or constitute (with or without notice or lapse of time, or both) a default (or give rise to a right of modification, termination, cancellation
or acceleration of any obligation or loss of any material benefit) under, require notice to any Person or a consent or waiver under,
constitute a change in control under, require the payment of a fee or penalty under or result in the creation or imposition of any Lien
upon or with respect to any asset owned or used by the Company under, any of the terms, conditions or provisions of any note, bond, mortgage,
indenture, lease, license, Contract or other agreement, including any labor or employment agreement, instrument or obligation to which
the Company is a party or by which it or any of its properties or assets may be bound; (iii) contravene, conflict with or violate, or
give any Person the right to challenge any of the transactions contemplated by this Agreement or any Shareholder Related Agreement or
to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which the Company or
any of its assets is subject; or (iv) contravene, conflict with or result in a violation of any of the terms or requirements of, or give
any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held
by the Company or that otherwise relates to the business of the Company or to any of the assets owned, used or controlled by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Governmental Authorization, or registration, declaration, notice or filing with, any Governmental Body, excluding to the extent
required, filings of applications or notices required under the Foreign Investments Act, is required by or with respect to the Company
in connection with the execution and delivery of this Agreement or any Shareholder Related Agreement by the Company or the consummation
by the Company of the transactions contemplated by this Agreement or any Shareholder Related Agreement or (ii) necessary for the Company
to operate its business as contemplated to be conducted after the Closing Date and after giving effect to the consummation of the transactions
contemplated by this Agreement and any Shareholder Agreement-.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Financial Statements; Books and Records</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.5(a) of the Disclosure Schedule sets forth true, correct and complete copies of the following financial statements and
notes thereto (collectively, the &ldquo;<B><I>Company Financial Statements</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The audited annual accounts (statement of financial position at December 31, 2019 and 2020 (the &ldquo;<B><I>Audited Balance Sheet</I></B>&rdquo;),
statements of profit-and-loss, other comprehensive income, changes in equity and cash flows of the Company for each of the years ended
December 31, 2019 and 2020 and the related notes, all audited in accordance with auditing standards generally accepted in the United States
of America (the &ldquo;<B><I>Audited Financial Statements</I></B>&rdquo;) and the unaudited statement of financial position of the Company
at October 31, 2021 (the &ldquo;<B><I>Unaudited Balance Sheet</I></B>&rdquo;) and the statements of profit-and-loss account, other comprehensive
income, changes in equity, and cash flows for the none months ended October 31, 2021 and 2020 and the related notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Company Financial Statement: (i) is true, correct and complete in all material respects and has been prepared in conformity
with (A) the books and records of the Company, which, in turn, are true, correct and complete in all material respects, and (B) IFRS consistently
applied throughout the periods covered thereby (except as may be indicated in the notes to such Company Financial Statement); (ii) fairly
presents the financial position of the Company as of such dates and the results of operations, changes in shareholders&rsquo; equity and
cash flow of the Company for the periods then ended, subject in the case of audited financial statements to (y) normal recurring year-end
audit adjustments, none of which would individually or in the aggregate be material, and (z) the absence of footnote disclosures, none
of which would, alone or in the aggregate, be materially adverse to the business, operations, assets, liabilities, financial condition,
operating results, value, cash flow or net worth of the Company; and (iii) contains and reflects adequate reserves, in accordance with
IFRS, for all reasonably anticipated losses, costs and expenses. No financial statement of any Person (other than the Company) is required
by IFRS to be included in the Company Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company Financial Statements were prepared from the books, records and accounts of the Company, which books, records and accounts
have been maintained in accordance with all applicable Laws and (i) reflect all items of income and expense and all assets and liabilities
required to be reflected in the Company Financial Statements in accordance with IFRS, and (ii) are true, correct and complete in all
material respects. The Company maintains accurate books and records reflecting its assets and liabilities and maintains proper and adequate
internal accounting controls which to provide assurance that (A) transactions are executed in accordance with management&rsquo;s authorization;
(B) transactions are recorded as necessary to permit preparation of the financial statements in conformity with IFRS and to maintain
accountability for the Company&rsquo;s assets; (C) access to the Company&rsquo;s assets is permitted only in accordance with management&rsquo;s
authorization; (D) the reporting of Company&rsquo;s assets is compared with existing assets at regular intervals; and (E) accounts, notes
and other receivables and inventory are recorded accurately, and proper and adequate procedures are implemented to effect the collection
thereof on a current and timely basis. The Company has delivered to the Purchaser copies of, all written descriptions of, and all policies,
manuals and other documents promulgating, such internal accounting controls, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Undisclosed Liabilities; Indebtedness</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on Section 2.6(c) of the Disclosure Schedule, the Company has no obligations or liabilities (whether or not
absolute, accrued, contingent, determined, determinable, unliquidated or otherwise, whether known or unknown, whether due or to become
due, whether or not required to be reflected in financial statements in accordance with IFRS and regardless of when or by whom asserted)
except for: (i) liabilities that are reflected or provided for in the Company Financial Statements; (ii) liabilities incurred in the ordinary
course of business consistent with past practice since the date of the Unaudited Balance Sheet and of a type reflected or provided for
in the Unaudited Balance Sheet (none of which is a liability for breach of contract, breach of warranty, tort, infringement, violation
of law, claim or lawsuit; and (iii) any such other obligations or liabilities that are not, in the aggregate, in excess of $25,000.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.6(b) of the Disclosure Schedule sets forth a true, correct and complete list of all loan or credit agreements, notes,
bonds, mortgages, indentures and other agreements and instruments pursuant to which any Indebtedness is outstanding or may be incurred
and the respective principal amounts outstanding thereunder as of the date of this Agreement. All of the outstanding Indebtedness may
be prepaid by the Company at any time without the consent or approval of, or prior notice to, any other Person, and without payment of
any premium or penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.6(c) of the Disclosure Schedule sets forth the Specified Indebtedness as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Company Material Adverse Effect</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Since December 31, 2020, the
Company has conducted its business only in the ordinary course of business consistent with past practice and, since such date, there has
not been (a) any event, occurrence, development or state of circumstances or facts that has had, or would reasonably be expected to result
in, a Company Material Adverse Effect, or (b) any event, occurrence, development or state of circumstances or facts that has, or could
reasonably be expected to have, the effect of preventing, delaying, making illegal or otherwise interfering with the transactions contemplated
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Certain Changes or Events</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except as set forth on Section
2.8 of the Disclosure Schedule, since December 31, 2020, the Company has not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>issued (i) any notes, bonds or other debt instruments, (ii) any share capital or rights convertible into or exchangeable or exercisable
for any share capital (except for Company Shares issued upon the exercise of Company Options), or (iii) any Company Rights (except for
Company Options set forth on Section 2.2(b) of the Disclosure Schedule);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>amended
or waived any of its rights under, or permitted the acceleration of vesting under, (i) any provision of the Company Stock Option
Plan; (ii) any provision of any agreement evidencing any outstanding Company Option; or (iii) any restricted share purchase
agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>borrowed any amount or incurred or become subject to any liabilities, except current liabilities incurred in the ordinary course
of business consistent with past practice, which in the aggregate are not in excess of $25,000 and which will be satisfied and discharged
by the Company as of immediately prior to the Closing and up to the $2,400,000 of liabilities to be assumed by Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>discharged or satisfied any Lien or paid any obligation or liability, other than current liabilities paid in the ordinary course
of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>declared, accrued, set aside or made any payment or distribution of cash or other property to any of its shareholders or its other
Affiliates with respect to such shareholders&rsquo; shares or otherwise, or purchased, redeemed or otherwise acquired any of its Company
Shares (including any options or other rights to acquire its Company Shares);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>mortgaged or pledged any of its properties or assets or subjected them to any Lien, except for Permitted Liens;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) acquired, leased or licensed any material right or other asset from any Person; (ii) sold, assigned, transferred, leased or
licensed to any Person, or otherwise encumbered, any of its assets, except in each case, in the ordinary course of business consistent
with past practice; or (iii) canceled any debts or claims;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sold, assigned, transferred, leased, licensed or otherwise encumbered any Intellectual Property Rights, disclosed any Confidential
Information to any Person (other than to the Purchaser and its Affiliates and other than disclosures made in the ordinary course of business
consistent with past practice in circumstances in which it has imposed reasonable confidentiality restrictions), or abandoned or permitted
to lapse any Intellectual Property Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(1) granted any severance or termination pay to (or amended any existing arrangement with) any current or former director, officer
or employee; (2) increased, or accelerated the payment of, the compensation or benefits payable under any existing severance or termination
pay policies or employment agreements; (3) entered into any employment, deferred compensation or other similar agreement (or any amendment
to any such existing agreement) with any director, officer or employee; (4) established, adopted or amended (except as required by applicable
Laws) any Employee Plan or any collective bargaining, works council, share option, restricted shares, bonus, insurance, severance, deferred
compensation, pension, retirement, profit sharing, or any other benefit plan, agreement or arrangement covering any employees, officers,
consultants or directors of the Company; or (5) increased, or accelerated the payment of, the compensation, bonus or other benefits payable
to any employees, officers, consultants or directors of the Company other than in the case of this clause (5) in accordance with the Company&rsquo;s
ordinary course of business and consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>suffered any extraordinary losses or waived any rights of value (whether or not in the ordinary course of business or consistent
with past practice) in excess of $25,000 in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>made capital expenditures or commitments therefor that exceed $25,000 individually or $50,000 in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &#9;delayed or postponed the payment of any accounts payable or commissions or any other liability or obligation or agreed or
negotiated with any party to extend the payment date of any accounts payable or commissions or any other material liability or obligation
or accelerated the collection of (or discounted) any accounts or notes receivable outside the ordinary course of business consistent
with past practice in amounts that do not exceed $10,000 in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>made any loans or advances to, guaranties for the benefit of, or any investments in, any Person (other than advances to the employees
of the Company in the ordinary course of business consistent with past practice);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>suffered any damage, destruction or casualty loss exceeding in the aggregate $25,000, whether or not covered by insurance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>made or changed any Tax election, changed any annual tax accounting period, changed or adopted any method of tax accounting, filed
any amended Tax Returns or claims for Tax refunds, entered into any closing agreement, settled any Tax claim, audit or assessment, consented
to any extension or waiver of the limitation period applicable to any claim or assessment of Taxes, or surrendered any right to claim
a Tax refund, offset or other reduction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>threatened, commenced or settled any Legal Proceeding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>made any investment in or taken any steps to incorporate or form any Subsidiary or to acquire any equity interest or other interest
in any other Entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amended any of its Organizational Documents or effected or been a party to any Acquisition Transaction, recapitalization, reclassification
of shares, stock split, reverse stock split or similar transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>entered into any agreement or arrangement prohibiting or restricting it from freely engaging in any business, from competing with
any Person in any line of business that is material to the Company or otherwise restricting the conduct of its business anywhere in the
world;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>entered into, amended or terminated any material Contract other than in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>received notice, whether written or oral, from any party to a Company Contract of such party&rsquo;s intention not to renew, not
to extend, to cancel or otherwise terminate or materially modify its business relationship with the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>entered into any transaction with any of its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>entered into any other material transaction (other than the entry into this Agreement and any Shareholder Related Agreement and
the agreements and transactions contemplated by this Agreement and any Shareholder Related Agreement), whether or not in the ordinary
course of business consistent with past practice, or materially changed any business practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>received any adverse event notice from any Regulatory Authority regarding any Product or any preclinical or clinical study or any
clinical trial site; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>agreed, whether orally or in writing, to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Tax Returns required to have been filed by or on behalf of, or with respect to the assets of, the Company through the date
of this Agreement have been timely filed in accordance with all applicable Laws (pursuant to an extension of time or otherwise) and are
true, correct and complete in all respects. The Company has provided to the Purchaser true, correct and complete copies of all Tax Returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.9(b) of the Disclosure Schedule sets forth a true, correct and complete list of all jurisdictions (whether foreign or
domestic) in which the Company is required to file Tax Returns. No claim has ever been made by a Governmental Body in a jurisdiction where
the Company does not file Tax Returns that it is or may be subject to taxation or to a requirement to file Tax Returns in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Taxes, estimated Taxes, deposits and other payments due and owing by or on behalf of the Company (whether or not shown on any
Tax Return) have been or will be timely paid in full through the date of this Agreement and through the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has accrued on the Company Financial Statements in accordance with Spanish GAAP all liabilities for unpaid Taxes through
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The amounts so paid, together with all amounts accrued as liabilities for Taxes (including Taxes accrued as currently payable but
excluding any accrual to reflect timing differences between book and Tax income) on the books of the Company, shall be adequate based
on the tax rates and applicable Laws in effect to satisfy all liabilities for Taxes of the Company in any jurisdiction through the Closing
Date, including Taxes accruable upon income earned through the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has withheld all amounts of Taxes required to be withheld from its employees, agents, contractors, creditors, shareholders
and third parties and timely remitted such amounts to the proper Governmental Body and filed all federal, state, local and foreign Tax
Returns and reports with respect to employee income Tax withholding, social security, unemployment, and other similar Taxes, all in compliance
with the withholding provisions of all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has collected all material sales, value-added and use Taxes required to be collected, and have remitted, or will remit
on a timely basis, such amounts to the appropriate Governmental Body (or have been furnished properly completed exemption certificates
and have maintained all such records and supporting documents in the manner required by all applicable sales and use Tax statutes and
regulations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No claims have been asserted and no proposals or deficiencies for any Taxes of the Company are being asserted, proposed or, to
the Knowledge of the Company, threatened, and no Legal Proceeding, audit, examination or investigation of any Tax Return of the Company
is currently underway, pending or, to the Knowledge of the Company, threatened. There have been no examinations or audits of any Tax Return
of the Company. The Company has provided to the Purchaser true, correct and complete copies of all audit reports, correspondence with
Tax authorities and similar documents (to which the Company has access) relating to the Tax Returns of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Tax deficiencies asserted by a Governmental Body against the Company have been paid in full, accrued on the books of the Company,
as applicable, or finally settled, and no indication of a Tax increase or other issue has been raised in any such examination that, by
application of the same or similar principles, could reasonably be expected to result in a proposed Tax deficiency for any other period
not so examined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> There are no outstanding waivers or agreements between any Governmental Body and the Company for the extension of time for the
assessment of any Taxes or deficiency thereof, nor are there any requests for rulings, outstanding subpoenas or requests for information,
notices of proposed reassessment of any property owned or leased by the Company or any other matter pending between the Company and any
Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no Liens for Taxes with respect to the Company or the assets or properties of the Company, nor is there any Lien that
is pending or, to the Knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not a party to or bound by any Tax allocation, Tax indemnification or Tax sharing agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company (i) does not have a permanent establishment, office or other fixed place of business, and (ii) has never filed or had
any obligation to file, and does not have any obligation to file, any Tax Return based on income or otherwise, in each case in any jurisdiction
other than Spain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not adopted any resolution or entered into any transaction that might be rejected on the grounds of Tax evasion
or that could be questioned under general anti-abuse rules including those set forth in sections 12 to 16 of the Spanish General Tax Act
(<I>Ley 58/2003 General Tributari</I>a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not used accounting methods involving deferred payment of Taxes or any alternative accounting methods that postpone
or defer Taxes to a period ending on or after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Tax allowance, deduction, subsidy, reduction or Tax exemption granted to the Company may be revoked, cancelled or removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Shareholders' best knowledge, the Shareholders hereby represent and warrant to the Purchaser that, the deferred tax assets
contained in the Financial Statements and Tax Returns of the Company are true, correct and complete in all material aspects. Notwithstanding,
except for any penalties that may be imposed by the tax authorities, the Shareholders shall not be liable to the Purchaser for any tax
adverse consequences incurred by the Company with respect to such assets if the amount of these assets or the requirements according to
which they have been computed by the Company are challenged by the Spanish tax authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not, directly or indirectly, transferred property to or supplied services to or acquired property or services from
a Person with whom it was not dealing at arm&rsquo;s length on terms that materially differ from those that would have been made between
Persons dealing at arm&rsquo;s length.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has all supporting documents relating to Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Real Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company does not own, and has never owned, any real property, and the Company is not obligated and does not have an option
to acquire an ownership interest in any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on Section 2.10 of the Disclosure Schedule, the Company does not have, lease or use any Leased Real Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Personal Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All items of equipment and other tangible personal property and assets owned by or leased to the Company: (i) are reasonably adequate
for the uses to which they are being put; (ii) are structurally sound, free of defects and deficiencies and in good operating condition,
maintenance and repair, subject to ordinary wear and tear; (iii) comply in all material respects with, and are being operated and otherwise
used in material compliance with, all applicable Laws; (iv) were acquired and are usable in the ordinary course of business consistent
with past practice; and (v) are adequate for the conduct of the business of the Company in the manner in which such business is being
conducted and as proposed to be conducted by the Company as of the Closing Date, in each case in all material respects. All of the tangible
personal property and assets of the Company are located at the Leased Real Property and are free and clear of all Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.11(b) of the Disclosure Schedule sets forth all the equipment used or owned by the Company or other tangible personal
property or asset that is necessary to the operation of the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.12(a) of the Disclosure Schedule sets forth all Company Intellectual Property, in each case enumerating specifically
the applicable filing or registration number, title, jurisdiction in which filing was made or from which registration was issued, date
of filing or issuance, status, and names of all current applicant(s) and registered owners(s), as applicable. All assignments of Company
Intellectual Property to the Company, or in the case of Company Licensed Intellectual Property, to the licensor, have been properly executed
and recorded. Except as set forth on Section 2.12(a) of the Disclosure Schedule, all issued Company Intellectual Property is valid and
enforceable, and all issuance, renewal, maintenance and other payments and fees that are or have become due with respect thereto have
been timely paid by or on behalf of the Company, or in the case of Company Licensed Intellectual Property, the licensor. Except as set
forth on Section 2.12(a) of the Disclosure Schedule, no application for a patent, copyright or trademark registration or any other type
of Company Intellectual Property filed by or on behalf of the Company, or in the case of Company Licensed Intellectual Property, the licensor,
has been abandoned, allowed to lapse or rejected, and there is no basis for a claim that any Intellectual Property Rights embodied in
any Company Intellectual Property is invalid or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no inventorship challenges, opposition or nullity proceedings or interferences declared or commenced or, to the Knowledge
of the Company, threatened, and there is no fact that is reasonably likely to result in an inventorship challenge, opposition or nullity
proceeding or interference, with respect to any Patent Rights included in the Company Registrations. The Company has complied with its
duty of candor and disclosure to the United States Patent and Trademark Office and any relevant foreign patent office with respect to
all patent, utility model, industrial design, trademark and tradename applications filed by or on behalf of the Company and has made no
misrepresentation in such applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#9;The Company exclusively owns all right, title and interest in and to the Company Owned Intellectual Property (including but
not limited to the rights of reproduction, distribution, public communication and transformation), free and clear of any Liens other than
Permitted Liens. The Company Intellectual Property constitutes all Intellectual Property Rights pertaining or relating to the Pipeline
Technologies that are used in or necessary to the conduct of the Company&rsquo;s business as now conducted and as contemplated to be conducted
by the Company after the Closing Date, free and clear of any Liens other than Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Company has taken all commercially reasonable steps necessary to maintain and protect the proprietary nature of each item
of Company Intellectual Property, and to maintain in confidence all trade secrets and Confidential Information comprising a part thereof.
No complaint or other communication relating to an improper use or disclosure of, or a breach in the security of, any such information
has been made or, to the Knowledge of the Company, threatened against the Company. To the Knowledge of the Company, there has been no:
(i) unauthorized disclosure of any third-party proprietary or Confidential Information in the possession, custody or control of the Company;
or (ii) breach of the Company&rsquo;s security procedures wherein Confidential Information has been disclosed to a third Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no product, product candidate or service marketed or sold (or proposed to be marketed or sold)
by the Company or conduct of the business of the Company, as it is currently conducted and as it is contemplated to be conducted by the
Company after the Closing Date, infringes, violates or constitutes a misappropriation, or will infringe, violate or constitute a misappropriation,
of any Intellectual Property Rights of any third-party. The Company has not received any complaint, claim, challenge or notice (i) alleging
any such infringement, violation or misappropriation, or that, by conducting its business, the Company would infringe, violate or misappropriate
any Intellectual Property Rights of any other Person; or (ii) advising that such Person is challenging or threatening to challenge the
ownership, use, legality, validity or enforceability of any Company Intellectual Property. The Company has not received any opinion from
its legal counsel concluding that any activities of its business infringes, misappropriates, or otherwise violates, Intellectual Property
Rights of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no Person (including any current or former employee or consultant of the Company) has infringed,
violated or misappropriated, or is infringing, violating or misappropriating, any of the Company Intellectual Property and, to the Knowledge
of the Company, there are no facts or circumstances that could reasonably be expected to result in any of the foregoing or of any current
or anticipated claims against a third Person relating to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.12(g) of the Disclosure Schedule sets forth each license, covenant or other agreement pursuant to which the Company has
(x) assigned or transferred to any Person, or (y) licensed or otherwise granted any right to any Person, or covenanted not to assert any
right, in each such instance of (x) or (y), with respect to any Company Intellectual Property. The Company has not agreed to indemnify
any Person against any infringement, violation or misappropriation of any Intellectual Property Rights with respect to any third-party
Intellectual Property Rights. The Company is not a member of or party to any patent pool, industry standards body, trade association or
other organization pursuant to the rules of which it is obligated to license any existing or future Intellectual Property Rights to any
Person, and, except as set forth on Section 2.12(g) of the Disclosure Schedule, none of the Company Owned Intellectual Property was developed
in whole or in part using any governmental funding or using any funding, facilities, or resources of any university or research institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.12(h) of the Disclosure Schedule sets forth (i) each item of Company Licensed Intellectual Property and the license or
agreement pursuant to which the Company has rights thereto (excluding currently-available, off the shelf software programs that are licensed
by the Company pursuant to &ldquo;shrink wrap&rdquo; licenses, the total fees associated with which are less than $10,000), and (ii) each
agreement, assignment or other instrument pursuant to which the Company has obtained any joint or sole ownership interest in or to each
item of Company Owned Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not subject to any proceeding or outstanding decree, order, judgment, agreement or stipulation (i) restricting in
any manner the use, transfer or licensing by the Company of any of the Company Intellectual Property; or (ii) that may affect the validity,
use or enforceability of the Company Intellectual Property or any product, product candidate or service of the Company related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Each current and former employee of the Company and each current and former independent contractor of or consultant to the Company
has executed a valid and binding written agreement, substantially in the form or forms provided to the Purchaser (each, an &ldquo;<B><I>Assignment
Agreement</I></B>&rdquo;), expressly assigning to the Company all right, title and interest in any inventions and works of authorship
generated on behalf of the Company and/or pertaining to the Pipeline Technologies, whether or not patentable, invented, created, developed,
conceived and/or reduced to practice by the employee, independent contractor or consultant for the Company, and all Intellectual Property
Rights therein (including but not limited to the rights of reproduction, distribution, public communication and transformation), and has
waived all moral rights therein to the extent legally permissible. All Company Owned Intellectual Property was developed by (i) an employee
of the Company working within the scope of his or her employment at the time of such development; or (ii) agents, consultants, contractors,
or other Persons who have executed appropriate Assignment Agreements. To the extent that any Company Intellectual Property has been developed
or created by a third party for the Company, the Company has a written agreement with such third party with respect thereto and the Company
thereby either (A) has obtained ownership of and is the exclusive owner of; or (B) has obtained a license (sufficient for the conduct
of its business as currently conducted and as proposed to be conducted by the Company after the Closing Date) to, all of such third party&rsquo;s
Intellectual Property in such work, material or invention by operation of law or by valid assignment. The Company has not embedded any
open source, copyleft or community source code in any of its products generally available or in development, including but not limited
to any libraries or code licensed under any General Public License, Lesser General Public License or similar license arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery of this Agreement by the Company and the Shareholders, the consummation by the Company and the Shareholders
of the transactions contemplated by this Agreement and any Shareholder Related Agreement and the Company continuing to operate its business
immediately after the Closing in the same manner as operated immediately prior to the Closing after giving effect to the consummation
of the transactions contemplated by this Agreement and any Shareholder Related Agreement will not result in the breach of, or create on
behalf of any third-party the right to terminate or modify, (i) any license, sublicense or other agreement relating to any Company Intellectual
Property; or (ii) any license, sublicense and other agreement to which the Company is a party and pursuant to which the Company is authorized
to use any third-party Intellectual Property Rights that are useful to the business of the Company, as it is currently conducted and as
it is contemplated to be conducted by the Company after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no current or former director, officer, employee, independent contractor, or consultant of the
Company (i) is in violation of any provision or covenant of any employment agreement, invention assignment agreement, nondisclosure agreement,
non-competition agreement or any other Contract with any other Person by virtue of such director&rsquo;s, officer&rsquo;s, employee&rsquo;s,
independent contractor&rsquo;s, or consultant&rsquo;s being employed by, performing services for or serving on the board of directors
of the Company; (ii) is using or has used any trade secrets or Confidential Information of any third Person in connection with performing
any services for the Company or the development or creation of any Company Intellectual Property without the permission of the Company
and such third Person; or (iii) has developed or created any Company Intellectual Property that is subject to any agreement under which
such director, officer, employee, independent contractor, or consultant has assigned or otherwise granted any third party any rights
in or to such Company Intellectual Property. To the Knowledge of the Company, no director, agent, employee, independent contractor, or
consultant of the Company is a party to, or is otherwise bound by, any Contract, including any confidentiality, non-competition or proprietary
rights agreement, with any other Person that in any way adversely affects or will affect his or her ability to assign to the Company
rights to any invention, improvement, discovery or information relating to Company Intellectual Property or affecting the Company&rsquo;s
ability to Exploit any Company Intellectual Property. Other than with respect to IDIBELL, no government funding, facilities of a university,
college, other educational institution or research center, or funding from third parties was used in the development of any Company Intellectual
Property. No Person who was involved in, or who contributed to, the creation or development of any Company Intellectual Property, has
performed services for the government, university, college, or other educational institution or research center in a manner that would
affect Company&rsquo;s rights in the Company Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All licenses for the use of the Intellectual Property Rights are valid, binding upon, and enforceable by or against the parties
thereto in accordance to its terms. The Company has complied in all material respects with, and is not in breach nor has received any
asserted or threatened claim of material breach of any Intellectual Property Rights license, and to the Knowledge of the Company there
has been no material breach or anticipated material breach by any other person to any Intellectual Property license to which the Company
is a party.&nbsp; The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or
payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the Company&rsquo;s right
to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for use in the conduct of the business as
currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on Section 2.13 of the Disclosure Schedule, the Company is not a party to or bound by any written or oral:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>pension, profit sharing, stock option, employee stock purchase, bonus or other plan or arrangement providing for deferred or other
compensation to employees, former employees or consultants, or any other employee benefit plan or arrangement, or any collective bargaining
agreement or any other Contract with any labor union, or severance agreements, programs, policies or arrangements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract for the employment of, or receipt of services from, any officer, individual employee or other Person on a full-time, part-time,
consulting or other basis or relating to loans to officers, directors, managers or Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract providing for indemnification of any officer, director, employee or agent or indemnification with respect to infringement
of proprietary rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract under which the Company has advanced or loaned any other Person amounts in the aggregate exceeding $25,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>agreement or indenture relating to borrowed money or other Indebtedness or the mortgaging, pledging or otherwise placing or creating
of a Lien on any asset or group of assets of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>guaranty, pledge, performance or completion bond, surety or similar agreement or arrangement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract creating or relating to any partnership or joint venture or any sharing of revenues, profits, losses, costs or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>lease or agreement under which the Company is lessee of or holds or operates any property, real or personal, owned by any other
party, except for any lease of real or personal property under which the aggregate annual rental payments do not exceed $25,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>lease or agreement under which the Company is lessor of or permits any third party to hold or operate any property, real or personal,
owned or controlled by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract or group of related Contracts with the same party or group of affiliated parties, the performance of which involves consideration
in the aggregate in excess of $50,000, other than purchase and sales orders incurred in the ordinary course of business consistent with
past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(1) assignment, (2) license, or (3) indemnification (other than agreements including indemnification obligations incidental to
the subject matter of such agreement), in each of (1) &ndash; (3), with respect to any intangible property (including any Intellectual
Property Rights);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract relating to the (1) acquisition, (2) transfer, (3) licensing or use, or (4) development, in each of (1) &ndash; (4), of
any technology or any Intellectual Property Rights, except for licenses to use shrink-wrap or off-the-shelf software with a cost to the
Company of less than $10,000 per user or per copy, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract relating to the purchase or sale of any product, product candidate or other asset by or to, or the performance of any
services by or for, any Related Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract under which it has granted any Person any registration rights (including demand or piggyback registration rights);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sales, distribution, supply or franchise agreement or other agreement involving an agency relationship;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>advertising, vendor rebate or product purchase or sale discount agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract for capital expenditures or the acquisition or construction of fixed assets requiring the payment by the Company of an
amount in excess of $25,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract constituting or relating to a Government Contract or Government Bid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract providing for an &ldquo;earn out&rdquo;, &ldquo;performance guarantee&rdquo; or other similar contingent payments by or
to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contracts for the cleanup, abatement or other actions in connection with any Materials of Environmental Concern, the remediation
of any existing environmental condition or relating to the performance of any environmental audit or study;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract granting any Person an option or a right of first refusal, first-offer or similar preferential right to purchase or acquire
any assets of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract for the granting or receiving of a license, sublicense or franchise or under which any Person is obligated to pay or has
the right to receive a royalty, license fee, franchise fee or similar payment, except for Contracts relating to the use of shrink-wrap
or off-the-shelf software with a cost to the Company of less than $10,000 per user or per copy, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract that grants rights to manufacture, produce, assemble, license, market or sell its products to any Person that limit the
Company&rsquo;s exclusive right to develop, manufacture, assemble, distribute, market or sell products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> outstanding power of attorney empowering any Person to act on behalf of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any tax-sharing Contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract that was entered into outside the ordinary course of business or was inconsistent with the Company&rsquo;s past practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>agreement with a term of more than 60 days which is not terminable by the Company upon less than 30 days&rsquo; notice without
penalty and involves a consideration in excess of $50,000 annually;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Contract regarding voting, transfer, issuance or other arrangements related to the Company&rsquo;s share capital , options or other
rights to acquire, or that relates to, the Company&rsquo;s share capital; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contract that (A) limits the ability of the Company, or to the Knowledge of the Company any of its officers or employees, to compete
in any line of business or with any Person or in any geographic area or during any period of time; (B) contains any so called &ldquo;most
favored nation&rdquo; provisions or any similar provision requiring the Company to offer a third party terms or concessions (including
levels of service or content offerings) at least as favorable as offered to one or more other parties; or (C) provides for &ldquo;exclusivity,&rdquo;
preferred treatment or any similar requirement or under which the Company is restricted, or which after the Closing would restrict the
Purchaser or any of its Affiliates, with respect to distribution, licensing, marketing, co-marketing or development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All of the Contracts, leases, agreements and instruments set forth or required to be set forth on Section 2.13(a) of the Disclosure
Schedule (the &ldquo;<B><I>Material Contracts</I></B>&rdquo;) are in full force and effect and are valid, binding and enforceable in accordance
with their respective terms and will be in full force and effect, valid, binding and enforceable on identical terms without penalty in
accordance with their terms upon consummation of the transactions contemplated by this Agreement. Except as set forth on Section 2.13(b)
of the Disclosure Schedule: (i) the Company has performed all material obligations required to be performed by it and is not in default
under or in breach of nor in receipt of any claim of default or breach under any Material Contract; (ii) no event has occurred which (with
or without the passage of time or the giving of notice or both) would, or could reasonably be expected to, (A) result in a default, breach
or event of noncompliance by the Company under any Material Contract; (B) give any Person the right to declare a default or exercise any
remedy under any Material Contract; (C) give any Person the right to accelerate the maturity or performance of any Material Contract;
or (D) give any Person the right to cancel, terminate or modify any Material Contract; (iii) the Company has no present expectation or
intention of not fully performing all such obligations; and (iv) to the Knowledge of the Company, there is no breach or anticipated breach
by the other parties to any Material Contract. The consummation of the transactions contemplated by this Agreement and the Shareholder
Related Agreements shall not (either alone or upon the occurrence of additional acts or events) result in any payment or payments becoming
due from the Company or the Purchaser or any of its Affiliates to any Person or give any Person the right to terminate or alter the provisions
of any Material Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not received any notice or other communication regarding any actual or possible violation or breach of, or default
under, any Material Contract or that any third party is or intends to terminate any Material Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not waived any of its rights under any Material Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Company is not a party to any Contract, agreement or commitment the performance of which could reasonably be expected to have
a Company Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There is no term, obligation, understanding or agreement that would modify any term of a written Material Contract or any right
or obligation of a party thereunder which is not reflected on the face of such Material Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Person is renegotiating, or has a right pursuant to the terms of any Material Contract to renegotiate, any amount paid or payable
to the Company under any Material Contract or any other material term or provision of any Material Contract. The Company is not a party
to any Contract that obligates the Company to provide products or services below the Company&rsquo;s cost of such product or service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has provided to the Purchaser a true, correct and complete copy of each of the written Material Contracts and a written
summary description of each of the oral Material Contracts, together with all amendments, waivers or other changes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no consents or waivers of any third persons or Governmental Bodies in order for the Purchaser to maintain the benefit
of any Material Contracts after the execution of this Agreement and the Closing of the contemplated transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as provided under Section 2.14 of the Disclosure Schedule, there are no Legal Proceedings pending or, to the Knowledge of
the Company, threatened (i) against or affecting the Company or any of the assets owned, used or controlled by the Company or any Person
whose liability the Company has retained or assumed, either contractually or by operation of law (or pending or, to the Knowledge of the
Company, threatened against or affecting any of the Shareholders or the officers, directors, managers or employees of the Company with
respect to its business or proposed business activities), or pending or threatened by the Company against any Person, at law or in equity,
or before or by any Governmental Body (including any Legal Proceedings with respect to the transactions contemplated by this Agreement),
or (ii) that relate to the ownership of share capital of the Company, or any option or other right to the share capital of the Company,
or any right to receive consideration as a result of this Agreement. There is no claim, action, suit, proceeding, arbitration, complaint,
charge or investigation pending or to the Company&rsquo;s Knowledge, currently threatened in writing (i) against the Company or any officer,
director or employee of the Company arising out of their employment or board relationship with the Company; or (ii) to the Company&rsquo;s
Knowledge, that questions the validity of this Agreements or the right of the Company to enter into them, or to consummate the transactions
contemplated by this Agreements; or (iii) to the Company&rsquo;s knowledge, that would reasonably be expected to have, either individually
or in the aggregate, a material adverse effect on the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not subject to any Legal Proceedings under collective bargaining agreements or otherwise or any governmental investigations
or inquiries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[The Company is fully insured with respect to each of the matters set forth on Section 2.14 of the Disclosure Schedule.] The Company
is not subject to any judgment, order or decree of any court or other Governmental Body, and the Company has not received any notice
from legal counsel to the effect that it is exposed, from a legal standpoint, to any material liabilities. There are no actions, suits,
proceedings (including any arbitration proceedings), orders, investigations or claims pending or, to the Knowledge of the Company, threatened
against or affecting any Shareholder in which it is sought to restrain or prohibit or to obtain damages or other relief in connection
with the transactions contemplated by this Agreement. The Company has provided to the Purchaser true, correct and complete copies of
all pleadings, correspondence and other written materials to which the Company has access and that relate to any Legal Proceeding set
forth on Section 2.14 of the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Environmental Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Other than as stated under this section, the Company is, and for the past three years has been, in compliance with all applicable
Environmental Laws, which compliance includes the use by the Company of all Governmental Authorizations required under applicable Environmental
Laws, and compliance with the terms and conditions thereof. All Governmental Authorizations currently held or used by the Company pursuant
to Environmental Laws are set forth on Section 2.15(a) of the Disclosure Schedule.&nbsp; The environmental license issued by the municipality
council of Sant Cugat del Valles in 2011 under the name of Gri-Cel, S.A. (now merged with Instituto Grifols, S.A.) is sufficient to satisfy
all required Governmental Authorizations pursuant to applicable Environmental Laws, other than for the fact that such environmental license
is not issued under the name of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not received any notice or other communication (in writing or otherwise), whether from a Governmental Body, citizens
group, employee or otherwise, that alleges that the Company is not in compliance with, or has liability under, any Environmental Law,
and to the Knowledge of the Company, there are no circumstances that could reasonably be expected to prevent or interfere with the Company&rsquo;s
compliance with, or give rise to liability under, any Environmental Law in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not at any time been subject to any administrative or judicial proceeding pursuant to, or paid any fines or penalties
pursuant to, applicable Environmental Laws. The Company has not entered into or agreed to enter into, or has any present intent to enter
into, any consent decree or order, and the Company is not subject to any judgment, decree or judicial or administrative order relating
to compliance with, or the cleanup of Materials of Environmental Concern under, any applicable Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, there has been no Release of Materials of Environmental Concern at any plant, facility, site,
area or property at which the Company currently operates or previously operated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no current or prior owner of any property leased or controlled by the Company has received any
notice or other communication (in writing or otherwise), whether from a Governmental Body, citizens group, employee (current or former)
or otherwise, that alleges that such current or prior owner or the Company is not in compliance with, or has liability under, any Environmental
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no improvement or equipment included in the property or assets of the Company contains any asbestos,
polychlorinated biphenyls, underground storage tanks, open or closed pits, sumps or other containers on or under any property or asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, the Company has not imported, received, manufactured, produced, processed, labeled or shipped,
stored, used, operated, transported, treated or disposed of any Materials of Environmental Concern other than in compliance with all Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#9;The Company has provided to the Purchaser true, correct and complete copies of all environmental reports, investigations and/or
audits relating to facilities at which the Company currently operates or previously operated (whether conducted by or on behalf of the
Company or a third party) of which the Company has possession or control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company currently has 8 employees (this notwithstanding, it is expected that 1 employee resigns by the end of year 2021). The
Company&rsquo;s records accurately reflect the employment or service histories of its employees, independent contractors, contingent workers
and leased employees, including their hours of service. The employment of each of the employees is terminable at will. The Company has
provided to the Purchaser true, correct and complete copies of all employee manuals and handbooks, disclosure materials, policy statements,
releases and other materials relating to the employment of the current and former employees of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.16(b) of the Disclosure Schedule sets forth a true, correct and complete list of all consultants and independent contractors
used by the Company as of the date of this Agreement, specifying the name of the consultant or independent contractor, type of services
provided, fees paid to such consultant or independent contractor for calendar year 2020 and 2021, work location and address, and accurately
reflects any compensation payable to them, their dates of service, their positions or titles and a true, correct and complete description
of the Company&rsquo;s obligations to each such consultant and independent contractor. The Company has provided to the Purchaser a true,
correct and complete copy of each written agreement with each consultant and independent contractor set forth on Section 2.16(b) of the
Disclosure Schedule. Each of the consultant and independent contractor relationships with the Persons set forth on Section 2.16(b) of
the Disclosure Schedule is terminable without notice and without pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, each prior employee has, at all times, properly been classified and treated as an employee for
all purposes including, but not limited to, the Employee Plans and Tax purposes. Each prior employee has at all times properly been classified
as subject to or exempt from overtime requirements. The Company has never had any temporary or leased employees that were not treated
and accounted for in all respects as employees of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, the Company is, and has at all times been, in compliance with all applicable Laws and in particular,
all Labor Laws applicable to its employees. To the Knowledge of the Company, the Company is not subject to or liable for any arrears of
wages, penalties, fines, orders to pay, assessments, charges, damages or taxes for failure to comply with the Labor Laws and the Company
is in compliance with all Laws (including all Labor Laws) and contracts relating to employment, employment practices, wages, hours, equal
opportunity, affirmative action, harassment, occupational health and safety, disability, workers compensation, unemployment, insurance,
benefits, taxes, bonuses and terms and conditions of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no claims pending, or, to the Knowledge of the Company, threatened or capable of arising, against the Company, by an
employee or workman or third party, in respect of any accident or injury, which are not fully covered by insurance or under applicable
workers compensation legislation. No levies, assessments or penalties have been made against the Company pursuant to Applicable Benefit
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No notice has been received by the Company of any employment related claims commenced by any employee against the Company, including
claims that the Company has violated Labor Laws or the common law with respect to an employee&rsquo;s employment, and, to the Knowledge
of the Company, no such claims are threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not made any written or verbal commitments to any officer, employee, former employee, consultant or independent
contractor of the Company with respect to compensation, promotion, retention, termination, severance or any similar matter in connection
with the transactions contemplated by this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, each Person classified as an independent contractor or other non-employee service provider of
the Company has, at all times, properly been classified and treated as an independent contractor or other non-employee service provider
for all purposes including, but not limited to, Tax purposes. To the Knowledge of the Company, the Company is, and has at all times been,
in compliance with all applicable Laws and contracts relating to its independent contractors and other non-employee service providers.
No independent contractor, consultant or other non-employee service provider of the Company is eligible to participate in any Employee
Plan. There are no claims pending or, to the Knowledge of the Company, threatened against the Company, by any independent contractor,
other non-employee service provider or third party, in respect of any accident or injury, which are not fully covered by insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All amounts due in relation to employees (whether arising under common law, statute, equity or otherwise) have been paid, including
all remuneration, expenses, social insurance, pension contributions, liability to taxation, levies and other amounts (other than amounts
owing with respect to the current salary or work period which are not yet due).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on Section 2.16(j) of the Disclosure Schedule, all amounts due in relation to any independent contractors or
other non-employee service providers of the Company have been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no Employee, since becoming an employee, has been, or currently is, represented by a labor organization
or group that was either certified or voluntarily recognized by any labor relations board or certified or voluntarily recognized by any
other Governmental Body. The Company is not and has never been a signatory to a collective bargaining agreement with any trade union,
labor organization or group. No representation election petition or application for certification has been filed by employees or is pending
with any Governmental Body and no union organizing campaign or other attempt to organize or establish a labor union, employee organization
or labor organization or group involving employees has occurred, is in progress or, to the Knowledge of the Company, is threatened. No
labor strike, work stoppage, slowdown, picketing, lockout or other material labor dispute has occurred, and none is underway or, to the
Knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not a United States federal or state contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No wrongful discharge, retaliation, libel, slander or other claim, complaint, charge or investigation that arises out of the employment
relationship between the Company and any of its Employees has been filed or is pending or, to the Knowledge of the Company, threatened
against the Company under any applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefit Plans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#9;<U>Section 2.17(a)</U> of the Company Disclosure Schedule is a list of all material Benefit Plans, including, without limitation,
each Benefit Plan that provides for retirement, change in control, deferred compensation, incentive compensation, severance or retiree
medical or life insurance benefits and the name of each individual that is entitled to payments pursuant thereto and the amount of each
payment. &ldquo;<B><I>Benefit Plan</I></B>&rdquo; means each pension, retirement, deferred compensation, excess benefit, profit sharing,
bonus, incentive, equity or equity-based, phantom equity, employment, consulting, severance, change-of-control, retention, health, life,
disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, contract, or arrangement (whether written
or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen or terminated), in any case, maintained,
contributed to, or required to be contributed to, by the Company for the benefit of any current or former employee, director, officer
or independent contractor of the Company or under which the Company has any actual or contingent liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As applicable with respect to each material Benefit Plan, the Company has made available to Purchaser, true and complete copies
of (i) each material Benefit Plan, including all amendments thereto, and in the case of an unwritten material Benefit Plan, a written
description thereof, (ii) all current trust documents, investment management contracts, custodial agreements, administrative services
agreements and insurance and annuity contracts relating thereto, (iii) the current summary plan description and each summary of material
modifications thereto, (iv) the most recently filed annual reports with any Governmental Body and all schedules thereto, (v) the most
recent Governmental Body determination, opinion or advisory letter, (vi) the most recent summary annual reports, nondiscrimination testing
reports, actuarial reports, financial statements and trustee reports, (vii) all records, notices and filings concerning Governmental Body
audits or investigations, prohibited transactions and (viii) all policies and procedures established to comply with the privacy and security
rules any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any
related documents or agreements and the applicable provisions of all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no pending audits or investigations by any Governmental Body involving any Benefit Plan, and no pending or, to the Knowledge
of the Company, threatened claims (except for individual claims for benefits payable in the normal operation of the Benefit Plans), suits
or Legal Proceedings involving any Benefit Plan, any fiduciary thereof or service provider thereto, in any case except as would not be
reasonably expected to result in material liability to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service
or retirement other than coverage mandated by Law and the Company has not made a written or oral representation promising the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the execution of, nor the performance of the transactions contemplated by this Agreement will either alone or in connection
with any other event(s) (i)&nbsp;result in any payment becoming due to any current or former employee, director, officer, or independent
contractor of the Company or any Subsidiary thereof, (ii) increase any amount of compensation or benefits otherwise payable under any
Benefit Plan, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Benefit Plan, (iv)
require any contribution or payment to fund any obligation under any Benefit Plan or (v)&nbsp;limit the right to merge, amend or terminate
any Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No current or former employee, officer, director or independent contractor of the Company has any &ldquo;gross up&rdquo; agreements
or other assurance of reimbursement for any Taxes imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company does not maintain any Benefit Plan outside of Spain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract
with a labor union, labor organization, or similar Person representing any of its employees, and there is no labor union, labor organization,
or similar Person representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the
Company or its Subsidiaries, including through the filing of a petition for representation election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Company and each of its Subsidiaries is and for the past five (5) years has been, in material compliance with all applicable
Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, tax
withholding, prohibited discrimination and retaliation, equal employment opportunities, harassment, fair employment practices, meal and
rest periods, immigration, employee safety and health, wages (including overtime wages), unemployment and workers&rsquo; compensation,
leaves of absence, and hours of work. Except as would not be reasonably likely to result in a material Liability to the Company, with
respect to employees of the Company and its Subsidiaries, each of the Company and its Subsidiaries, since January 1, 2018: (i) has withheld
and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments,
benefits, or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes
or any penalty for failure to comply with any of the foregoing, and (iii) is not liable for any payment to any trust or other fund governed
by or maintained by or on behalf of any Governmental Body, with respect to unemployment compensation benefits, disability, social security
or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are
no actions, suits, claims, charges, lawsuits, investigations, audits or administrative matters pending or, to the Knowledge of the Company,
threatened or reasonably anticipated against the Company relating to any employee, applicant for employment, consultant, employment agreement
or Benefit Plan (other than routine claims for benefits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as would not be reasonably likely to result in a material liability to the Company, with respect to each individual who
currently renders services to the Company, the Company a has accurately classified each such individual as an employee, independent contractor,
or otherwise under all applicable Laws and, for each individual classified as an employee, the Company has accurately classified him or
her as overtime eligible or overtime ineligible under all applicable Laws. The Company has no material liability with respect to any misclassification
of: (a) any Person as an independent contractor rather than as an employee, (b) any employee leased from another employer, or (c) any
employee currently or formerly classified as exempt from overtime wages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of, any
strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to
the Knowledge of the Company, any union organizing activity, against the Company. No event has occurred, and no condition or circumstance
exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown,
work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the
Company, any union organizing activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There is no Legal Proceeding, claim, unfair labor practice charge or complaint, labor dispute or grievance pending or, to the Knowledge
of the Company, threatened against the Company relating to labor, employment, employment practices, or terms and conditions of employment.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of the date hereof, no Key Employee has submitted his or her resignation or, to the Knowledge of the Company, intends to resign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date hereof, the Company has paid all social security contributions required to be made under Spanish employment legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance With Laws; Governmental Authorizations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is, and has at all times been, in compliance with all applicable Laws, except where non-compliance could not reasonably
be expected to result in a Company Material Adverse Effect. The Company has never received any notice or other communication from any
Governmental Body or any other Person regarding (i) any actual, alleged, possible or potential material violation of, or failure to materially
comply with, any Law; or (ii) any actual, alleged, possible or potential obligation on the part of the Company to undertake, or to bear
all or any portion of the cost of, any cleanup or any remedial, corrective or response action of any nature under any applicable Law.
The Company has provided to the Purchaser a true, correct and complete copy of each report, study, survey or other document to which
the Company has access that addresses or otherwise relates to the compliance of the Company with, or the applicability to the Company
of, any Laws. To the Knowledge of the Company, no Governmental Body has proposed or is considering any Law that, if adopted or otherwise
put into effect, (A) may have an adverse effect on the business, condition, assets, liabilities, operations, financial performance, net
income or prospects of the Company or on the ability the Company to comply with or perform any covenant or obligation under this Agreement
or any Shareholder Related Agreements; or (B) may have the effect of preventing, delaying, making illegal or otherwise interfering with
the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.18(b) of the Disclosure Schedule sets forth each Governmental Authorization held by the Company, and the Company has
provided to the Purchaser true, correct and complete copies of all such Governmental Authorizations. The Governmental Authorizations held
by the Company are valid and in full force and effect, and collectively constitute all Governmental Authorizations necessary (i) to enable
the Company to conduct its business legally and as contemplated to be conducted by the Company after the Closing Date; and (ii) to permit
the Company to own and use its assets in the manner in which it is currently owned and used. The Company is, and at all times since its
incorporation has been, in compliance with the terms and requirements of the Governmental Authorizations held by the Company. The Company
has not received any notice or other communication from any Governmental Body regarding (A) any actual or possible violation of or failure
to comply with any term or requirement of any Governmental Authorization; or (B) any actual or possible revocation, withdrawal, suspension,
cancellation, termination or modification of any Governmental Authorization. All of Governmental Authorizations set forth or required
to be set forth on Section 2.18(b) of the Disclosure Schedule will be available for use by the Company immediately after the Closing.
In respect of approvals, licenses or permits requisite for the conduct of any part of the business of the Company which are subject to
periodic renewal, the Company has no reason to believe that such renewals will not be timely granted by the relevant Governmental Body.
Neither the execution or performance of this Agreement nor the consummation of the transactions contemplated by this Agreement (i) require
the consent or approval of any Governmental Body, and (ii) affect the validity or require the amendment of a Governmental Authorization
for the Company to conduct it business as contemplated to be conducted after the Closing Date .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) The Company has at all times been, in full compliance with all of the terms and requirements of each Governmental Authorization
set forth or required to be set forth on Section 2.18(b) of the Disclosure Schedule; (ii) to the Knowledge of the Company, no event has
occurred, and no condition or circumstance exists, that might (with or without notice or lapse of time or both) (A) constitute or result
directly or indirectly in a violation of or a failure to comply with any term or requirement of any Governmental Authorization set forth
or required to be set forth on Section 2.18(b) of the Disclosure Schedule; or (B) result directly or indirectly in the revocation, withdrawal,
suspension, cancellation, termination or modification of any Governmental Authorization set forth or required to be set forth on Section
2.18(b) of the Disclosure Schedule; (iii) the Company has never received, and, to the Knowledge of the Company, no employee has ever
received, any notice or other communication from any Governmental Body or any other Person regarding (x) any actual, alleged, possible
or potential violation of or failure to comply with any term or requirement of any Governmental Authorization; or (y) any actual, proposed,
possible or potential revocation, withdrawal, suspension, cancellation, termination or modification of any Governmental Authorization;
and (iv) all applications required to have been filed for the renewal of the Governmental Authorizations required to be set forth on
Section 2.18(b) of the Disclosure Schedule have been duly filed on a timely basis with the appropriate Governmental Bodies, and each
other notice or filing required to have been given or made with respect to such Governmental Authorizations has been duly given or made
on a timely basis with the appropriate Governmental Body. The rights and benefits of each Governmental Authorization Company Permit will
be available to the Company immediately after the Closing Date on terms substantially identical to those enjoyed by the Company as of
the date of this Agreement and immediately prior to the Closing Date without the need to obtain any consent or waiver from any Governmental
Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Section 2.19 of the Disclosure Schedule sets forth a
true, correct and complete list of all insurance policies and fidelity bonds maintained by, at the expense of or for the benefit of the
Company and its Employees, officers and directors for the current policy year, and the Company has provided to the Purchaser accurate
and complete copies of the insurance policies set forth on Section 2.19 of the Disclosure Schedule. The Company has not reached or exceeded
its policy limits for any insurance policy in effect at any time during the past three (3) years. During the past three (3) years, the
Company has not received any notice or other communication regarding any actual or possible (a) cancellation or invalidation of any insurance
policy; (b) refusal of any coverage or rejection of any claim under any insurance policy; or (c) material adjustment in the amount of
the premiums payable with respect to any insurance policy. All premiums required to be paid with respect thereto covering all periods
up to and including the Closing Date have been or will be paid in a timely fashion and there has been no lapse in coverage under such
policies or failure of payment that will cause coverage to lapse during any period for which the Company has conducted its operations.
The Company does not have any obligation for retrospective premiums for any period prior to the Closing Date. All such policies are in
full force and effect and will remain in full force and effect up to and including the Closing Date, unless replaced with comparable insurance
policies having comparable or more favorable terms and conditions. No insurer has provided the Company with notice that coverage will
be denied with respect to any claim submitted to such insurer by the Company. Section 2.19 of the Disclosure Schedule sets forth all claims
by the Company pending under any of such policies or bonds as to which coverage has been questioned, denied or disputed by the underwriters
of such policies or bonds or in respect of which such underwriters have reserved their rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokerage and Transaction Bonuses</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Except as set forth on Section
2.20 of the Disclosure Schedule, there are no claims for brokerage commissions, finders&rsquo; fees or similar compensation in connection
with the transactions contemplated by this Agreement based on any arrangement or agreement binding upon the Company or any Shareholder.
There are no special bonuses or other similar compensation payable to any employee of the Company in connection with the transactions
contemplated by this Agreement and the Shareholder Related Agreements. The Shareholders shall pay, and hold the Company, the Purchaser
and its Affiliates harmless against, any liability, loss or expense (including reasonable attorneys&rsquo; fees and out of pocket expenses)
arising in connection with any such claim, brokerage commission, finders&rsquo; fee or special bonus or other similar compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title to and Sufficiency of Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company owns, and has good, valid, transferable and marketable title to, or a valid leasehold interest in (i) all properties
and assets used by it, located on its premises, shown on the Annual Accounts or acquired after the date thereof, free and clear of all
Liens (other than properties and assets disposed of in the ordinary course of business consistent with past practice since the date of
the Annual Accounts and except for Permitted Liens); (ii) all of its rights under the Material Contracts; and (iii) all other material
assets used by the Company or reflected in the books and records of the Company as being owned by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by the Company are in good
operating condition and repair and are reasonably fit and usable for the purposes for which they are being used. The Company is in compliance
with all material terms of each lease to which it is a party or is otherwise bound. The Company owns, has a valid leasehold interest in
or has the valid and enforceable right to use all assets, tangible or intangible, necessary for the conduct of its business as currently
conducted and as proposed to be conducted by the Company after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.22<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Inventory</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">All of the inventory of the Company: (a) was acquired
and is sufficient for the operation of its business in the ordinary course of business consistent with the Company&rsquo;s past practice;
(b) is of a quality and quantity usable or saleable in the ordinary course of business consistent with the Company&rsquo;s past practice;
(c) is valued on the books and records of the Company at the lower of cost or market with the cost determined under the first-in-first-out
inventory valuation method consistent with the Company&rsquo;s past practice; and (d) is free of any material defect or deficiency. The
inventory levels maintained by the Company are adequate in all material respects for the conduct of the operations of the Company in the
ordinary course of business and consistent with the Company&rsquo;s past practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bank Accounts</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Section 2.23 of the Disclosure Schedule sets forth
true, correct and complete information with respect to each account maintained by or for the benefit of the Company at any bank or other
financial institution, including the name of the bank or financial institution, the account number, the balance as of the date of this
Agreement (and whether any cash comprising such balances is &ldquo;restricted cash&rdquo;) and the names of all individuals authorized
to draw on or make withdrawals from such accounts (and no changes to such information shall have occurred as of the Closing Date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounts Payable</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Section 2.24(a) of the Disclosure Schedule sets
forth a true, correct and complete breakdown and aging of the accounts payable of the Company as of November 30, 2021, shall be updated
by the Company and provided to Purchaser prior to the Closing as of the Closing Date, and any outstanding accounts payable is reflected
in Section 2.6(c) of the Disclosure Schedule. All accounts payable were incurred in the ordinary course of business consistent with past
practice, are valid payables for products or services purchased by the Company and except as set forth on the Disclosure Schedule are
not past due and in no event are any payables more than 60 days past the invoice date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.25<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Related Party Transactions</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Except as set forth on Section 2.25
of the Disclosure Schedule, no Related Party has any direct or indirect interest in any asset used in or otherwise relating to the business
of the Company. No Related Party is indebted to the Company. No Related Party has entered into any Material Contract, transaction or business
dealing involving the Company. No Related Party is competing directly or indirectly, with the Company. No Related Party has any claim
or right against the Company (other than claims or rights to receive compensation for services performed as an employee or as a director).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.26<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Customers and Suppliers</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Section 2.26 of the Disclosure Schedule
sets forth a true, correct and complete list of the names and addresses of the material Suppliers. No material Supplier (or former Supplier)
during the prior 12 months has canceled, terminated or, to the Knowledge of the Company, made any threat to cancel or otherwise terminate
any of such material Supplier&rsquo;s Contracts with the Company or to decrease such Supplier&rsquo;s supply of services or products
to the Company. The Company has provided to the Purchaser true, correct and complete copies of all of such material Supplier Contracts,
and all such Contracts are in full force and effect, have not been withdrawn, amended, modified or terminated and are enforceable by
the Company, as applicable. The Company has not received any notice and the Company does not have any Knowledge to the effect that any
current customer or supplier may withdraw, terminate or materially alter, amend or modify its business relations with the Company, either
as a result of the </FONT>transactions contemplated by this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.27<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Payments</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Neither the Company nor, to the Knowledge of
the Company, any manager, officer, employee, agent, consultant or other Person associated with or acting for or on behalf of the Company,
has at any time, directly or indirectly: (a) used any corporate funds (i) to make any unlawful political contribution or gift or for any
other unlawful purpose relating to any political activity; (ii) to make any unlawful payment to any governmental official or employee,
including without limitation any payments made in violation of the FCPA, the UK Bribery Act or the Spanish Criminal Code; or (iii) to
establish or maintain any unlawful or unrecorded fund or account of any nature; (b) made any false or fictitious entry, or failed to make
any entry that should have been made, in any of the books of account or other records of the Company; (c) made any payoff, influence payment,
bribe, rebate, kickback or unlawful payment to any Person; (d) performed any favor or given any gift which was not deductible for corporate
income tax purposes; (e) made any payment (whether or not lawful) to any Person, or provided (whether lawfully or unlawfully) any favor
or anything of value (whether in the form of property or services, or in any other form) to any Person, for the purpose of obtaining or
paying for (i) favorable treatment in securing business, or (ii) any other special concession; or (f) agreed, committed, offered or attempted
to take any of the actions described in clauses (a) through (e) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.28<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Personal Information and Privacy</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is in compliance in all material respects with the requirements of all Privacy Laws applicable to it which govern the
collection, use and disclosure of Personal Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.28(b) of the Disclosure Schedule sets forth and describes each distinct electronic or other database containing (in whole
or in part) Personal Information maintained by or for the Company at any time (each, a &ldquo;<B><I>Company Database</I></B>&rdquo;),
the types of Personal Information in each such database, the means by which the Personal Information was collected, and the security policies
that have been adopted and maintained with respect to each such database.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.28(c) of the Disclosure Schedule sets forth each privacy policy of the Company and any other industry privacy code or
privacy procedures to which the Company subscribes or is bound which governs its collection, use and disclosure of Personal Information
(each, a &ldquo;<B><I>Privacy Policy</I></B>&rdquo;) and identifies, with respect to each Privacy Policy, (i) the period of time during
which such privacy policy was or has been in effect; (ii) whether the terms of a later Privacy Policy apply to the data or information
collected under such Privacy Policy; and (iii) if applicable, the mechanism (such as opt-in, opt-out, or notice only) used to apply a
later Privacy Policy to data or information previously collected under such Privacy Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There is no complaint to or audit, proceeding, investigation or claim against, or to the Knowledge of the Company, threatened against,
the Company by any Governmental Body, or by any Person in respect of the collection, use or disclosure of Personal Information by any
Person in connection with the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) no breach or violation of any Privacy Policy has occurred or, to the Knowledge of the Company, is threatened; and (ii) there
has been no unauthorized or illegal uses of or access to any of the data or information in any of the Company Databases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is in compliance with all of the Privacy Policies and all applicable Privacy Laws and other Laws, User Data or Personal
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of (i) the execution, delivery, or performance of this Agreement or any Shareholder Related Agreements (or any of the other
ancillary agreements); (ii) the consummation of the transactions contemplated by this Agreement or any Shareholder Related Agreements
(or any of the other ancillary agreements); or (iii) to the Knowledge of the Company, the Purchaser&rsquo;s possession or use of the
User Data or any data or information in any of the Company Databases, will result in any breach or violation of any Privacy Policy or
any Privacy Laws and other Laws, User Data or Personal Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.29<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Filings</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company has made all required registrations
and filings with and submissions to all applicable Governmental Bodies relating to the operation of the business of the Company. There
is no false or misleading information or significant omission in any product application or other submission to the FDA or any other comparable
Governmental Body. All such registrations, filings and submissions were in compliance in all material respects with all Laws and other
requirements when filed. No material deficiencies have been asserted by any such applicable Governmental Bodies with respect to such registrations,
filings or submissions and no facts or circumstances exist which would indicate that a material deficiency may be asserted by any such
authority with respect to any such registration, filing or submission. The Company has delivered to the Purchaser copies of (a) all material
reports of inspection observations; (b) all material establishment inspection reports; (c) all material warning letters; and (d) any other
material documents received by the Company from the FDA or any other Governmental Body relating to the business of the Company that assert
ongoing material lack of compliance with any laws (including regulations promulgated by the FDA and any other Governmental Body) by the
Company. The Company has not received any Negative FDA Correspondence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.30<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Products and Product Candidates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Pipeline Technologies comprise all Company products or product candidates. Each of the Company&rsquo;s products and product
candidates is being, and at all times has been, developed, tested, authorized, manufactured, processed, labeled, stored, transported and
distributed, as applicable, in compliance in all respects with all applicable Laws, including those requirements relating to current good
manufacturing practices, good laboratory practices and good clinical practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company currently holds no Marketing Authorizations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Where the Company products or product candidates or their active ingredients are manufactured by third parties for the Company,
the Company has acted diligently in ensuring (including when executing the relevant contracts) that such Company products or product candidates
and active ingredients have the relevant Good Manufacturing Certificate and are compliant with all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not received any court or out-of-court claims or any complaints, warnings or notifications of any kind due to contingencies
resulting from nonconformity of any Company products, contingencies resulting from poor product safety, damages caused by defective Company
products, and they are not aware of any issue of this kind occurring now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has all Registrations and all other such permits, licenses, clearances, registrations, exemptions, patents, franchises,
certificates of need and other approvals, consents and other authorizations issued by the appropriate domestic or foreign regional, federal,
state, or local regulatory agencies or bodies necessary to conduct the business of the Company. The Company has not received any notice
of proceedings any court or out-of-court claims or any complaints, warnings or notifications relating to the revocation, termination,
modification or impairment of rights of any of the Registrations that, individually or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would reasonably be expected to result in a Company Material Adverse Effect; the Company has not failed
to submit to the FDA or EMA or AEMPS or any other Governmental Body any filings necessary to conduct the business of the Company, any
such filings that were required to be made were in compliance with applicable laws when filed, and no deficiencies have been asserted
by the FDA, the EMA, the AEMPS or any other Governmental Body with respect to any such filings or submissions that were made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the execution of this Agreement nor the consummation of the transactions contemplated by this Agreement require any consent
or approval of any third party or any Registration or authorization, permit, license, clearance, registration, exemption, patent, franchise
or any third party or any domestic or foreign regional, federal, state, or local regulatory agencies or bodies in order for the Company
to continue conducting its business as contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The clinical and pre-clinical trials of the product candidates conducted by or on behalf of the Company were, and if still pending,
are, being conducted in all respects in accordance with all clinical protocols, standard medical and scientific research procedures and
applicable Laws. The Company has not been notified by the FDA, EMA, AEMPS or any other Governmental Body of any restriction on the pre-clinical
trials conducted or currently being conducted by or on behalf of the Company. The descriptions of, protocols for, and data and other results
of, the pre-clinical and clinical studies and trials conducted or currently being conducted by or on behalf of the Company that have been
provided to the Purchaser are true, accurate, correct and complete, fairly present the data derived from such trials and comply with the
applicable Law. The Company has no knowledge of any other trials the results of which are inconsistent&nbsp;in any respect&nbsp;with or
otherwise call into question the results described to Purchaser; the Company&nbsp;has&nbsp;operated and&nbsp;is currently in compliance
with all applicable Law, statutes, rules and regulations of the Regulatory Authorities; the&nbsp;Company,&nbsp;has&nbsp;not received any
written notices, correspondence or other&nbsp;written&nbsp;communication from the Regulatory Authorities (including but not limited to
ethics committees of hospitals were the clinical trials of the product candidates are being conducted) or any governmental authority which
could lead to the termination or suspension of any clinical or pre-clinical trials and there are no reasonable grounds for same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, any third-party that is a supplier, manufacturer, or contractor for the Company is in compliance
with applicable Law, all Registrations and the authorizations, approvals, licenses, permits, certificates, or exemptions (including, without
limitation, pre-market approval applications, pre-market notifications, investigational new drug applications, biologic license applications,
manufacturing approvals and authorizations, pricing and reimbursement approvals, labeling approvals or their foreign equivalent) held
by the Company that are required for, among other things, the research, development, manufacture, processing, labeling, distribution,
marketing, storage, transportation, use, sale and provision of the products and services of the Company, of FDA, EMA, AEMPS or any other
comparable Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 2.30(k) of the Disclosure Schedule sets forth a true, correct and complete list of all of the Company&rsquo;s products
and product candidates, noting, where applicable, (i) the phase of clinical trial or development each product or product candidate is
in; and (ii) those products or product candidates where FDA, EMA, AEMPS and/or other Governmental Body, including foreign approvals, has
been applied for and/or received, and listing the application made and/or the approval or decision thereon obtained. The Company has provided
to the Purchaser true, correct and complete copies of, without limitation, (A) any investigational new drug applications or new drug applications
submitted to the FDA or EMA or AEMPS or any other Governmental Body by or on behalf of the Company, including any supplements thereto;
(B) all final study results and/or reports relating to Company products or product candidates; (C) all correspondence to or from the FDA,
EMA, AEMPS or other Governmental Bodies, including meeting minutes and records of contacts; (D) all documents in the Company&rsquo;s possession
related to inspections by the FDA, EMA, AEMPS or other Governmental Bodies; and (E) all information relating to adverse drug experiences
obtained or otherwise received by the Company from any source with respect to the Company products or product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.31<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>OFAC</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Neither the Company nor Representative of the Company, nor,
to the Knowledge of the Company, any other Person acting for or on behalf of the Company has: (a) been or is currently subject to any
United States sanctions administered by the Office of Foreign Assets Control of the United States Treasury Department (&ldquo;OFAC&rdquo;);
or (b) engaged or is currently engaging in any business or other dealings with, in, involving, or relating to (i) any country subject
to a comprehensive embargo under the sanctions administered by OFAC; or (ii) any Person subject to sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.32<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Anti-Bribery and Anti-Money Laundering Laws</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each of the Company,
its affiliates and any of their respective officers, directors, supervisors, managers, or employees, or to the Company&rsquo;s knowledge,
any agents acting on behalf of the Company, has not violated, its consummation of the contemplated transactions will not violate, and
the Company and each of its subsidiaries will institute and maintain policies and procedures designed to ensure continued compliance with,
each of the following laws to the extent applicable to the Company and its subsidiaries:&nbsp;&nbsp;anti-bribery laws, including but not
limited to, any applicable law, rule, or regulation of any locality, including but not limited to the Spanish Criminal Code (Organic Act
10/1995), as amended, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other&nbsp;applicable
anti-corruption or anti-bribery&nbsp;law, rule or regulation, or anti-money laundering laws, including but not limited to, applicable
federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without
limitation, Title 18 US. Code section 1956 and 1957, the Patriot Act,&nbsp;and&nbsp;the Bank Secrecy Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.33<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Related Party Transactions</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company has caused to be paid to
the Company all amounts owed to the Company by any Shareholder or any Related Party and any debts of the Company owed to any of the Shareholders
or any Related Party shall have been cancelled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.34<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices To Third Parties</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company shall have given all notices
to third parties and obtained all third-party consents (i) necessary, proper or advisable to consummate the transactions contemplated
by this Agreement; (ii) required to be given or obtained; or (iii) required to prevent a Company Material Adverse Effect, whether prior
to, on or following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.35 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Business</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company is a foreign business that is not organized under the
laws of the U.S. or any state thereof, is majority owned by persons who are not U.S. citizens or residents, more than 50% of its assets
are located outside the U.S &nbsp;and the majority of its executive officers and director are not U.S. citizens or residents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
III</FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><B>REPRESENTATIONS
AND WARRANTIES OF EACh shareholder</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on the
Disclosure Schedule, each Shareholder hereby represents and warrants to the Purchaser, severally and not jointly, as of the date of this
Agreement and as of the Closing Date, as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority, No Conflict; Required Filings and Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Shareholder has full power and authority to do and perform all acts and things to be done by him under this Agreement and
any Shareholder Related Agreement to which such Shareholder is a party. The Shareholder has all requisite power and authority to enter
into this Agreement and any Shareholder Related Agreement to which such Shareholder is a party, perform his obligations under this Agreement
and any Shareholder Related Agreement to which such Shareholder is a party and to consummate the transactions contemplated by this Agreement.
This Agreement has been duly executed and delivered by the Shareholder and constitutes the legal, valid and binding obligation of the
Shareholder, enforceable against the Shareholder in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting or relating to creditors&rsquo; rights generally; and (ii) the
availability of injunctive relief and other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the execution, delivery or performance by the Shareholder of this Agreement or any Shareholder Related Agreements, nor
the consummation of the transactions contemplated by this Agreement or any Shareholder Related Agreements, will directly or indirectly
(with or without notice or lapse of time, or both): (i) contravene, conflict with, or result in any violation or breach of, or constitute
(with or without notice or lapse of time, or both) a default (or give rise to a right of modification, termination, cancellation or acceleration
of any obligation or loss of any material benefit) under, require notice to any Person or a consent or waiver under, constitute a change
in control under, require the payment of a fee or penalty under or result in the creation or imposition of any Lien upon or with respect
to any asset owned or used by the Shareholder under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture,
lease, license, Contract or other agreement, instrument or obligation to which the Shareholder is a party or by which he or any of his
properties or assets may be bound; (ii) contravene, conflict with or violate, or give any Person the right to challenge any of the transactions
contemplated by this Agreement or any Shareholder Related Agreement or to exercise any remedy or obtain any relief under, any Law or any
order, writ, injunction, judgment or decree to which the Shareholder is subject; or (iii) contravene, conflict with or result in a violation
of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify,
any Governmental Authorization that is held by the Shareholder or that otherwise relates to the business of the Shareholder or to any
of the assets owned, used or controlled by the Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ownership; Title to Company Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Shareholder is the legal and full owner of the Shares shown as owned by the Shareholder on Section 3.2 of the Disclosure Schedule,
and the Shareholder has sole voting and dispositive power over such shares of Shares. The Shareholder has, and immediately prior to the
Closing, will have, good and valid title to the Shares to be sold by the Shareholder pursuant to this Agreement, free and clear of all
Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon (i) receipt by Grifols of Grifols&rsquo; portion of the Closing Consideration, and (ii) receipt by the Remaining Shareholders
of the Closing Shares in accordance with the terms of this Agreement, the Purchaser will receive good and valid title to the Shares, free
and clear of all Liens, without prejudice to the formalization of the transfer into public deed in Spain in accordance with Section 9.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no options, , calls, rights, commitments or agreements of any character to which the Shareholder is a party or by which
the Shareholder is bound obligating the Shareholder to exchange, transfer, deliver or sell, or cause to be exchanged, transferred, delivered
or sold, the Shares of the Company owned by the Shareholder or any security or rights convertible into or exchangeable or exercisable
for any such Shares. The Shareholder is not a party to or bound by any agreements or understandings with respect to the voting (including
pooling agreements, voting trusts and proxies) or sale or transfer (including agreements imposing transfer restrictions) of any of the
Shares or other equity interests of the Company owned by the Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">There are no Legal Proceedings pending or, to the
Knowledge of the Shareholder, threatened that relate to such Shareholder&rsquo;s ownership of any Share of the Company, or any option
or other right of such Shareholder to any Shares of the Company, or any right of such Shareholder to receive consideration as a result
of this Agreement, and there is no reasonable basis for any of the foregoing. There are no actions, suits, proceedings (including any
arbitration proceedings), orders, investigations or claims pending or, to the Knowledge of the Shareholder, threatened against or affecting
</FONT>the Shareholder in which it is sought to restrain or prohibit or to obtain damages or other relief in connection with the transactions
contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokerage and Transaction Bonuses</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">There are no claims for brokerage
commissions, finders&rsquo; fees or similar compensation in connection with the transactions contemplated by this Agreement based on any
arrangement or agreement binding upon the Shareholder. There are no special bonuses or other similar compensation payable to any employee
of the Shareholder in connection with the transactions contemplated by this Agreement and the Shareholder Related Agreements. The Shareholder
shall pay, and hold the Company, the Purchaser and its Affiliates harmless against, any liability, loss or expense (including reasonable
attorneys&rsquo; fees and out of pocket expenses) arising in connection with any such claim, brokerage commission, finders&rsquo; fee
or special bonus or other similar compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement
of Closing Cash Consideration and Milestone Consideration</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">Each Shareholder
acknowledges that the consideration being paid to Grifols is cash consideration, which includes the Closing Cash Consideration and the
Milestone Payments, and that the Remaining Shareholders have no interest in such payments and no objection to the different forms of consideration
provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
IV</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">REPRESENTATIONS
AND WARRANTIES OF REMAINING SHAREHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as set forth on the Disclosure Schedule,
each Remaining Shareholder hereby represents and warrants to the Purchaser, severally and not jointly, as of the date of this Agreement
and as of the Closing Date, as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restricted Securities</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Remaining Shareholder understands that
the Closing Shares have not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration
provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy
of the Remaining Shareholder&rsquo;s representations as expressed herein. The Remaining Shareholder understands that the Closing Shares
are &ldquo;restricted securities&rdquo; under applicable United States federal and state securities laws and that, pursuant to these laws,
the Remaining Shareholder must hold the Closing Shares indefinitely unless they are registered with the SEC and qualified by state authorities,
or an exemption from such registration and qualification requirements is available. The Remaining Shareholder further acknowledges that
if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited
to, the time and manner of sale, the holding period for the Closing Shares, and on requirements relating to the Purchaser which are outside
of the Remaining Shareholder&rsquo;s control, and which the Purchaser is under no obligation and may not be able to satisfy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accredited Investor; Non-U.S. Person</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Remaining
Shareholder is either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D promulgated under the Securities
Act or (ii) not a U.S. Person as defined in Regulation S promulgated under the Securities Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Bad Actor Disqualification Events</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Remaining Shareholder
is not subject to any &ldquo;bad actor&rdquo; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Experience</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Remaining Shareholder represents that
he is a sophisticated investor experienced in evaluating and investing in private placement transactions of securities of companies in
similar stage of development as the Purchaser and acknowledges that the Remaining Shareholder can bear the economic risk of his investment
for an indefinite period of time, and has such knowledge and experience in financial and business matters that he is capable of evaluating
the merits and </FONT>risks of the investment in the Closing Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Investors</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Remaining Shareholder
is not a United States person (as defined by Section 7701(a)(30) of the Code), the Remaining Shareholder hereby represents that he has
satisfied himself as to the full observance of the laws of Spain in connection with any invitation to subscribe for the Closing Shares
or any use of this Agreement, including (a) the legal requirements within his jurisdiction for the purchase of the Closing Shares; (b)
any foreign exchange restrictions applicable to such purchase; (c) any governmental or other consents that may need to be obtained; and
(d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of
the Closing Shares. The Remaining Shareholder&rsquo;s beneficial ownership of the Closing Shares will not violate any applicable securities
or other laws of Spain. If any Remaining Shareholder is not an accredited investor then the Remaining Shareholder is not a U.S. Person
as that term is defined in Regulation S promulgated under the Securities Act; has a principal address is outside the United States, has
no present intention of becoming a resident of or moving its principal place of business to the United States, executed and delivered
this Agreement when located outside the United States and acquiring the Closing Shares solely for the Buyer&rsquo;s own account and not
for the account or the benefit of a U.S. Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No General Solicitation</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Neither the Remaining Shareholder, nor
any of his officers, managers, employees, agents, members or partners has either directly or indirectly, including through a broker or
finder (a) engaged in any general solicitation; or (b) received or reviewed any advertisement in connection with the offer and sale of
the Closing Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Residence</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Remaining Shareholder resides in the state or province
identified in the address of the Shareholder set forth on the signature page hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Legends</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Remaining Shareholder understands that the Closing
Shares acquired hereunder and any securities issued in respect of or exchange therefor may bear any one or more of the following legends:
(a) any legend required by the securities laws of any state to the extent such laws are applicable to the Closing Shares represented by
the certificate so legended; and (b) customary legends to the effect that the Closing Shares has not been registered under the Securities
Act and that the transfer thereof may be accordingly restricted; provided, however, that such legends shall be removed by the Purchaser
from any certificate or book-entry security entitlement evidencing the Closing Shares upon delivery by a Remaining Shareholder to the
Purchaser of a written request to that effect if at the time of such written request a registration statement under the Securities Act
is at that time in effect with respect to the legended security and such Shareholder is not an affiliate of the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Purpose; Disclosure of Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Remaining Shareholder has requested, received, reviewed and considered all the information the Remaining Shareholder deems necessary,
appropriate or relevant as a prudent and knowledgeable investor in evaluating the investment in Closing Shares, including, without limitation,
the Purchaser SEC Documents. The Remaining Shareholder further represents that the Remaining Shareholder has had an opportunity to ask
questions of and receive answers from the Purchaser regarding the terms and conditions of the offering of the Closing Shares and the business,
prospects and financial condition of the Purchaser necessary to verify the accuracy of any information furnished to the Remaining Shareholder
or to which the Remaining Shareholder had access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Remaining Shareholder is acquiring the Closing Shares pursuant to this Agreement for the Remaining Shareholder&rsquo;s own account for
investment purposes only and with no present intention of distributing any Closing Shares, and no arrangement or understanding exists
with any other persons regarding the distribution of Closing Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
V.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">REPRESENTATIONS
AND WARRANTIES OF THE PURCHASER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Purchaser represents and warrants to the Company
and each of the Shareholders, as of the date of this Agreement and as of the Closing Date, as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization and Good Standing</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Purchaser is a corporation
duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, has all requisite and necessary
power and authority to own, lease, use and operate its properties and assets and to carry on and conduct its business as now being conducted
and as proposed to be conducted as of the Closing Date and is in good standing as a foreign corporation (or equivalent status in the relevant
jurisdiction) in each jurisdiction in which the character of the properties it owns, operates or leases or the nature of its activities
makes such qualification necessary or advisable. The Purchaser has full corporate power and authority to do and perform all acts and things
to be done by it under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority, No Conflict; Required Filings and Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has all requisite corporate power and authority to enter into this Agreement, perform its obligations under this Agreement and
to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and the consummation of the
transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of the Purchaser,
and no other corporate action or proceeding on the part of the Purchaser or its boards of directors is necessary to authorize the execution,
delivery or performance of this Agreement, or the consummation of the transactions contemplated by this Agreement. This Agreement has
been duly executed and delivered by the Purchaser and constitutes the legal, valid and binding obligations of the Purchaser, enforceable
against the Purchaser in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting or relating to creditors&rsquo; rights generally; and (ii) the availability of injunctive relief
and other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution, delivery or performance by the Purchaser of this Agreement, nor the consummation of the transactions contemplated by this Agreement,
will directly or indirectly (with or without notice or lapse of time, or both): (i) contravene, conflict with, or result in any violation
or breach of, any of the Organizational Documents of the Purchaser; (ii) contravene, conflict with, or result in any violation or breach
of, or constitute (with or without notice or lapse of time, or both) a default (or give rise to a right of modification, termination,
cancellation or acceleration of any obligation or loss of any material benefit) under, require notice to any Person or a consent or waiver
under, constitute a change in control under, require the payment of a fee or penalty under or result in the creation or imposition of
any Lien upon or with respect to any asset owned or used by the Purchaser under, any of the terms, conditions or provisions of any note,
bond, mortgage, indenture, lease, license, Contract or other agreement, instrument or obligation to which the Purchaser is a party or
by which it or any of its properties or assets may be bound; (iii) contravene, conflict with or violate, or give any Person the right
to challenge any of the transactions contemplated by this Agreement or to exercise any remedy or obtain any relief under, any Law or any
order, writ, injunction, judgment or decree to which the Purchaser is subject; or (iv) contravene, conflict with or result in a violation
of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify,
any Governmental Authorization that is held by the Purchaser or that otherwise relates to the business of the Purchaser or to any of the
assets owned, used or controlled by the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Governmental Authorization, or registration, declaration, notice or filing with, any Governmental Body, excluding to the extent required,
filings of applications or notices required under the Foreign Investments Act, is required by or with respect to the Purchaser: (i) in
connection with the execution and delivery of this Agreement or by the Purchaser or the consummation by the Purchaser of the transactions
contemplated by this Agreement; or (ii) necessary for the Purchaser to operate its business immediately after the Closing in the same
manner as operated immediately prior to the Closing after giving effect to the consummation of the transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SEC Filings; Financial Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
January 1, 2021, the Purchaser has filed with the SEC all required reports and filings (the &ldquo;<B><I>Purchaser SEC Documents</I></B>&rdquo;).
As of the time of filing with the SEC (or, if amended or superseded by a filing prior to the date hereof, then on the date of such filing):
(i) each of the Purchaser SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the
Exchange Act (as the case may be); and (ii) none of the Purchaser SEC Documents contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The Purchaser is in compliance, in all material respects, with the applicable listing rules
of NYSE American LLC (the &ldquo;<B><I>NYSE American</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#9;&#9;The consolidated
financial statements contained in the Purchaser SEC Documents: (i) complied as to form in all material respects with the published rules
and regulations of the SEC applicable thereto; (ii) were prepared in accordance with United States generally accepted accounting principles
as in effect from time to time, applied on a consistent basis throughout the periods covered, except as may be indicated in the notes
to such consolidated financial statements and (in the case of unaudited statements) as permitted by Form 10-Q of the SEC, and except that
unaudited financial statements may not contain footnotes and are subject to year-end audit adjustments; and (iii) fairly present, in all
material respects, the consolidated financial position of the Purchaser as of the respective dates thereof and the consolidated results
of operations of the Purchaser for the periods covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchaser Stock Consideration</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Closing Shares will be, prior
to the issuance, duly authorized, and when issued in accordance with the terms of this Agreement, will be validly issued, fully paid and
non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sufficiency of Funds</U><FONT STYLE="font-size: 10pt">. Purchaser has and will as of the Closing have sufficient cash on hand
or other sources of immediately available funds to enable it to make payment of the Closing Cash Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
VI</FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">CERTAIN
COVENANTS AND AGREEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Due Diligence Access and Investigation</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">During the period from
the date of this Agreement to the earlier of the termination of this Agreement pursuant to <B>ARTICLE X</B> and the Closing Date (the
 &ldquo;<B><I>Pre-Closing Period</I></B>&rdquo;), the Company and the Shareholders agree that the Purchaser shall be entitled, through
its officers, employees and representatives (including, without limitation, its legal advisors and accountants), to make such investigation
of the properties, businesses and operations of the Company and such examination of the books, records and financial condition of the
Company as it reasonably requests and to make extracts and copies of such books and records. No investigation by the Purchaser prior
to or after the date of this Agreement shall diminish or obviate any of the representations, warranties, covenants or agreements of the
Company or any Shareholder contained in this Agreement or the Related Shareholder Documents. In order that the Purchaser may have full
opportunity to make such physical, business,</FONT> accounting and legal review, examination or investigation as it may reasonably request
of the affairs of the Company, the Company and the Shareholders shall cause the officers, employees, consultants, agents, accountants,
attorneys and other representatives of the Company to cooperate fully with such representatives in connection with such review and examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Operation of the Company&rsquo;s Business</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Pre-Closing Period, the Shareholders shall cause the Company to: (i) ensure that the Company conducts its business and operations
(A) in the ordinary course of business consistent with past practice, and (B) in compliance with all applicable Laws and the requirements
of all Material Contracts and Governmental Authorizations held by the Company; (ii) use best efforts to ensure that the Company preserves
intact its current business organization, keep available the services of its current officers, directors, employees and consultants and
maintain its relations and goodwill with all suppliers, customers, landlords, creditors, licensors, licensees, employees, consultants
and other Persons having business relationships with the Company; (iii) maintain the books, records and financial statements of the Company
in accordance with Spanish GAAP and consistent with past practice; (iv) provide all notices, assurances and support required by any Company
Contract in order to ensure that no condition under such Company Contract occurs which could result in, or could increase the likelihood
of any transfer or disclosure by the Company of any Intellectual Property Rights; and (v) keep in full force and effect (with the same
scope and limits of coverage) all insurance policies in effect as of the date of this Agreement covering all material assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the foregoing, except as expressly contemplated by the terms of this Agreement, during the Pre-Closing Period the Company shall
not (without the prior written consent of the Purchaser):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) declare, accrue, set aside or pay any dividends on, or make any other distributions (whether in cash, stock, shares or property)
in respect of, any of its share capital or other equity or voting interests; (B) authorize for issuance or issue and deliver any additional
shares of its share capital or rights convertible into or exchangeable for shares of its share capital, or grant any right, option or
other commitment for the issuance of shares of its share capital; (C) split, combine or reclassify any of its shares of share capital
or other equity or voting interests; (D) purchase, redeem or otherwise acquire any of its share capital of the Company, any Company Option
or any Company Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend or waive any of its rights under, or accelerate the vesting under, any provision of the Company Stock Option Plan, any provision
of any Contract related to any Company Option or any restricted share purchase agreement as in effect as of the date of this Agreement,
or otherwise modify any of the terms of any Company Option or any related Contract as in effect as of the date of this Agreement, other
than as required to terminate all outstanding Company Options as of the Closing in accordance with Section 1.5;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend or permit the adoption of any amendment to the Organizational Documents of the Company, or effect, become a party to or authorize
any Acquisition Transaction, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>adopt a plan of complete or partial liquidation or dissolution or resolutions providing for or authorizing such a liquidation or
a dissolution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>form any Subsidiary or acquire any equity interest or other interest in any other Entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> make any capital expenditure outside the ordinary course of business or make any single capital expenditure in excess of $25,000;
<I><U>provided</U>, <U>however</U></I>, that the maximum amount of all capital expenditures made on behalf of the Company, taken as a
whole, during the Pre-Closing Period shall not exceed $50,000 in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>enter into or become bound by, or permit any of the assets owned or used by it to become bound by, any Material Contract or any
Contract, lease, agreement or instrument that would be required to be set forth on Section 2.13(a) of the Disclosure Schedule if it were
entered into on or prior to the date of this Agreement, or amend or terminate, or waive or exercise any material right or remedy under,
any Material Contract or any Contract, lease, agreement or instrument that would be required to be set forth on Section 2.13(a) of the
Disclosure Schedule if it were entered into on or prior to the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>acquire, lease or license any right or other asset from any other Person or sell or otherwise dispose of, or lease, license or
encumber, any right or other asset to any other Person (except in each case for assets acquired, leased, non-exclusively licensed, encumbered
or disposed of by the Company in the ordinary course of business consistent with past practice and not having a value, or not requiring
payments to be made or received, in excess of $25,000 individually, or $50,000 in the aggregate), or waive or relinquish any claim or
right;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>repurchase, repay or prepay any Indebtedness, or incur any Indebtedness in excess of $25,000, or guarantee any Indebtedness of
another Person, guarantee any debt securities of another Person, enter into any &ldquo;keep well&rdquo; or other agreement to maintain
any financial statement condition of another Person or enter into any arrangement having the economic effect of any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>grant, create, incur or suffer to exist any Lien on the assets of the Company that did not exist on the date of this Agreement
or write down the value of any asset or investment on the books or records of the Company, except for depreciation and amortization in
the ordinary course of business consistent with the Company&rsquo;s past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make any loans, advances or capital contributions to, or investments in, any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>increase in any manner the compensation or benefits of, or pay any bonus to, any officer, director or independent contractor of
the Company or hire any employees, except for (A) increases in the ordinary course of business consistent with the Company&rsquo;s past
practice in base compensation for any employee or independent contractor of the Company (other than executive officers or directors of
the Company whose annualized compensation is $125,000 or more or whose annual compensation for the 12-month period following the Expiration
Date is expected to be $125,000 or more) that were communicated to such employee or independent contractor prior to the date of this Agreement;
or (B) as required by Applicable Benefit Laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>hire any new Employee at the level of vice president or above or with an annual base salary in excess of $75,000, dismiss any Employee,
promote any Employee except in order to fill a position vacated after the date of this Agreement, or engage any independent contractor
whose relationship may not be terminated by the Company on seven days&rsquo; notice or less;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as required applicable Laws, make or change any Tax election, change its fiscal year, revalue any of its material assets
or adopt or make any changes in financial or Tax accounting methods, principles or practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> enter into any closing agreement or Tax ruling, settle or compromise any Tax claim or assessment, consent to any extension or
waiver of the limitation period applicable to any Tax claim or assessment, or file any Tax Return (including any amended Tax Return) unless
such Tax Return has been provided to the Purchaser for review within a reasonable period prior to the due date for filing and the Purchaser
has consented to such filing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>commence, settle or compromise any Legal Proceedings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) dispose of or permit to lapse any ownership and/or right to the use of, or fail to protect, defend and maintain the ownership,
validity and registration of, the Company Intellectual Property, or (B) dispose of or disclose to any Person, any Confidential Information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>take or omit to take any action that could, or is reasonably likely to, (A) result in any of its representations and warranties
set forth in this Agreement or any Shareholder Related Agreement to which it is a party being or becoming untrue in any material respect
at any time at or prior to the Closing; (B) result in any of the conditions to the consummation of the transactions contemplated by this
Agreement not being satisfied; (C) cause the Company to be unable to conduct its business after the Closing in accordance with its past
practice and as contemplated to be conducted by the Company as of the Closing after giving effect to the transactions contemplated by
this Agreement; or (D) constitute or result in a breach of any of the provisions of this Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>authorize, agree, commit or enter into any Contract to take any of the actions described in clauses (i) through (xviii) of this
Section 6.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Contract
Manufacturing and Regulatory Services Agreements</U>. (a) Under the prior direction and determination of the Purchaser and as soon
as reasonably practicable as of the execution of this Agreement, the Company shall (and the Shareholders shall cause the Company to)
enter into a contract manufacturing services agreement (the &quot;<B><I>Contract Manufacturing Agreement</I></B>&quot;) a contract
regulatory services (the &quot;<B><I>Contract Regulatory Agreement</I></B>&quot;) and clinical services agreement (the
 &quot;<B><I>Clinical Services Agreement</I></B>&quot; and together with the Contract Manufacturing Agreement and the Contract
Regulatory Agreement, the &quot;<B><I>Interim Agreements</I></B>&quot;) that have been pre-approved by Purchaser with corresponding
counterparties of good standing and capabilities in the market and in customary terms to these type of transactions, all of which
with the aim of accelerating the completion of certain research and development activities of the Company as further foreseen in <B>EXHIBIT
E</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For the purposes of the financing of such transactions, the Purchaser and the Company shall enter into an interim financing facility
as further outlined in <B>EXHIBIT F</B> (the &quot;<B><I>Interim Financing Loan</I></B>&quot;), whereby the Purchaser agrees to loan
to the Company (i) the lesser of (i)(a) $250,000 and (b) the amount of money necessary to secure the next production slot with Thermo
Fisher, which loan shall be used by the Company solely to secure such slot, (ii) the lesser of (a) $125,000 and (b) the amount of money
necessary to secure the next production slot with GenIBET, which loan shall be used by the Company solely to secure such slot, and (iii)
the lesser of (a) $50,000 and (b) the amount required to pay a CRO for a feasibility study, such loaned funds to be used solely to pay
for the feasibility study. If the Agreement is terminated for any reason prior to any such funding, Purchaser shall not be required to
fund any of the foregoing. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company shall refund to Purchaser by wire transfer
of immediately available funds any amounts then outstanding under the Interim Financing Facility upon the earlier of: (i) five Business
Days after this Agreement is terminated by mutual written consent under Section 10.1(a)(i); (ii) five Business Days after this Agreement
is terminated by Purchaser under Section 10.1(a)(ii) ; <B><I>subject to, and provided that,</I></B> a Company Material Adverse Event
shall have occurred; (iii) five Business Days after the Expiration Date; or (iv) five Business Days after notification of the Spanish
competent body in accordance with Article 7 bis of the Foreign Investments Act that it will not approve the transactions </FONT>contemplated
by this Agreement<FONT STYLE="font-family: Times New Roman, Times, Serif">. Any amounts not paid to Purchaser when due shall bear interest
at the rate of 5% per annum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification</U>. During the Pre-Closing Period, the Company and each Shareholder shall immediately notify the Purchaser in
writing of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
discovery by the Company or any Shareholder of any event, condition, fact or circumstance that occurred or existed on or prior to the
date of this Agreement and that caused or constitutes an inaccuracy in or breach of any representation or warranty made by the Company
or the Shareholders in this Agreement, any Shareholder Related Agreement or any agreements contemplated by this Agreement or the Shareholder
Related Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any event, condition, fact or circumstance that occurs, arises or exists after the date of this Agreement and that would cause
or constitute an inaccuracy in or breach of any representation or warranty made by the Company or any Shareholder in this Agreement if
(i) such representation or warranty had been made as of the time of the occurrence, existence or discovery of such event, condition, fact
or circumstance; or (ii) such event, condition, fact or circumstance had occurred, arisen or existed on or prior to the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
breach of any covenant or obligation of the Company or any Shareholder under this Agreement, any Shareholder Related Agreement or any
agreements contemplated by this Agreement or the Shareholder Related Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
event, condition, fact or circumstance that has made, could reasonably be expected to make, or is likely to make, the timely satisfaction
of any condition set forth in this Agreement impossible or unlikely or that has had or could reasonably be expected to have a Company
Material Adverse Effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;receipt
of any Negative FDA Correspondence or trial results, including any serious adverse events or adverse events; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)
any notice or other communication from any Person alleging that the consent or approval of such Person is or may be required in connection
with the transactions contemplated by this Agreement; and (ii) any Legal Proceeding or claim threatened, commenced or asserted against
or with respect to the Company or the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">No notification given to the Purchaser pursuant to
this Section 6.3 shall limit or otherwise affect any of the representations, warranties, covenants or obligations of the Company or the
Shareholders, or any of the rights of the Purchaser, contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interim Financials</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">As promptly as practicable following each
calendar month prior to the Closing Date, the Company shall deliver to the Purchaser periodic financial reports in the form that it customarily
prepares for its internal purposes and, if available, unaudited statements of the financial position of the Company as of the last day
of such calendar month and statements of income and changes in financial position of the Company for the calendar month then ended (the
 &ldquo;<B><I>Monthly Financial Statements</I></B>&rdquo;). In addition, as promptly as practicable following each calendar quarter prior
to the Closing Date, the Company shall deliver to the Purchaser periodic financial reports in the form that it customarily prepares for
its internal purposes, including an unaudited balance sheet of the Company as of the end of such quarter and the related unaudited statements
of income, shareholders&rsquo; equity and cash flow for the six, nine or twelve months then ended, as applicable (the &ldquo;<B><I>Quarterly
Financial Statements</I></B>&rdquo;). The Company shall support the Purchaser in any and all financial reporting as required by governing
bodies. The Company </FONT>covenants that the Monthly Financial Statements and the Quarterly Financial Statements (a) shall present fairly
the financial condition of the Company as of their respective dates and the related results of its operations for the respective calendar
month then ended; and (b) shall be prepared on a basis consistent with prior interim periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Release of Grifols' Guarantees</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">As soon as reasonably practicable
following the date hereof, the Parties hereby commit to collaborate and devote commercially reasonable efforts to effectively as of the
Closing Date replace and release Grifols from any guarantee, security or bond granted by Grifols to the Company in connection with any
obligation of the Company with respect to any third parties that are creditors under the liabilities related to the Specified Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Public Announcements</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">During the Pre-Closing Period, none of the
Parties shall (and the Shareholders shall cause the Company not permit any of its Representatives to) issue any press release or make
any public statement regarding this Agreement or any of the transactions contemplated by this Agreement without obtaining the prior written
approval (which approval will not be unreasonably withheld or delayed) of the other Parties hereto, unless in the reasonable judgment
of the Party intending to make such issuance, disclosure is otherwise required by applicable Law. Each of the Parties agrees that until
the Purchaser files this Agreement with the U.S Securities and Exchange Commission the terms of this Agreement shall not be disclosed
or otherwise made available to the public and that copies of this Agreement shall not be publicly filed or otherwise made available to
the public, except where such disclosure, availability or filing is required by applicable Law and only to the extent required by such
Law and except to such Parties&rsquo; equity holders and lenders. In the event that such disclosure, availability or filing is required
by applicable Law, each Party agrees to use its commercially reasonable efforts to obtain confidential treatment of this Agreement with
any governmental authority and to redact such terms of this Agreement the other Parties shall request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reasonable Efforts; Further Assurances; Cooperation</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to
the other provisions of this Agreement, each party shall use its reasonable, good faith efforts to perform its obligations under this
Agreement and to take, or cause to be taken, and do, or cause to be done, all things necessary, proper or advisable under applicable Law
to cause the transactions contemplated by this Agreement to be effected as soon as practicable, but in any event on or prior to the Expiration
Date, in accordance with the terms of this Agreement, and shall cooperate fully with each other party and its Representatives in connection
with any step required to be taken as a part of its obligations under this Agreement, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each party shall promptly and as soon as reasonably practicable as of the execution of this Agreement, make its filings and submissions
and shall take all actions necessary, proper or advisable under applicable Laws to obtain any required approval of any Governmental Body
with jurisdiction over the transactions contemplated by this Agreement, including any filings, documentation, writs as required under
the Foreign Investment Act. (except that the Purchaser shall have no obligation to take or consent to the taking of any action required
by any such Governmental Body that could adversely affect the business or assets of the Purchaser or the transactions contemplated by
this Agreement or the Purchaser Related Agreements). The Company shall provide to the Purchaser all information required for any application
or other filing to be made by the Company pursuant to any applicable Law in connection with the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each party shall promptly notify the other parties of (and provide written copies of) any communications from or with any Governmental
Body in connection with the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event any claim, action, suit, investigation or other proceeding by any Governmental Body or other Person is commenced
that questions the validity or legality of the transactions contemplated by this Agreement or seeks damages in connection therewith,
the parties shall (i) cooperate and use all reasonable efforts to defend against such claim, action, suit, investigation or other proceeding,
(ii) in the event an injunction or other order is issued in any such action, suit or other proceeding, use all reasonable efforts to
have such injunction or other order lifted, and (iii) cooperate reasonably regarding any other impediment to the consummation of the
transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall, at the Company&rsquo;s sole cost and expense, give all notices to third parties and use its commercially reasonable
efforts (in consultation with the Purchaser) to obtain all third-party consents (i) necessary, proper or advisable to consummate the transactions
contemplated by this Agreement by the Company; (ii) required to be given or obtained by the Company; or (iii) required to prevent a Company
Material Adverse Effect, whether prior to, on or following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Periods Ending on or Before the Closing Date</U>. The Shareholders shall cause the Company to prepare or cause to be prepared
and timely file or cause to be timely filed all Tax Returns for the Company for all Tax periods ending on or prior to the Closing Date
that are due after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Periods Beginning Before and Ending After the Closing Date</U>. The Shareholders shall cause the Company to prepare or cause
to be prepared and timely file or cause to be timely filed any Tax Returns of the Company for Tax periods that begin on or before the
Closing Date and end after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation on Tax Matters</U>. The Purchaser, the Company and the Shareholders shall cooperate as and to the extent reasonably
requested by the other party, in connection with the filing of Tax Returns pursuant to this Section 6.7 and any audit, litigation or other
proceeding with respect to Taxes. Such cooperation shall include the retention and (upon the other party&rsquo;s request) the provision
of records and information that are reasonably relevant to any such audit, litigation or other proceeding and making employees or agents
available on a mutually convenient basis to provide additional information and explanation of any material provided under this Section
6.7(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Taxes</U>. Any transfer, documentary, stamp or other similar Taxes or recording fees payable as a result of the purchase
and sale of the Company Shares and the transfer of the certificates representing the same (other than any domestic or foreign Taxes measured
by or based upon income or gains imposed upon the Purchaser) shall be paid by the Shareholders (severally but not jointly). The parties
shall cooperate in the preparation, execution and filing of all returns, questionnaires, applications and other documents regarding any
such transfer, documentary, stamp or other similar Taxes and recording fees that become payable in connection with the transactions contemplated
by this Agreement that are required or permitted to be filed at or prior to the Closing. For the avoidance of doubt, the sole transfer,
documentary, stamp and other Taxes and recording fees within the purview of this Section 6.7(d) are those specifically relating to the
transfer of the Shares and the certificates representing the same, and any other transfer or recording fees arising out of the transactions
(such as fees in connection with applications or re-applications for state licenses as a result of a change in control, and in connection
with any applications for transfers of Company Registrations with the USPTO), are expressly excluded from this Section 6.7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Tax Allocation, Indemnity or Sharing Agreements</U>. Any Tax allocation, indemnity or sharing agreement between
the Company and any other Person shall be terminated as to the Company on or prior to the Closing Date, and after the Closing Date neither
the Company nor the Purchaser shall have any liability thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other</U>.
The Company shall have received all Spanish and Catalonia tax credits, rebates and related research and development benefits that are
available to it prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation with Financial Reporting</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Shareholders shall cooperate
to the extent reasonably requested by the Purchaser after the Closing, in connection with the preparation and auditing of financials for
the Company. The Remaining Shareholders&rsquo; shall provide all of the financial records and supporting documentation of the Company
within ten (10) days following the Closing and shall make employees or agents available on a mutually convenient basis to provide additional
information and explanation of any information provided under this Section 6.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Release</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">In consideration for the Closing Consideration, and by
executing this Agreement, as of and following the Closing Date, each Shareholder knowingly, voluntarily and unconditionally releases,
forever discharges, and covenants not to sue the Company or the Purchaser from or for any and all claims, causes of action, demands, suits,
debts, obligations, liabilities, damages, losses, costs and expenses (including attorneys&rsquo; fees) of every kind or nature whatsoever,
known or unknown, actual or potential, suspected or unsuspected, fixed or contingent, that such Shareholder has or may have, now or in
the future, arising out of, relating to, or resulting from any act or omission, error, negligence, breach of contract, tort, violation
of law, matter or cause whatsoever from the beginning of time to the Closing Date, including without limitation any claim related to Company
Options or Company Rights held by such Shareholder that are terminated as of the Closing; provided, however, that the foregoing release
shall not apply to any claims arising out of this Agreement, the Shareholder Related Agreements or claims as an employee or otherwise
unrelated to a Shareholder&rsquo;s status as an equity holder of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.12 <U>Shareholder Approval
and Waiver of Right of First Refusal</U>. By execution and delivery of this Agreement, each Shareholder (i) consents, ratifies and approves
the transactions contemplated by this Agreement for purposes of Article 9 of the Bylaws of the Company (the &ldquo;<B><I>Company Shareholder
Approval</I></B>&rdquo;), and (ii) waives the provisions of Article 9 of the Bylaws of the Company with respect to the transfer of the
Shares contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
VII</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">CONDITIONS
PRECEDENT TO THE OBLIGATIONS OF THE PURCHASER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligations of the Purchaser to consummate
the transactions contemplated by this Agreement are subject to the satisfaction (or written waiver by the Purchaser), at or prior to the
Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accuracy of Representations</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each of the representations and warranties
of the Shareholders contained in this Agreement that are qualified as to materiality shall be true and correct in all respects, and each
of the representations and warranties of the Shareholders contained in this Agreement and the Shareholder Related Agreements that are
not so qualified shall be true and correct in all material respects, in each case as of the date of this Agreement and the Shareholder
Related Agreements and as of the Closing Date with the same force and effect as though made as of the Closing Date (except to the extent
that any such representation and warranty expressly speaks as of a specific date, in which case the accuracy </FONT>of such representation
and warranty shall be determined as of such date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Covenants</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each of the covenants and obligations
set forth in this Agreement that the Company and each of the Shareholders is required to comply with or perform at or prior to the Closing
shall have been complied with or performed in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Compliance Certificate</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company shall have delivered,
or caused to be delivered, to the Purchaser a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company
as to compliance with the conditions set forth in Section 7.1, Section 7.2, and Section 7.8 (the &ldquo;<B><I>Company Compliance Certificate</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consents</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">All consents, approvals, orders or authorizations of,
or registrations, declarations or filings with, any Person required in connection with the execution, delivery or performance of this
Agreement, the Shareholder Related Agreements, and approval of the Spanish government of the foreign direct investment of the Purchaser
shall have been obtained by the Company, or made by or on behalf of the Company (with the Purchaser advancing to the Company any funds
required for any payments to be made in connection therewith), and shall be in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Secretary&rsquo;s Certificate</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company shall have delivered
a certificate, dated as of the Closing Date, signed by the Secretary of the board of directors of Company certifying that (i) according
to the Shareholders Registry Book, the Shareholders are the owners of the Shares, (ii) according to the Shareholders Registry Book, the
Shares are free and clear from any Liens, and that (iii) all requirements for the transfer of the Shares to the Purchaser set forth under
applicable Law, the Company&rsquo;s by-laws and any applicable agreement have been duly fulfilled and (iv) the incumbency, signature and
authority of the officers of the Company authorized to execute, deliver and perform this Agreement and all other documents, instruments
or agreements related thereto executed or to be executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ancillary Agreements and Deliveries</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company and the Shareholders
shall have delivered, or caused to be delivered, to the Purchaser the following agreements and documents, each of which shall be in full
force and effect as of the Closing and shall not have been amended or modified as of the Closing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the consents, in substantially the form of <B>EXHIBIT C</B> hereto, executed by the spouse of each of the Shareholders that is
married in any other regime than the Catalan supplementary regime and the resolutions of the General Shareholders Meeting of each Shareholder,
where applicable and legally required, to comply with Article 160 (f) of the Spanish Companies Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the organizational record books and minute books of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>written resignations of the directors and officers of the Company, effective as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>an electronic copy of the Shareholders Registry Book, duly updated until Closing, containing the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the name and address of record of each Shareholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the number, class and numbering of the Shares of the Company held by each Shareholder immediately prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>each Remaining Shareholder&rsquo;s Consideration Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> evidence that each consent, approval, order or authorization of, or registration, declaration or filing with any Person required
in connection with the execution, delivery or performance of this Agreement has been obtained or made and is in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>true, correct and complete copies, certified by the Chief Executive Officer of the Company, of the Company Financial Statements
and any Quarterly Financial Statements required to be delivered pursuant to Section 6.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) a true, correct and complete copy of resolutions adopted by the general meeting of shareholders and/or the board of directors
of the Company providing for the termination of each of the Company Options, and Company Rights in order to give effect to the transactions
contemplated by this Agreement, and (ii) certificate issued by the Secretary and Chairman of the Company's board of directors certifying
that no holder of Company Options or Company Rights has any right to acquire Company Shares and that all liabilities of the Company under
the Company Options or Company Rights are fully extinguished at no cost, and with no liability, to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>copy of the termination agreement terminating the Existing Shareholders Agreement in relation to the Company in force prior to
the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all other documents required to be entered into by the Company and the Shareholders pursuant to this Agreement or reasonably requested
by the Purchaser to convey the Shares to the Purchaser or to otherwise consummate the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evidence
of the revocation of powers of attorney to draw on or make withdrawals of the bank accounts listed on <U>Section 2.23</U> of the Company
Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Release of Liens</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company shall have delivered, or caused to
be delivered, to the Purchaser evidence that all Liens (other than Permitted Liens) affecting any of the assets of the Company have been
released.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Adverse Effect</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">There shall not have occurred a Company
Material Adverse Effect that is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Restraints</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">No temporary restraining order, preliminary or permanent
injunction or other order preventing the consummation of the transactions contemplated by this Agreement shall have been issued by any
Governmental Body, and there shall not be any Law enacted or deemed applicable to the transactions contemplated by this Agreement that
makes the transactions contemplated by this Agreement illegal or unduly burdensome to the Parties or would subject the Parties to sanctions
if the transactions contemplated by this Agreement are consummated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>No
Negative Regulatory Correspondence</U>.<FONT STYLE="font-family: Times New Roman, Times, Serif"> The Company shall not have received
any Negative Regulatory Correspondence. No clinical trials shall be subject to a hold or termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Financial Statements</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">The Company and the Shareholders hereby
covenant with and undertake to the Purchaser that they shall cause the Company&rsquo;s independent registered public accounting firm,
to: deliver to the Purchaser any consent that the Purchaser is obligated to file with the SEC with respect to the Company Financial Statements,
any Quarterly Financial Statements required to be delivered pursuant to Section 5.4 and the reference to them as &ldquo;experts&rdquo;
in any filing of the Purchaser with the SEC that includes the Company Financial Statements and any Quarterly Financial Statements required
to be delivered pursuant to Section 5.4 and audited financial statements of the Company for the years ended December 31, 2019 and 2020
(and if the closing occurs after the Purchaser files its annual report on Form</FONT> 10-K for the year ended December 31, 2021, then
audited financial statement of the Company for the year ended December 31, 2021) and the unaudited financial statements of the Company
for the nine months ended September 301, 2021. The Company and the Remaining Shareholders hereby covenant with and undertake to the Purchaser
that they shall use their best efforts to cooperate with the Purchaser to permit the Purchaser to prepare and file, in compliance with
SEC reporting requirements (Rule 3-05 Regulation S-X of the Exchange Act), a Current Report on Form 8-K with respect to the transactions
contemplated by this Agreement. In addition, the Company and the Remaining Shareholders hereby covenant with and undertake to the Purchaser
that they shall use their best efforts to cooperate with the Purchaser to provide the information necessary for the Purchaser&rsquo;s
preparation of pro forma financial statements specified and described in Article 11 of Regulation S-X of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>NYSE Matters.</U> NYSE shall have (i) completed its review of the Supplemental Listing Application submitted by the Purchaser
and (ii) approved the Purchaser&rsquo;s issuance of the Closing Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.13<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Laboratory Sublease</U>. The Company, as lessee, and Grifols (or a designated Affiliate), as lessor, shall have entered into a laboratory
sublease agreement, substantially in the form set forth in Schedule 7.13.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accredited Investor and Bad Actor Questionnaire</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each Remaining
Shareholder shall be an accredited investor and shall not have engaged in any bad actor disqualifying events and shall have completed
an Accredited Investor and Bad Actor Questionnaire in the form attached as EXHIBIT D to this Agreement evidencing that they are an Accredited
Investor and have engaged in any bad actor disqualifying events. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transition Services Agreement</U>. If requested by Purchaser, the Company and Grifols shall have entered into a transition
services agreement to be mutually agreed between the Parties, whereby Grifols shall provide certain transition services to the Company
for a period up to 6 months after Closing and at the cost incurred by Grifols for the provision of any such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of the Pooling Agreement</U>. The cash pooling agreement dated July 16, 2021 entered into between GrifolsS.A.
Banco Bilbao Vizcaya Argentaria, S.A. and the Company and other companies and banks that had acceded such agreement shall be terminated
with respect to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
VIII</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">CONDITIONS
PRECEDENT TO OBLIGATIONS OF THE COMPANY AND THE SHAREHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligations of the Company and the Shareholders
to consummate the transactions contemplated by this Agreement are subject to the satisfaction (or written waiver by the Shareholders&rsquo;),
at or prior to the Closing, of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accuracy of Representations</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each of the representations and warranties
of the Purchaser contained in this Agreement shall be true and correct, in each case as of the date of this Agreement and as of the Closing
Date with the same force and effect as though made as of the Closing Date (except to the extent that any such representation and warranty
expressly speaks as of a specific date, in which case the accuracy of such representation and warranty shall be determined as of such
date) except where the failure of such representations and warranties to be so true and correct (without regard for any &ldquo;material,&rdquo;
 &ldquo;Purchaser Material Adverse Effect&rdquo; or similar qualification) would not, individually or in the aggregate, constitute a Purchaser
Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Covenants</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each of the covenants and obligations
set forth in this </FONT>Agreement that the Purchaser is required to comply with or perform at or prior to the Closing shall have been
complied with or performed in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchaser Compliance Certificate</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Purchaser shall have delivered,
or caused to be delivered, to the Company, a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Purchaser
as to compliance with the conditions set forth in Section 8.1, Section 8.2, and Section 8.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ancillary Agreements and Deliveries</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Purchaser shall have delivered,
or caused to be delivered, to the Shareholders, all other documents required to be entered into or delivered by the Purchaser at or prior
to the Closing pursuant to this Agreement, each of which shall be in full force and effect as of the Closing and shall not have been amended
or modified as of the Closing including evidence of registration with the Purchaser&rsquo;s transfer agent in the books of the Purchaser
of the issuance to each Remaining Shareholder of the number of Closing Shares to be issued to such Remaining Shareholder as set forth
on Schedule 1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Restraints</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">No temporary restraining order, preliminary or permanent
injunction or other order preventing the consummation of the transactions contemplated by this Agreement shall have been issued by any
Governmental Body, and there shall not be any Law enacted or deemed applicable to the transactions contemplated by this Agreement that
makes the transactions contemplated by this Agreement illegal or unduly burdensome to the Purchaser or would subject the Purchaser or
the Company to sanctions if the transactions contemplated by this Agreement are consummated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consents</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">All consents approvals, orders or authorizations of,
or registrations, declarations or filings with, any Governmental Body shall have been obtained. In particular, the investment resulting
from the transactions contemplated under this Agreement shall have been authorized (without being subject to any conditions) by the Spanish
competent body in accordance with Article 7 bis of the Foreign Investments Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>NYSE Matters.</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">The Purchaser shall have delivered to the Company
written evidence that NYSE has (i) completed its review of the Supplemental Listing Application submitted by the Purchaser and (ii) approved
the Purchaser&rsquo;s issuance of the Closing Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Adverse Effect</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Since the date of this Agreement, there
shall not have occurred a Purchaser Material Adverse Effect that is continuing. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Release of Guaranty</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Grifols (and any Affiliates thereto) shall
have received documentation evidencing its release for all purposes and with effects as of the Closing Date, from each and all security,
guaranties granted by Grifols (or any Affiliates thereto) with respect to the performance and payment of any obligations assumed by the
Company in connection with the Specified Indebtedness or the Purchaser shall simultaneously with the Closing cause the Company to repay
(or cause Purchaser to assume) any loan set forth on Section 2.6(c) of the Disclosure Schedule of which Grifols or any Affiliate thereto
has provided any guarantee not released at Closing with respect to such Specified Indebtedness. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
IX</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">CLOSING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Closing</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Unless otherwise mutually agreed in writing between the
Purchaser and the Shareholders, the Closing shall take place at the offices of Gracin &amp; Marlow, LLP, on or before 4:00 P.M. (Eastern
Time) on the fourth Business Day after the last conditions set forth in <B>ARTICLE VII</B> and <B>ARTICLE VIII</B> are satisfied or waived
in accordance with this Agreement (other than those conditions that by their terms are to be satisfied at the Closing, it being understood
that the occurrence of the Closing shall remain subject to the satisfaction or waiver of such conditions at the Closing). The date on
which the Closing actually takes place is referred to in this Agreement as the &ldquo;<B><I>Closing Date</I></B>&rdquo;. All actions to
be taken and documents to be executed and delivered by the Parties at the Closing shall be deemed to have been taken and executed simultaneously,
and no actions shall be deemed to have been taken nor documents executed or delivered until all have been taken, executed and delivered.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Shareholder and Company Closing Deliveries</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">At the Closing, the
Shareholders and the Company, as applicable, shall deliver, or cause to be delivered, to the Purchaser, the deliverables, agreements and
documents required pursuant to Section 8.6, each of which shall be in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchaser Closing Deliveries</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">At the Closing, the Purchaser shall
deliver, or cause to be delivered, to the Shareholders the deliverables, agreements and documents required by Section 8.4, each of which
shall be in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Actions</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">At the Closing, the Parties shall carry on the
following actions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Shareholders will deliver letters of resignation from all the directors of the Company, all stating that they have no claims
against the Company. The Shareholders will ensure that the members of the Company&rsquo;s governing bodies and anyone who, owing to their
position, has authority to certify under article 109 of the Spanish Commercial Registry Regulations (<I>Reglamento del Registro Mercantil</I>)
execute the pertinent resolutions for the purposes provided under article 111 of the Spanish Commercial Registry Regulations or sign the
corresponding letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Purchaser will sign the corporate resolutions to appoint a new management body for the Company or a management team, or both,
and will adopt any other corporate resolutions it considers appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Protocolization of this Agreement before a Spanish notary public</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
Parties shall notarize this Agreement before a notary public in Barcelona (Spain) no later than 10 days as of Closing, both the notary
and the date to be agreed by the Parties. To that effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Parties shall exhibit powers of attorney granting sufficient authority for the execution of the referred public deed and all
complementary actions foreseen in this Agreement to this end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Shareholder, where applicable, shall exhibit to the notary public the certification of the minutes of the shareholders meeting
authorizing the transaction under article 160 (f) of the Spanish Companies Act.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Shareholders shall deliver to the Purchaser the corresponding deeds of ownership of the Shares, the notary public will record
this purchase in the deeds, and the newly appointed secretary to the board of directors of the Company shall also make a record of the
purchase in the Shareholders Registry Book.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Purchaser shall cause the Company to notarize the corporate resolutions approved at Closing, including, among others, the dismissal
of the directors of the Company and the appointment of new ones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Purchaser shall cause the Company to execute a public deed stating the Company has become a sole shareholder company, to the
effects provided for in article 13 of the Spanish Companies Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
X</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement may be terminated prior to the Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by mutual written consent of the Purchaser and the Shareholders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by written notice from the Purchaser to the Shareholders, if there has been a material breach of any representation, warranty,
covenant or agreement by the Company or the Shareholders, or any such representation or warranty shall become untrue after the date of
this Agreement, such that the conditions in Section 7.1 or Section 7.2 would not be satisfied and such breach is not curable or, if curable,
is not cured within the earlier of (A) thirty (30) days after written notice thereof is given by the Purchaser to the Shareholders, and
(B) the Expiration Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by written notice from the Shareholders to the Purchaser, if there has been a material breach of any representation, warranty,
covenant or agreement by the Purchaser, or any such representation or warranty shall become untrue after the date of this Agreement, such
that the conditions in Section 8.1 or Section 8.2 would not be satisfied and such breach is not curable or, if curable, is not cured within
the earlier of (A) thirty (30) days after written notice thereof is given by the Shareholders to the Purchaser; and (B) the Expiration
Date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by five (5) days&rsquo; prior written notice by the Shareholders to the Purchaser or the Purchaser to the Shareholders, as the
case may be, in the event the Closing has not occurred on or prior to 31 July 2022 (the &ldquo;<B><I>Expiration Date</I></B>&rdquo;) for
any reason other than delay or nonperformance of or breach by the party seeking such termination; <I>provided</I> that the parties may
mutually agree, in writing, to extend the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">All fees and expenses incurred in connection with this
Agreement and the contemplated transactions shall be paid by the Party incurring such expenses, whether or not the contemplated transactions
is consummated. All fees and expenses incurred or to be incurred by the Parties in connection with the notarization of this Agreement
shall be borne by the Shareholders and the Purchaser on a 50/50 basis. Any other fees and expenses incurred or to be incurred by any the
Shareholders or the Purchaser in connection with contemplated transactions and preparing, negotiating and entering into this Agreement
and the performance of their obligations under this Agreement shall be paid by such Party. Any other fees and expenses incurred or to
be incurred by the Company in connection with contemplated transactions and preparing, negotiating and entering into this Agreement and
the performance of their obligations under this Agreement shall be paid by the Shareholders in cash at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
XI</FONT>.&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">INDEMNIFICATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1 Intentionally Omitted</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of the Purchaser Indemnified Parties</U><FONT STYLE="font-size: 10pt">. (a) From and after the Closing Date,
subject to the limitations set forth in Section 11.3 and Section 11.6, the Shareholders will jointly and severally indemnify and hold
harmless the Purchaser (including the Company after the Closing), the officers and directors of the Purchaser, and their respective successors
and assigns (other than Persons who were officers, directors, managers, employees, agents, partners, Representatives, successors and assigns
of the Company immediately prior to the Closing) (collectively, the &ldquo;<B><I>Purchaser Indemnified Parties</I></B>&rdquo;) from and
against, any and all Losses incurred or sustained by, or imposed upon, any of the Purchaser Indemnified Parties based upon, arising or
resulting from (a) any breach of any representation or warranty of the Shareholders set forth in Article II, Article III or Article IV
or in any related certificate or instrument delivered by or on behalf of the Shareholders or the Company pursuant to this Agreement, (b)
any breach of any covenant or agreement of the Shareholders or the Company set forth in this Agreement or (c) any penalties or liabilities
incurred by Company or Purchaser for the failure to have its own separate environmental license issued by the municipality council of
Sant Cugat del Valles (the &ldquo;Permit Failure&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Shareholder shall, severally and not jointly, indemnify the Indemnified Parties and save and hold each of them harmless against and pay
on behalf of or reimburse such Indemnified Parties as and when incurred for any Losses which any such Indemnified Party may suffer, sustain
or become subject to, as a result of, in connection with, arising out of, relating or incidental to or by virtue of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any inaccuracy in or breach of any representation or warranty of such Shareholder set forth in <B>ARTICLE III or IV</B>, whether
such representation or warranty is made as of the date of this Agreement or as of the Closing Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any non-fulfillment or breach of any covenant, agreement or undertaking made by such Shareholder in this Agreement or any of the
Schedules or Exhibits attached to this Agreement, or in any Shareholder Related Agreement to which such Shareholder is a party; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any penalties or liabilities incurred by Company or Purchaser resulting from a Permit Failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the Company suffers, incurs or otherwise becomes subject to any Losses as a result of or in connection with any inaccuracy
in or breach or alleged breach of any representation, warranty, covenant or obligation of the Company or the Shareholders or other matter
referred to in Section 11.1(a) or Section 11.1(b), then (without limiting any of the rights of the Purchaser as an Indemnified Party)
the Purchaser shall also be deemed, by virtue of their ownership of the Company Shares, to have suffered, incurred or otherwise become
subject to Losses as a result of and in connection with such inaccuracy, breach, alleged breach or other matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Shareholders shall not have and shall not exercise or assert (or attempt to exercise or assert), any right of contribution, right of indemnity
or other right or remedy against the Company in connection with any indemnification obligation or any liability to which such current
or former shareholders of the Company may become subject under or in connection with this Agreement or any other agreement or document
delivered to the Purchaser in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
Procedure</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A Party that seeks indemnity under this Article XI (an &ldquo;<B><I>Indemnified Party</I></B>&rdquo;) will give written notice
(a &ldquo;<B><I>Claim Notice</I></B>&rdquo;) to the Party from whom indemnification is sought (an &ldquo;<B><I>Indemnifying Party</I></B>&rdquo;)
whether the Losses sought arise from matters solely between the Parties or from Third Party Claims described in this Article. The Claim
Notice must contain (i) a description and, if known, the estimated amount of any Losses incurred or reasonably expected to be incurred
by the Indemnified Party, (ii) the basis for the Claim Notice to the extent of the facts then known by the Indemnified Party and (iii)
a demand for payment of those Losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly following receipt by an Indemnified Party of notice by a third-party (including any Governmental Body) of any complaint,
dispute or claim or the commencement of any audit, investigation, action or proceeding with respect to which such Indemnified Party may
be entitled to indemnification pursuant to this Agreement (a &ldquo;<B><I>Third-Party Claim</I></B>&rdquo;), or upon realization of a
Loss by an Indemnified Party for which the Indemnified Party is entitled to indemnification under this <B>ARTICLE XI</B>, such Indemnified
Party shall provide written notice thereof to the Indemnifying Party; <I><U>provided</U>, <U>however</U></I>, that the failure to so notify
the Indemnifying Party shall relieve the Indemnifying Party from liability under this <B>ARTICLE XI</B> with respect to such Third-Party
Claim only if, and only to the extent that, such failure to so notify the Indemnifying Party materially prejudices the rights and defenses
otherwise available to the Indemnifying Party with respect to such Third-Party Claim or otherwise materially adversely affects the rights
of the Indemnifying Party with respect thereto. The Indemnifying Party shall have the right, upon written notice from the Indemnifying
Party delivered to the Indemnified Party within ten (10) Business Days thereafter assuming full responsibility for any Losses resulting
from such Third-Party Claim, to assume the defense of such Third-Party Claim, including the employment of counsel reasonably satisfactory
to the Indemnified Party and the payment of the fees and disbursements of such counsel <I><U>provided</U></I>, <I><U>however</U></I>,
that the Indemnifying Party shall not have the right to assume the defense of any Third-Party Claim that (i) affects any Intellectual
Property Rights that the Company owns or has a right to use in the conduct of its business as currently conducted and as proposed to be
conducted by the Company as of the Closing Date, (ii) is asserted directly by or on behalf of any Person that is a supplier or a customer
of the Company, the Indemnified Party or their Affiliates, (iii) seeks an injunction or other equitable relief against the Indemnified
Party or its Affiliates, (iv) involves a finding of any violation of Law or other wrongdoing by the Indemnified Party, the Company or
their Affiliates, (v) relates to or arises in connection with any criminal proceeding, action, indictment, allegation or investigation,
or (vi) does not seek only monetary damages and, in the case of this clause (vi), the Indemnified Party reasonably believes an adverse
determination with respect to the Third-Party Claim would be detrimental to or materially injure the reputation or future business prospects
of the Indemnified Party. In the event, however, that the Indemnifying Party declines or fails to assume the defense of such Third-Party
Claim on the terms of this Section within such ten (10) Business Day period, or thereafter defaults in continuing to defend the Indemnified
Party, then any Losses shall include the reasonable fees and disbursements of counsel for the Indemnified Party as incurred..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In any Third-Party Claim for which indemnification is being sought under this <B>ARTICLE XI</B>, the Indemnified Party or the Indemnifying
Party, whichever is not assuming the defense of such Third-Party Claim, shall have the right to participate in such matter and to retain
its own counsel at such party&rsquo;s own expense. The Indemnifying Party or the Indemnified Party (as the case may be) shall at all times
use reasonable efforts to keep the Indemnifying Party or Indemnified Party (as the case may be) reasonably apprised of the status of the
defense of any matter, the defense of which it is maintaining, and to cooperate in good faith with the other party with respect to the
defense of any such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Indemnified Party may settle or compromise any Third-Party Claim or consent to the entry of any judgment with respect to which
indemnification is being sought under this <B>ARTICLE XI</B> without the prior written consent of the Indemnifying Party. An Indemnifying
Party may not, without the prior written consent of the Indemnified Party, settle or compromise any Third-Party Claim or consent to the
entry of any judgment with respect to which indemnification is being sought under this <B>ARTICLE XI</B> unless such settlement, compromise
or consent (A) includes an unconditional release of the Indemnified Party and its officers, directors, employees and Affiliates from
all liability arising out of, or related to, such Third-Party Claim, (B) does not contain any admission or statement suggesting any wrongdoing
or liability on behalf of the Indemnified Party, and (C) does not contain any equitable order, judgment or term that in any manner affects,
restrains or interferes with the business of the Indemnified Party or any of the Indemnified Party&rsquo;s Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event an Indemnified Party claims a right to payment pursuant to this Agreement with respect to any Loss or other matter
not involving a Third-Party Claim (a &ldquo;<B><I>Direct Claim</I></B>&rdquo;), such Indemnified Party shall send written notice of such
claim to the Indemnifying Party (a &ldquo;<B><I>Notice of Claim</I></B>&rdquo;). Such Notice of Claim shall specify the basis for such
Direct Claim. The failure by any Indemnified Party to so notify the Indemnifying Party shall not relieve the Indemnifying Party from any
liability that it may have to such Indemnified Party with respect to any Direct Claim made pursuant to this Section, it being understood
that Notices of Claim in respect of a breach of a representation or warranty must be delivered prior to the expiration of the survival
period for such representation or warranty under Section 11.3. In the event the Shareholders does not notify the Indemnified Party within
ten (10) Business Days following its receipt of such Notice of Claim that the Shareholders disputes the Indemnifying Parties&rsquo; liability
to the Indemnified Party under this <B>ARTICLE XI</B> or the amount thereof, the Direct Claim specified by the Indemnified Party in such
Notice of Claim shall be conclusively deemed a liability of the Indemnifying Party under this <B>ARTICLE XI</B>. In the event the Shareholders
has timely disputed its liability with respect to such Direct Claim as provided in this Section 11.2(d), as promptly as reasonably practicable,
such Indemnified Party and the Shareholders shall establish the merits and amount of such Direct Claim (by mutual agreement, litigation
or otherwise) and, within five (5) Business Days following the final determination of the merits and amount of such Direct Claim, the
Indemnifying Party shall pay to the Indemnified Party in accordance with the offset mechanism pursuant to Section 11.5 or otherwise an
amount equal to such Direct Claim as determined pursuant to this Section 11.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival Period</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The representations, warranties and covenants
made by the Company and the Shareholders in this Agreement shall not be extinguished by the Closing, but shall survive the Closing for,
and all claims for indemnification in connection therewith shall be asserted not later than, twenty one (21) months following the Closing
Date; provided, however, that (a) each of the Fundamental Representations shall survive the Closing without limitation as to time, and
the period during which a claim for indemnification may be asserted in connection therewith shall continue indefinitely; (b) each of
the representations and warranties contained in Section 2.12 (Intellectual Property) shall survive the Closing for, and all claims for
indemnification in connection therewith shall be asserted not later than, six (6) years following the Closing Date; (c) each of the representations
and warranties in Section 2.15 (Environmental Matters), shall survive the Closing until, and all claims for indemnification in connection
therewith shall be asserted not later than 60 days following, the expiration of any statute of limitations applicable to the rights of
any Person to bring any claim with respect to such matters; and (d) each of the representations and warranties contained in Section 2.9
(Taxes) shall survive until, and all claims for indemnification in connection therewith shall be asserted not later than the later to
occur of: (i) the 180th day following the end of the period, if any, during which an assessment, reassessment or other form of document
assessing liability for Taxes or Social Security contributions in respect of any fiscal year to which these representations and warranties
extend could be issued to the Company, and (ii) 60 days following the expiration of any statute of limitations applicable to the rights
of any Person to bring any claim with respect to such matters. Notwithstanding the foregoing, if, prior to the close of business on the
last day a claim for indemnification may be asserted under this ARTICLE XI, the Shareholders shall have been properly notified of a claim
for indemnity under this ARTICLE XI and such claim shall not have been finally resolved or disposed of as of such date, such claim shall
continue to survive and shall remain a basis for indemnity under this ARTICLE XI until such claim is finally resolved or disposed of
in accordance with the terms of this Agreement. All representations, warranties and covenants made by the Purchaser shall </FONT>continue
in accordance with their respective terms. Subject at all times to the limitations set forth in this <B>ARTICLE XI</B>, the covenants
and agreements of the parties pursuant to this <B>ARTICLE XI</B> shall survive without limitation as to time, and the period during which
a claim for indemnification may be asserted in connection therewith shall continue indefinitely, subject to applicable statutes of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investigations.</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">This Agreement (including the Schedules and Exhibits
hereto and the documents and instruments referred to in this Agreement that are to be delivered at the Closing) constitutes the entire
agreement among the Parties and supersedes any prior understandings, agreements or representations by or among the Parties, or any of
them, written or oral, with respect to the subject matter of this Agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Purchaser acknowledges and agrees that the representations and warranties set forth in <U>Article II, Article III</U> and <U>Article
IV </U>are the only representations and warranties made by the applicable Party with respect to the Company or any other matter relating
to the transactions contemplated by this Agreement. The Purchaser acknowledges and agrees that the representations and warranties contained
in Article II, Article III and Article IV are in lieu of, and the Purchaser hereby expressly waives all rights to, any implied or legal
warranties that may otherwise be applicable because of the provisions of any Law, including the warranties of merchantability and fitness
for a particular purpose. without limiting the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Purchaser is relying on its own investigation, examination and valuation of the Company in effecting the transactions contemplated
by this Agreement. The Purchaser has made all inspections and investigations of the Company deemed necessary or desirable by the Purchaser.
The Purchaser is entering into this Agreement and consummating the transactions contemplated by this Agreement based on the results of
its inspections and investigations, and not on any representation or warranty of the Shareholders or any of their respective Affiliates
not expressly set forth in this Agreement. in light of these inspections and investigations and the representations and warranties made
to the Purchaser in this Agreement, the Purchaser is relinquishing any right to any claim based on any representations and warranties
other than those expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In connection with the Purchaser&rsquo;s investigation of the Company, the Purchaser has received from the Shareholders and the
Company various forward&ndash;looking statements regarding the Company and its businesses, including estimates, assumptions, projections,
budgets, forecasts and plans. the Purchaser acknowledges and agrees that (i) there are uncertainties inherent in forward&ndash;looking
statements of this type, (ii) the Purchaser is familiar with such uncertainties, (iii) the Purchaser is taking full responsibility for
making its own investigation, examination and valuation of the Company and has employed outside professionals to assist it with the foregoing,
(iv) the Purchaser is taking full responsibility for making its own evaluation of the adequacy and accuracy of all forward&ndash;looking
statements, the Purchaser is not relying on any forward&ndash;looking statement in any manner whatsoever and (v) with respect to the foregoing,
the Purchaser will have no recourse or remedy against the Company or any of the Shareholders Indemnified Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Offset Against Milestone Payments</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">In furtherance of the foregoing,
in addition to any other remedies, in the event any Indemnified Party shall suffer any Losses for which such Indemnified Party is entitled
to indemnification under this <B>ARTICLE XI</B>, such Indemnified Party shall be entitled to recover such Losses by offsetting such Losses
against any Milestone Payments that have yet to be paid or are otherwise payable by the Purchaser or the Company to any Shareholder or
other Indemnifying Party. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnity Cap</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Purchaser Indemnified Party shall not be entitled to indemnification under Article XI unless the aggregate amount of the Losses
for which a right of indemnification is provided thereunder, exceeds $50,000 (the &quot;<B><I>Indemnification Basket</I></B>&quot;),
in which event the Purchaser Indemnified Party shall be entitled to indemnification for all such Losses from the first dollar; provided,
however, that the Indemnification Basket shall not apply to claims resulting from breaches of any of the Fundamental Representations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth in this Section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the aggregate amount of Losses for which the Shareholders shall be required to indemnify Purchaser Indemnified Parties under this
Article XI shall not exceed fifty percent (50%) of the then aggregate consideration received by Grifols under the Closing Cash Consideration
and the then paid Milestone Payments from time to time (the &quot;<B><I>General Indemnification Cap</I></B>&quot;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>notwithstanding the foregoing, the aggregate amount of Losses for which Shareholders shall be required to indemnify any Person
under this Article XI, in connection with Losses related to any breach of, or inaccuracy in any of the Fundamental Representations, or
the representations set forth in Sections 2.9, 2.12 and 2.15 shall not exceed 100% of the then aggregate consideration received by Grifols
under the Closing Cash Consideration and the then paid Milestone Payments from time to time (the &quot;<B><I>Special Indemnification Cap</I></B>&quot;).
In addition, neither the General Indemnification Cap nor the Special Indemnification Cap shall apply with respect to Losses related to
fraud or willful or intentional misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any time the Losses exceed either the General Indemnification Cap or the Special Indemnification Cap then the amount of any such excess
shall be applied against future increases in the General Indemnification Cap or the Special Indemnification Cap. For example if a Loss
for which the Shareholders shall be required to indemnify Purchaser Indemnified Parties under this Article XI is $10,000,000 and the only
consideration paid to date has been the Closing Cash Consideration then the $5,3000,000 Loss shall be applied to and reduce the Milestone
Payments when achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Double Recovery and no Double Counting</U><FONT STYLE="font-size: 10pt">. No Party may recover for breach of or under this
Agreement or otherwise more than once in respect of the same Losses suffered or amount for which the Party is otherwise entitled to claim
(or part of such Losses or amount), and no amount (including any relief) (or part of any amount) shall be taken into account or credited
more than once for breach of or under this Agreement or otherwise, with the intent that there will be no double counting for breach of
or under this Agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Shareholders shall not be liable for any claim if
and to the extent that the Losses in respect of which such claim is made are covered by an insurance policy or other recovery which the
Purchaser and/or the Company have in place and for which the Company is fully reimbursed for such Losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Characterization of Indemnification Payments</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Purchaser and
the Shareholders agree to treat any payment made under this <B>ARTICLE XI</B> as an adjustment to the Closing Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
XII</FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>POST CLOSING COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Research Funding</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Purchaser will commit to fund Company&rsquo;s
research and development programs, including but not limited to VCN01 PDAC phase 2 trial, VCN01 RB pivotal trial and necessary G&amp;A
within the budgetary plan in EXHIBIT E. If discussions with the FDA, the EMA, the AEMPS or any other regulatory agency materially impact
the cost and timing of the proposed VCN01 clinical trials for PDAC and RB, Purchaser and Company VCN will use their best efforts to continue
to advance these</FONT> programs after taking into account any new guidance from the regulators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Project Commitment</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Purchaser will use commercially reasonable
efforts to cause the milestone events specified in Section 1.3 to be satisfied as promptly as reasonably possible following the Closing.
Without limiting the generality of the foregoing, the Purchaser will cause the Company to use commercially reasonable efforts to carry
out its research and development programs for VCN01 PDAC phase 2 trial and VCN01 RB pivotal trial in such manner as is reasonably necessary
in order to achieve each of the milestones associated with the Milestone Payments. Notwithstanding the foregoing, the Company shall only
be required to use the same efforts that a similarly situated company would reasonably devote with respect to its own product with similar
commercial potential at a similar stage in the research, development or commercialization lifecycle, taking into consideration the anticipated
profitability and cost to obtain the supplemental BLA</FONT> and <FONT STYLE="font-family: Times New Roman, Times, Serif">shall not be
required to continue any research and development program if a prior study does not meet its primary endpoints.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bhatavia</U> Litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As regards certain litigation procedure against [<FONT STYLE="font-family: Times New Roman, Times, Serif">Bhatavia</FONT>], the
Purchaser commits to cause the Company to allow Grifols to continue assuming exclusive control over such proceedings and any related negotiations,
settlements or conducts of such Bhatavia Litigation. The Purchaser agrees, and undertakes to cause the Company, to use reasonable efforts
to cooperate if the cost or expense for such efforts is paid by Grifols, as regards the Bhatavia Litigation with Grifols and counsel so
designated by Grifols in the Bhatavia Litigation and the Purchaser also agrees, and undertakes to cause the Company to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>provide Grifols and counsel designated thereby in connection with Bhatavia Litigation with full access to the books and records
of the Company and to provide any assistance as may reasonably be requested for the purposes of defending, settling, appealing, or otherwise
pursuing such Bhatavia Litigation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>provide any supporting documentation reasonably requested for the purposes of defending, settling, appealing, or otherwise pursuing
the Bhatavia Litigation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>cooperate appropriately, including granting powers of attorney to the legal counsel designated by Grifols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Grifols shall bear all costs and expenses related to the conduct of the Bhatavia Litigation and, as the case may be, provide the
Company with any provisions of funds (<I>provisi&oacute;n de fondos</I>) that may be required to attend such cost and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Parties further acknowledge and agree that the Company and the Purchaser shall (i) be hold harmless for any Losses arising
from the Bhatavia Litigation; and (ii) not participate or take the benefit from any actual benefit, payment, indemnification or other
reimbursement to the Company or any of its Affiliates that is derived from the Bhatavia Litigation, which will be promptly paid to Grifols
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any payments made by the Purchaser or Grifols under this Clause shall be deemed to reduce or increase, as applicable, the Purchase
Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Non-Competition</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>&#9;For a period of three (3) years from and after the Closing Date, none of the Shareholders who either have served as an officer
of director of the Company or helped organize the Company as a founder or any of the officers or directors of Grifols shall directly
or indirectly engage in a business or enterprise (either as proprietor, partner, employee, agent, consultant, or controlling shareholder)
or sell, pledge, assign or license any product or Intellectual Property Rights related and limited to oncolytic virus technology that
would be competitive with the products currently contemplated by the Company (a &quot;<B><I>Competing Business</I></B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>&#9;The provisions of this Section 12.2 shall not prevent a Shareholder from investing its assets in securities of any corporation,
or otherwise acquiring an equity interest in any enterprise, equity securities of which are publicly owned and traded, provided that such
investments or interests shall not result in (i) the Shareholder owning beneficially, in the aggregate, five percent (5%) or more of the
equity securities of any enterprise engaged in a Competing Business or (ii) the Shareholder being able to control or actively participate
in the policy decisions of such Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT> &#9;It is the desire and intent of the parties that the provisions of this <U>Section 12.2</U> shall be enforced to the fullest
extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. If any particular provision
or portion of this <U>Section 12.2</U> shall be adjudicated to be invalid or unenforceable in any jurisdiction, this <U>Section 12.2</U>
shall be deemed amended to delete there from such provision or portion adjudicated to be invalid or unenforceable, such amendment to apply
only with respect to the operation of this subsection (c) in the particular jurisdiction in which such adjudication is made. The Shareholders
each agree that it would be difficult to measure the damages to Purchaser from the breach by of the provisions of this <U>Section 12.2</U>,
that injury to Purchaser from such breach may be impossible to calculate, and that monetary damages may therefore be an inadequate remedy;
accordingly, the Shareholders each agree that Purchaser shall be entitled, in addition to all other remedies it might have, to seek injunctions
or other appropriate orders to restrain any such breach without showing or proving any actual damages. Nothing herein shall be construed
as prohibiting Purchaser from pursuing any other remedies for such breach or threatened breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>&#9;The undertakings and covenants of the Shareholders contained in this <U>Section 12.2</U> are an integral part of the transactions
set forth in this Agreement and the consideration paid by Purchaser pursuant to this Agreement shall be consideration not only for the
Shares but also for such undertakings and covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
XIII</FONT>&#9;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">MISCELLANEOUS
PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Further Assurances</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each party to this Agreement shall execute
and cause to be delivered to each other party to this Agreement such instruments and other documents, and shall take such other actions,
as such other parties may reasonably request (prior to, at or after the Closing) for the purpose of carrying out or evidencing any of
the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fees and Expenses</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each party to this Agreement shall bear and
pay all fees, costs and expenses (including legal fees and accounting fees) that have been incurred or that are incurred by such party
in connection with the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver; Amendment</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Any agreement on the part of a party to this
Agreement to any extension or waiver of any provision of this Agreement shall be valid only if set forth in an instrument in writing
signed on behalf of such party. A waiver by a party to this Agreement of the performance of any covenant, agreement, obligation, condition,
representation or warranty shall not be construed as a waiver of any other covenant, agreement, obligation, condition, representation
or warranty. A waiver by any party to this Agreement of the performance of any act shall not constitute a waiver of the performance of
any</FONT> other act or an identical act required to be performed at a later time<FONT STYLE="font-family: Times New Roman, Times, Serif">.
Prior to the Closing, this Agreement may not be amended, modified or supplemented except by written agreement among the Purchaser, the
Company and the Shareholders. Following the Closing, this Agreement may not be amended, modified, altered or supplemented except by written
agreement between the Purchaser and the Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">This Agreement and the other agreements referred
to in this Agreement constitute the entire agreement among the parties to this Agreement and supersede all other prior agreements and
understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement and thereof;
provided, however, that the confidentiality agreement between the Purchaser and the Company (the &ldquo;<B><I>Confidentiality Agreement</I></B>&rdquo;)
shall not be superseded by this Agreement and shall remain in effect in accordance with its terms until the earlier of: (a) the Closing
Date, or (b) the date on which the Confidentiality Agreement is terminated in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Execution of Agreement; Counterparts; Electronic Signatures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which, when taken
together, shall constitute one and the same instrument, and shall become effective when counterparts have been signed by each of the parties
to this Agreement and delivered to the other parties to this Agreement; it being understood that all parties to this Agreement need not
sign the same counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement and any amendments to this Agreement may be executed in one or more counterparts, each of which shall be enforceable
against the parties to this Agreement that execute such counterparts, and all of which together shall constitute one and the same instrument.
Facsimile and &ldquo;.pdf&rdquo; copies of signed signature pages shall be deemed binding originals and no party to this Agreement shall
raise the use of facsimile machine or electronic transmission in &ldquo;.pdf&rdquo; as a defense to the formation of a contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law; Exclusive Jurisdiction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement and the relationship of the parties hereto shall be governed by and construed in accordance with the internal laws
(and not the law of conflicts) of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the parties hereto agrees that any suit, action, or proceeding seeking to enforce any provision of, or based on any matter
arising out of or in connection with, this Agreement shall be brought solely in any state or federal court sitting in the State of Delaware.
Each of the parties hereto consents to the jurisdiction of such court (and of the appropriate appellate courts therefrom) in any such
suit, action, or proceeding and irrevocably agrees not to commence any litigation relating thereto except in such court, and each further
waives any objection to the laying of venue of any such litigation in such court and agrees not to plead or claim in such court that such
litigation brought therein has been brought in an inconvenient forum. Any party hereto may make service on another party by sending or
delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section
13.10. Nothing in this Section 13.6, however, shall affect the right of any Person to serve legal process in any other manner permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>WAIVER OF JURY TRIAL</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">EACH OF THE PARTIES TO THIS AGREEMENT HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ALL RIGHTS TO A TRIAL BY JURY IN ANY ACTION, PROCEEDINGS OR COUNTERCLAIM (WHETHER
BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Assignment and Successors</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">No party to this Agreement may assign
any of its rights or delegate any of its obligations under this Agreement without the prior written consent of the other parties to this
Agreement. Subject to the preceding sentence, this Agreement shall apply to, be binding in all respects upon and inure to the benefit
of the successors and permitted assigns of the parties to this Agreement. Any Shareholder Entity may dissolve after execution of this
Agreement and assign its rights and obligations under this Agreement to its partners, members or shareholders; provided, however, that
no such dissolution shall be permitted unless each proposed assignee (i) executes and delivers a Joinder Agreement and becomes a party
to this Agreement, and (ii) executes and delivers all documents required by the Shareholders under this Agreement, including the Shareholders&rsquo;
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Parties in Interest</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Except for the provisions of <B>ARTICLE XI</B>,
none of the provisions of this Agreement is intended to provide any rights or remedies to any Person other than the parties to this Agreement
or any of the Shareholder Related Agreements and their respective successors and assigns (if any). Each of the Indemnified Parties is
an express third party beneficiary of <B>ARTICLE XI</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">All notices, requests, claims, demands, consents, waivers
and other communications required or permitted by this Agreement shall be in writing and shall be deemed given to a party to this Agreement
when (a) delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid), or (b) sent
e-mail with confirmation of transmission by the transmitting equipment confirmed with a copy delivered as provided in clause (a), in each
case to the following addresses, facsimile numbers or e-mail addresses and marked to the attention of the Person (by name or title) designated
below (or to such other address, facsimile number, e-mail address or Person as a party may designate by notice to the other parties to
this Agreement):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If to the Company (before the Closing):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">VCN Biosciences SL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Av de la&nbsp;Generalitat 152</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">08174 - Sant Cugat del Vall&egrave;s&nbsp;(Barcelona,
SPAIN)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">VCN Biosciences,
S.L. (after the Closing)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">VCN Biosciences SL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Av de la&nbsp;Generalitat 152</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">08174 - Sant Cugat del Vall&egrave;s&nbsp;(Barcelona,
SPAIN)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">with a mandatory copy to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attention: Steven Shallcross</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">with a mandatory copy to (which copy shall not
constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Oscar Calsamiglia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Osborne Clarke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Av. Diagonal, 477,
planta 20, 08036 Barcelona</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #424243">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If to the Shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Oscar Calsamiglia&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Osborne Clarke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Av. Diagonal, 477, planta 20, 08036 Barcelona</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If to the Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0.55pt">Synthetic Biologics, Inc.<BR>
9605 Medical Center Drive, Suite 270<BR>
Rockville, MD 20850<BR>
Attention: Steven Shallcross<BR> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">with a mandatory copy to (which copy shall not
constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0.55pt">Gracin &amp; Marlow, LLP<BR>
The Chrysler Building<BR>
405 Lexington Avenue, 26th Floor<BR>
New York, New York 10174<BR>
Attention: Leslie Marlow, Esq.<BR> &nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in"><U>Construction; Usage.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interpretation</U>. In this Agreement, unless a clear contrary intention appears:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the singular number includes the plural number and vice versa;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>reference to any Person includes such Person&rsquo;s successors and assigns but, if applicable, only if such successors and assigns
are not prohibited by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity or
individually;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>reference to any gender includes each other gender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>reference to any agreement, document or instrument means such agreement, document or instrument as amended or modified and in effect
from time to time in accordance with the terms thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>reference to any Law means such Law as amended, modified, codified, replaced or reenacted, in whole or in part, and in effect from
time to time, including rules and regulations promulgated thereunder, and reference to any section or other provision of any Law means
that provision of such Law from time to time in effect and constituting the substantive amendment, modification, codification, replacement
or reenactment of such section or other provision;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;hereunder,&rdquo; &ldquo;hereof,&rdquo; &ldquo;hereto&rdquo; and words of similar import shall be deemed references to this
Agreement as a whole and not to any particular Article, Section or other provision of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;including&rdquo; means including without limiting the generality of any description preceding such term;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>references to documents, instruments or agreements shall be deemed to refer as well to all addenda, exhibits, schedules or amendments
thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>reference to a &ldquo;Section&rdquo; or &ldquo;Article&rdquo; in this Agreement shall mean a Section or Article, respectively,
of this Agreement unless otherwise provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Legal Representation of the Parties</U>. This Agreement was negotiated by the parties to this Agreement with the benefit of
legal representation and any rule of construction or interpretation otherwise requiring this Agreement to be construed or interpreted
against any party to this Agreement shall not apply to any construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings contained in this Agreement are for the convenience of reference only, shall not be deemed to be
a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dollar Amounts</U>. All references to &ldquo;$&rdquo; contained in this Agreement shall refer to United States Dollars unless
otherwise stated and shall be converted into &euro; in accordance with the Exchange Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforcement of Agreement</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The parties to this Agreement acknowledge
and agree that the Purchaser, the Company and the Shareholders may be irreparably damaged if any of the provisions of this Agreement are
not performed in accordance with their specific terms and that any breach of this Agreement by the Purchaser, the Company or the Shareholders
may not be adequately compensated in all cases by monetary damages alone. Accordingly, in addition to any other right or remedy to which
the Purchaser, the Company and the Shareholders may be entitled, at law or in equity, each of the Purchaser, the Company and, the Shareholders,
shall be entitled to enforce any provision of this Agreement by a decree of specific performance and temporary, preliminary and permanent
injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without posting any bond or other
undertaking. The rights and remedies of the parties to this Agreement shall be cumulative (and not alternative).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">If any provision of this Agreement is held invalid
or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect.
Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent
not held invalid or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Time of Essence</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">With regard to all dates and time periods set
forth or referred to in this Agreement, time is of the essence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure Schedule</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Except as set forth in the Disclosure Schedule,
nothing in the Disclosure Schedule shall be adequate to disclose an exception to a representation or warranty made in this Agreement except
to the extent the Section thereof identifies the exception and describes the facts. Without limiting the generality of the foregoing,
the mere listing (or inclusion of a copy) of a document or other item shall not be adequate to disclose an exception to a representation
or warranty made in this Agreement unless the representation or warranty has to do with the existence of the document or other item itself.
No exceptions to any representations or warranties disclosed on one Section of the Disclosure Schedule shall constitute an exception to
any other representations or warranties made in this Agreement except to the extent the disclosure is clear in its disclosure or cross-referenced
in such other applicable Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedules and Exhibits</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Schedules and Exhibits attached to
this Agreement (including the Disclosure Schedule) are hereby incorporated into this Agreement and are hereby made a part of this Agreement
as if set out in full in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Share Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
	<TD>&nbsp;</TD>
	<TD COLSPAN="2"><B>THE PURCHASER:</B></TD>
	<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
	<TD STYLE="width: 54%">&nbsp;</TD>
	<TD STYLE="width: 5%">&nbsp;</TD>
	<TD STYLE="width: 36%">&nbsp;</TD>
	<TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
	<TD>&nbsp;</TD>
	<TD COLSPAN="2"><B>SYNTHETIC BIOLOGICS, INC.</B></TD>
	<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
	<TD>&nbsp;</TD>
	<TD>&nbsp;</TD>
	<TD>&nbsp;</TD>
	<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
	<TD>&nbsp;</TD>
	<TD>&nbsp;</TD>
	<TD>&nbsp;</TD>
	<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
	<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
	<TD STYLE="padding-bottom: 1pt">By:</TD>
	<TD STYLE="border-bottom: Black 1pt solid">/s/ Steven Shallcross</TD>
	<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
	<TD>&nbsp;</TD>
	<TD>Name:</TD>
	<TD>Steven Shallcross</TD>
	<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>Title:</TD>
<TD>Chief Executive Officer</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD COLSPAN="2"><B>THE COMPANY:</B></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD COLSPAN="2"><B>VCN BIOSCIENCES, S.L.</B></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">By</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Manuel Cascello</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>Name:</TD>
<TD>Manuel Cascall&oacute;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>Title:</TD>
<TD>CEO, VCN Biosciences</TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Share Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SHAREHOLDER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For individuals:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature: <U>/s/ Gabriel Capell&aacute; Munar</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Gabriel Capell&aacute; Munar</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For entities</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 66; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Share
Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SHAREHOLDER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For individuals:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature: <U>/s/ Ram&oacute;n Alemany </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Ram&oacute;n Alemany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For entities:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Share Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SHAREHOLDER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For individuals:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature: <U>/s/ Manuel Cascall&oacute; </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Manuel Cascall&oacute;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For entities</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Share Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SHAREHOLDER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For individuals:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For entities</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bio Cape Group, S.L.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature<U>:/s/ Guadalupe Foyo Ballesta</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Guadalupe Foyo Ballesta</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: Administrator</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Share Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SHAREHOLDER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For individuals:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For entities</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioVCN Patrimonial, S.L.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature: /<U>s/ Margarita Nadal</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Margarita Nadal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: Administrator</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Share Purchase Agreement to be duly executed, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SHAREHOLDER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For individuals:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For entities</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grifols Innovation and New Technologies Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature: <U>/s/ Oscar Calsamiglia Mendlewicz</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Oscar Calsamiglia Mendlewicz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:Authorized Signatory</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to the Share Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX OF DEFINED TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 80%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 19%"><B>Section</B></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Acquisition Proposal</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">5.11(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Assignment Agreement</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.12(j)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Annual Accounts</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.5(a)(i)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Closing Date</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">8.1</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Preamble</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company Compliance Certificate</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">6.3</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company Constituent Documents</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.1(c)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company Database</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.28(b)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company Financial Statements</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.5(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company Rights</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.2(d)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Company Shareholder Approval</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">5.12</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Confidentiality Agreement</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">12.4</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Direct Claim</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">10.2(d)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Closing Consideration</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">1.3(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Exchange Act</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.2(i)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Expiration Date</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">9.1(a)(iv)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Future Product Payments</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">1.4(c)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Indemnified Parties</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">10.1(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Indemnifying Parties</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">10.1(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Joinder Agreement</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Preamble</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Losses</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">10.1(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Material Contracts</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.13(b)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Milestone Payment</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">1.4(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Monthly Financial Statements</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">5.4</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Nasdaq</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">6.19</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Non-Royalty Sublicense Payments</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">1.4(c)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Notice of Claim</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">10.2(d)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">OFAC</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.32</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Pre-Closing Period</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">5.1</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Privacy Policy</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">2.28(c)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Purchaser</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Preamble</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Purchaser SEC Documents</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">4.3(a)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Quarterly Financial Statements</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">5.4</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Royalty Payments</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">1.4(b)(iii)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">SEC</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">2.2(i)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Specified Indebtedness </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">1.3(b)</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Shareholders</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Preamble</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Shareholders&rsquo; Agreement</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">6.18</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">Third-Party Claim</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">10.2</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><B>Capitalization
table of the Company </B>(as of the date of the Agreement)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 36%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shareholders&rsquo; name</B></FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares Held and<BR>
numeration</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>% Ownership</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mr. Gabriel Mar&iacute;a Capell&aacute; Munar</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7,002 Company Shares, numbers 1 to 300; 9,865 to
    12,126; 12,127 to 14,766; and 19,207 to 21,006, all inclusive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3.243%</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mr. Ram&oacute;n Alemany Bonastre</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7,002 Company Shares, numbers 301 to 600; 7,603
    to 9,864; 14,767 to 17,406; 17,407 to 19,206, all inclusive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3.243%</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mr. Manuel Mar&iacute;a Cascall&oacute; PiqExhibit
    ueras</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7,002 Company Shares, numbers 601 to 3,006; 3,007
    to 7,602, all inclusive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3.243%</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Bio Cape Grup, S.L.</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3,544 Company Shares, numbers 21,007 to 24,550,
    both inclusive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1.641%</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BioVCN Patrimonial, S.L.</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3,894 Company Shares, numbers 24,551 to 28,444,
    both inclusive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1.803%</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Grifols Innovation and New Technologies, Limited</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">187,486 Company Shares, numbers 28,445 to 88,912;
    88,913 to 152,421; 152,422 to 215,930, all inclusive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">86.827%</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TOTAL</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>215,930 Company Shares, numbers 1 to 215,930, both inclusive</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>100%</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the Agreement (including this
<B>EXHIBIT B</B>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Acceptance of BLA Submission</I></B>&rdquo;
means acceptance by the Regulatory Authority of a BLA Submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Acquisition Transaction</I></B>&rdquo;
means any transaction or series of transactions involving:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any merger, consolidation,
share exchange, business combination, issuance of securities, direct or indirect acquisition of securities, recapitalization, tender offer,
exchange offer or other similar transaction involving the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any acquisition or purchase
of all or any portion of the share capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) any direct or indirect
sale, lease, exchange, transfer, license, acquisition or disposition of all or any portion of the business or assets of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) any liquidation, dissolution
or winding up of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>AEMPS</I></B>&rdquo; means the Spanish
Agency of Medicines and Medical Devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Affiliate</I></B>&rdquo; means, with
respect to any specified Person, any other Person who or which, directly or indirectly, controls, is controlled by, or is under common
control with such specified Person, including, without limitation, any general partner, limited partner, member, officer, director or
manager of such Person and any venture capital or private equity fund now or hereafter existing that is controlled by one or more general
partners or managing members of, or shares the same management company with, such Person. For purposes of this definition, the terms &ldquo;<B><I>controls</I></B>,&rdquo;
 &ldquo;<B><I>controlled by</I></B>,&rdquo; or &ldquo;<B><I>under common control with</I></B>&rdquo; means the possession, direct or indirect,
of power to direct or cause the direction of management or policies (whether through ownership of voting securities, by contract or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Agreement</I></B>&rdquo; means the
Share Purchase Agreement of which this <B>EXHIBIT B</B> is a part, as amended or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Applicable Benefit Laws</I></B>&rdquo;
means all Laws, including those of a jurisdiction outside of the United States or Spain, applicable to any Employee Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>BLA</I></B>&rdquo; means a Biologics
License Application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;<B><I>BLA Approval</I></B>&rdquo; means
approval by the FDA for marketing and sale of a Product in the United States, including any applicable final labelling approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>BLA Submission</I></B>&rdquo; means
an application and all amendments and supplements thereto filed with the Regulatory Authority, including all documents, data, and other
information concerning a pharmaceutical product which are necessary for gaining Regulatory Approval to market and sell such pharmaceutical
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Business Day</I></B>&rdquo; means
a weekday on which banks are open for general banking business in New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Closing</I></B>&rdquo; means the
consummation of the purchase and sale of the Shares as set forth in Section 8.1 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Closing Cash Consideration</I></B>&rdquo;
means an amount in cash equal to $4,700,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Closing Date</I></B>&quot; has the
meaning given in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Closing Shares</I></B>&rdquo; means
such number of shares of Purchaser Common Stock as is equal to 19.99% of the outstanding shares of Purchaser Common Stock on the date
of this Agreement (as adjusted as appropriate to reflect any stock splits, stock dividends, reverse stock splits, combinations, reorganizations,
reclassifications or similar events affecting the Purchaser Common Stock after the date of this Agreement), rounded down to the nearest
whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Code</I></B>&rdquo; means the United
States Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Contract</I></B>&rdquo; means
any Contract, including any amendment or supplement thereto: (a) to which the Company is a party, (b) by which the Company or any of its
assets is or may become bound or under which the Company has, or may become subject to, any obligation, or (c) under which the Company
has or may acquire any right or interest other than the Contract Manufacturing and Contract Regulatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Contract Manufacturing Agreement</I></B>&quot;
has the meaning given in Section 6.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Contract Regulatory Agreement</I></B>&quot;
has the meaning given in Section 6.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Direct Claim</I></B>&rdquo; has the
meaning given in Section 11.2(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Dispute Notice</I></B>&rdquo; has
the meaning set forth in Section [__].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Intellectual Property</I></B>&rdquo;
means the Company Owned Intellectual Property and the Company Licensed Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Licensed Intellectual Property</I></B>&rdquo;
means all Intellectual Property Rights that are licensed to the Company by any other third-party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Material Adverse Effect</I></B>&rdquo;
means any state of facts, change, event, effect, occurrence or circumstance that, individually or in the aggregate (considered together
with all other state of facts, change, event, effect, occurrence or circumstance) has, has had or could reasonably be expected to have
or give rise to a material adverse effect on (a) the business, condition (financial or otherwise), results of operations, prospects,
capitalization, assets, liabilities, operations or financial performance of the Company, (b) the ability of the Company to consummate
the transactions contemplated by the Agreement or to perform any of its obligations under the Agreement, or (c) the Purchaser&rsquo;s
ability to vote, receive dividends with respect to or otherwise exercise ownership rights with respect to the shares of the Company but
will not constitute, or be considered in determining whether there has been, a Material Adverse Effect: (a) any outbreak or escalation
of war or major hostilities, man made or natural disaster, national or international calamity or crisis, epidemic, pandemic, plague,
or any act of terrorism, (b) changes in financial, credit or capital markets, general economic conditions (including prevailing interest
rates, exchange rates, commodity prices and fuel costs) or political conditions, (c) changes in Laws, the Applicable Accounting Standards,
or enforcement or interpretation thereof, (d) changes that generally affect the industries and markets in which the Company operates,
(e) any action taken or failed to be taken pursuant to or in accordance with this Agreement or at the request of, or consented to by,
the Purchaser, or the failure to take any action prohibited by this Agreement or to which the Purchaser refuses to provide consent pursuant
to this Agreement, (f) the execution or delivery of this Agreement, the consummation of the transactions contemplated by this Agreement
or the public announcement or other publicity with respect to any of the foregoing, or (g) any failure of the Company to meet any projections,
budgets, plans or forecasts of revenues, earnings or other financial performance measures or operating statistics (it being understood
that the facts and circumstances underlying any such failure that are not otherwise excluded from the definition of a &ldquo;Material
Adverse Effect&rdquo; may be considered in determining whether there has been a Material Adverse Effect). For the avoidance of doubt,
a Material Adverse Effect shall be measured only against past performance of the Company, taken as a whole, and not against any forward-looking
statements, financial projections or forecasts of the Seller or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Options</I></B>&rdquo; means
all options to purchase Company Shares, as listed on Section 2.2(b) of the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Shares</I></B>&rdquo; means
the shares (<I>participaciones sociales</I>), par value $1.00 per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Owned Intellectual Property</I></B>&rdquo;
means all Intellectual Property Rights that are owned or purported to be owned by the Company, in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Registrations</I></B>&rdquo;
means, registered Intellectual Property Rights and applications (including intent to use applications) for each of the foregoing that
are registered or filed or recorded with any Person in the name of or licensed by the Company, alone or jointly with others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Stock Option Plan</I></B>&rdquo;
means the Company&rsquo;s [Equity Incentive Plan].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Confidential Information</I></B>&rdquo;
means any data or information concerning the Company or Purchaser(including trade secrets), without regard to form, regarding (for example
and including) (a) business process models, (b) proprietary software, (c) research, development, products, services, marketing, selling,
business plans, budgets, unpublished financial statements, licenses, prices, costs, contracts, suppliers, customers, and customer lists,
(d) the identity, skills and compensation of employees, contractors, and consultants, (e) specialized training, or (f) discoveries, developments,
trade secrets, processes, formulas, data, lists, and all other works of authorship, mask works, ideas, concepts, know-how, designs, and
techniques, whether or not any of the foregoing is or are patentable, copyrightable, or registrable under any intellectual property Laws
or industrial property Laws in the United States or elsewhere. Notwithstanding the foregoing, no data or information constitutes &ldquo;Confidential
Information&rdquo; if such data or information is publicly known and in the public domain through means that do not involve a breach by
the Company or a Shareholder of any covenant or obligation set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Consideration Percentage</I></B>&rdquo;
means the quotient obtained by dividing (i) the number of Company Shares to be sold to the Purchaser by the Shareholder (as calculated
pursuant to Section 1.2) <I>by</I> (ii) the number of Shares owned by all Remaining Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Contract</I></B>&rdquo; means any
written, oral or other agreement, contract, subcontract, lease, understanding, instrument, note, warranty, license, sublicense, insurance
policy, benefit plan or legally binding commitment or undertaking of any nature, whether express or implied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Disclosure Schedule</I></B>&rdquo;
means the disclosure schedule (dated as of the date of the Agreement) delivered to the Purchaser on behalf of the Company and the Shareholders
on the date of the Agreement. The representations and warranties contained in <B>ARTICLE II</B> and <B>ARTICLE III</B> of this Agreement
are subject to the qualifications and exceptions set forth in the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>EMA</I></B>&rdquo; means the European
Medicines Agency or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Employee</I></B>&rdquo; means each
of the employees of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Employee Plan</I></B>&rdquo; means
any employee benefit plan including: (i) any (a) nonqualified deferred compensation or retirement plan or arrangement or superannuation
plan; (b) qualified defined contribution retirement plan or arrangement; or (c) qualified defined benefit retirement plan or arrangement,
which is an &ldquo;employee pension benefit plan&rdquo;; (ii) any &ldquo;employee welfare benefit plan&rdquo; or material fringe benefit
plan or program; or (iii) any share purchase, stock option, profit sharing, deferred compensation, welfare, pension, retirement, severance
pay, employment, change-in-control, vacation pay, company awards, salary continuation, sick leave, excess benefit, bonus or other incentive
compensation, life insurance, or other employee benefit plan, contract, program, policy or other arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Entity</I></B>&rdquo; means any corporation
(including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate,
trust, company (including any limited liability company or joint stock company), firm or other enterprise, association, organization or
entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Environmental Law</I></B>&rdquo;
means any national, provincial, territorial, federal, state, local or foreign Law relating to pollution or protection of human health
or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law, regulation,
permit or certificate of approval relating to emissions, discharges, releases or threatened releases of Materials of Environmental Concern,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials
of Environmental Concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Exchange Rate</I></B>&quot; means
the euro / US dollar exchange reference rate with respect to such currency as published in the Wall Street Journal according to the average
exchange rate in such publication within the immediate thirty (30) Business Days prior to 11:59 p.m. CET on the day immediately before
the date upon which the performance of an obligation or right is claimed for under the terms and conditions contemplated under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Existing Shareholders Agreement</I></B>&quot;
means certain shareholders agreement entered into by and between the Shareholders and the Company on 6 July 2012 and notarized before
the notary public of Barcelona, Mr. Juan Carles Farres Ustrell, on the same date, under 1206 of his records</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Exploit</I></B>&rdquo; means develop,
design, test, modify, make, use, sell, have made, used and sold, import, reproduce, market, distribute, commercialize, support, maintain,
correct and create derivative works of.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>FCPA</I></B>&rdquo; means the Foreign
Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>FDA</I></B>&rdquo; means the United
States Food and Drug Administration or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&ldquo;<B>Foreign Investments Act</B>&rdquo;</I>
Law 19/2003, of July 4<SUP>th</SUP>, on the legal regime applicable to foreign capital movements and economic transactions and on certain
measures regarding anti-money laundering (as amended).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Fundamental Representations</I></B>&rdquo;
means each of the representations and warranties contained in Section 2.1 (Organization and Good Standing), Section 2.2 (Capitalization),
Section 2.4 (Authority; No Conflict; Required Filings and Consents), Section 2.20 (Brokerage and Transaction Bonuses), Section 2.25 (Related
Party Transactions), Section 3.1 (Authority, No Conflict; Required Filings and Consents), Section 3.2 (Ownership; Title to Company Shares)
and Section 3.4 (Brokerage and Transaction Bonuses) and the representations and warranties contained in the Shareholder Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Government Bid</I></B>&rdquo; means
any quotation, bid or proposal submitted to any Governmental Body or any proposed prime contractor or higher-tier subcontractor of any
Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Government Contract</I></B>&rdquo;
means any prime contract, subcontract, letter contract, purchase order or delivery order executed or submitted to or on behalf of any
Governmental Body or any prime contractor or higher-tier subcontractor, or under which any Governmental Body or any such prime contractor
or subcontractor otherwise has or may acquire any right or interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Governmental Authorization</I></B>&rdquo;
means any (a) approval, permit, license, certificate, certificate of approval, franchise, permission, clearance, registration, qualification
or other authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant
to any Law, or (b) right under any Contract with any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Governmental Body</I></B>&rdquo;
means any domestic or foreign multinational, federal, state, provincial, municipal or local government (or any political subdivision thereof)
or any domestic or foreign governmental, regulatory or administrative authority or any department, commission, board, agency, court, tribunal,
judicial body or instrumentality thereof, or any other body exercising, or entitled to exercise, any administrative, executive, judicial,
legislative, police, regulatory or taxing authority or power of any nature (including any arbitral body).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>HSR Act</I></B>&rdquo; means the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>IFRS</I></B>&rdquo; means international
financial reporting standards as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Indebtedness</I></B>&rdquo; means,
without duplication, the aggregate of the following: (a) all obligations for borrowed money (including the current portion thereof and
all sums due on early termination and repayment or redemption calculated to the Closing Date), whether or not contingent, or issued or
incurred in substitution or exchange for any such liability for borrowed money, or extensions of credit (including under credit cards,
bank overdrafts and advances), (b) all obligations evidenced by bonds, debentures, notes or other similar instruments (and including
all sums due on early termination and repayment or redemption calculated to the Closing Date), (c) all obligations to pay the deferred
purchase price of property or services, except trade accounts payable arising in the ordinary course of business consistent with past
practice, (d) all obligations as lessee under leases that have been or should be, in accordance with IFRS, recorded as capital leases
in respect of which the Company is liable as a lessee (excluding operating real estate leases which would otherwise be required to be
capitalized under rule 16 IFRS), (e) all obligations of others secured by a Lien on any asset of the Company (including accounts and
contract rights), whether or not such obligations are assumed, (f) all obligations, contingent or otherwise, directly or indirectly guaranteeing
any obligations of any other Person, all obligations to reimburse the issuer in respect of letters of credit or under performance or
surety bonds, or other similar obligations; all obligations under which the Company has agreed (contingently or otherwise) to purchase
or otherwise acquire the liability of any other Person or in respect of which the Company has otherwise assured a creditor against loss,
(g) all obligations in respect of bankers&rsquo; acceptances, note purchases or similar facilities and under reverse repurchase agreements,
(h) all obligations in respect of futures contracts, other financial contracts and other similar obligations (determined on a net basis
as if such contract or obligation was being terminated early on such date), (i) the amount of any termination payments in connection
with the payment in full of any obligations for borrowed money, (j) accrued employment obligations, including without limitation, accrued
salary, accrued vacation and accrued bonuses, (k) deferred revenue, (l) all obligations created or arising under any conditional sale
or other title retention agreement with respect to property acquired by the Company (even though the rights and remedies of the seller
or lender under such agreement in the event of default are limited to repossession or sale of such property), (m) all obligations to
purchase, redeem, retire or otherwise acquire for value any ownership interests or share capital of the Company or any rights to acquire
any ownership interests or share capital of the Company, valued, in the case of redeemable ownership interests or share capital, at the
greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends, (n) any obligations under any interest
rate, foreign exchange, currency, commodity, credit or equity swap, cap, collar, floor, option, forward or other hedging agreement or
derivative contract, net of any obligations to the Company thereunder, and (o) amounts due to the Purchaser or its subsidiaries and other.
For purposes of the Agreement, &ldquo;<B><I>Indebtedness</I></B>&rdquo; includes (i) any and all accrued interest, fees, change of control
payments, prepayment premiums, make whole premiums or penalties and fees or expenses actually incurred (including attorneys&rsquo; fees)
associated with the repayment of any Indebtedness, and (ii) any and all amounts of the nature described in clauses (a) through (o) above
owed by the Company to any of its Affiliates, including any of the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Indemnified Party</I></B>&quot; has
the meaning given in Section 11.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Indication</I></B>&rdquo; means a
separate and distinct disease, disorder or medical condition, in humans, that a Product is intended to treat, prevent and/or ameliorate
for which a separate Marketing Authorization Application is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Intellectual Property Rights</I></B>&rdquo;
means all (a) Patent Rights, inventions and industrial designs, (b) Internet domain names, trademarks, service marks, trade dress, trade
names, logos and corporate or company names (both foreign and domestic) and registrations and applications for registration thereof together
with all of the goodwill associated therewith, (c) copyrights (registered or unregistered) and copyrightable works (both foreign and domestic)
and registrations and applications for registration thereof and all related, <I>sui generis</I> or other analogue rights, (d) mask works
and registrations and applications for registration thereof, (e) computer software, data, data bases and documentation thereof, including
rights to third party software used in the business, (f) trade secrets and other Confidential Information (including ideas, formulas,
compositions, inventions (whether patentable or unpatentable and whether or not reduced to practice), know-how, manufacturing and production
processes and techniques, research and development information, drawings, specifications, designs, plans, proposals, technical data, copyrightable
works, financial and marketing plans and customer and supplier lists and information), (g) other intellectual or industrial property rights,
and (h) copies and tangible embodiments thereof (in whatever form or medium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Interim Agreements</I></B>&quot; has
the meaning given in Section 6.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;<B><I>Interim Financing Loan&quot;</I></B>&quot;
has the meaning given in Section 6.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Issued Patent Claim</I></B>&rdquo;
means, on a country by country basis, a claim of an issued patent that covers a Product, respectively, and that has not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;lapsed,
expired, been formally disclaimed by written submission to any United States or foreign patent office, withdrawn, cancelled or abandoned;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;been
held revoked, invalid or unenforceable in an unappealable or unappealed decision of a court or other body of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If there should be two or more decisions within
the same country which are conflicting with respect to the invalidity or unenforceability of the same claim, the unappealed or unappealable
decision of the highest tribunal shall thereafter control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Knowledge</I></B>&rdquo; An individual
shall be deemed to have &ldquo;Knowledge&rdquo; of a particular fact or other matter if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
individual is actually aware of such fact or other matter after due inquiry and investigation of the matter; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
individual would have had knowledge of such fact following a reasonable investigation, if under the circumstances a reasonable person
would have determined such investigation was required or appropriate in the normal course of fulfillment of such individual&rsquo;s duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall be deemed
to have &ldquo;Knowledge&rdquo; of a particular fact or other matter if any officer, director or Shareholder of the Company has Knowledge
of such fact or other matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Labor Laws</I></B>&rdquo; means all
Laws governing or concerning labor relations, unions and collective bargaining, conditions of employment, termination of employment, employee
classification, background checks, employment discrimination and harassment, wages, hours, meal and rest periods, accrual and payment
of vacation pay and paid time off, or occupational safety and health and the payment and withholding of Taxes and other sums as required
by the appropriate Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Law</I></B>&rdquo; means any federal,
national, state, provincial, territorial, local, municipal, foreign or international, multinational other law, statute, constitution,
principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted,
promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Leased Real Property</I></B>&rdquo;
means the parcels of real property of which the Company is the lessee or sublessee (together with all fixtures and improvements thereon).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Legal Proceeding</I></B>&rdquo; means
any ongoing or threatened action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative
or appellate proceeding), hearing, order, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before,
or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Lien</I></B>&rdquo; means any lien,
pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, infringement, interference, option, right of first refusal,
preemptive right, community property interest or restriction of any nature affecting property, real or personal, tangible or intangible,
including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction
on the receipt of any income derived from any asset, any restriction on the use of any asset, any restriction on the possession, exercise
or transfer of any other attribute of ownership of any asset, any lease in the nature thereof and any filing of or agreement to give any
financing statement under the Uniform Commercial Code (or equivalent statute of any jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loss</I></B>&rdquo; means any direct
and actual loss, damage, Judgment, fine, penalty, cost or expense, including reasonable attorneys&rsquo; fees and other out-of-pocket
expenses; but shall exclude any special, incidental, indirect, exemplary, punitive or consequential damages, damages relating to lost
sales, revenues or profits, or damages calculated as a multiple of sales, revenues, profits or other similar measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B><I>Marketing Authorization Application</I></B>&rdquo; or
 &ldquo;<B><I>MAA</I></B>&rdquo; means a New Drug Application (&ldquo;<B><I>NDA</I></B>&rdquo;) or any other application to the FDA for
approval to market a pharmaceutical or biologic product (Biologics License Application, &ldquo;<B><I>BLA</I>&rdquo;</B>, for the application
in FDA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B><I>Materials of Environmental Concern</I></B>&rdquo;
means any chemicals, pollutants, contaminants, wastes, toxic substances, petroleum, petroleum products, petroleum by-products,
asbestos-containing material, lead-containing paint, pipes or plumbing, polychlorinated biphenyls, radioactive materials or radon,
infectious, biological or medical waste, including biohazards, radioactive materials and blood-borne pathogens and any other
substances that are now or hereafter: (a) listed, classified, regulated or fall within the definition of a &ldquo;hazardous
substance,&rdquo; &ldquo;hazardous waste&rdquo; or &ldquo;hazardous material&rdquo; pursuant to any Environmental Law, (b) a danger
to health, or (c) the subject of regulatory action by any Governmental Body pursuant to any Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Negative Regulatory Correspondence</I></B>&rdquo;
means any oral or written communication from FDA, EMA or AEMPS that it has not approved a protocol submitted for any proposed clinical
trial of any Company product or that any product will not in the future entertain further submissions in support of approval of such product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Notice of Claim</I></B>&rdquo; has
the meaning given in Section 11.2(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Organizational Documents</I></B>&rdquo;
means, with respect to any Entity, the constitution, certificate of incorporation, articles of incorporation, by-laws, articles of organization,
articles of association, partnership agreement, limited liability company agreement, trust deed, formation agreement, joint venture agreement
or other similar organizational documents of such Entity (in each case, as amended through the date of the Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Patent Rights</I></B>&rdquo; means
all foreign and domestic patents, patent applications, patent disclosures, utility models, utility model applications, design registrations
and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related
continuations, continuations-in-part, divisionals, reissues and reexaminations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>PDAC</I></B>&rdquo; means pancreatic
cancer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Permitted Lien</I></B>&rdquo; means
any (a) Lien for Taxes not yet due and payable (excluding Liens arising under ERISA or the Code), (b) Liens of carriers, warehousemen,
mechanics, materialmen and repairmen incurred in the ordinary course of business consistent with past practice and not yet delinquent,
and (c) in the case of real property, zoning, building, occupancy or other restrictions, variances, covenants, rights of way, encumbrances,
easements and other minor irregularities in title, none of which, individually or in the aggregate, (i) interfere in any material respect
with the present use of or occupancy of the affected parcel by the Company, (ii) have more than an immaterial effect on the value thereof
or its use, or (iii) would impair the ability of such parcel to be sold for its present use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Person</I></B>&rdquo; means any individual,
Entity, trust, Governmental Body or other organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Personal Information</I></B>&rdquo;
means any &ldquo;personal information&rdquo; (as defined in the Privacy Laws) about an identified or identifiable individual accessed
by, in the possession, custody or control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B><I>Phase 2 Clinical Trial</I></B>&rdquo; means a human clinical
trial of a Product conducted mainly to test the effectiveness of chemical or biologic agents or other types of interventions for purposes
of identifying the appropriate dose for a Phase 3 Clinical Trial for a particular Indication or Indications that would satisfy the requirements
that satisfies the requirements for a Phase 2 study as defined in 21 C.F.R. Part 312.21(b) (or its successor regulation). A &ldquo;Phase
2/3 Clinical Trial&rdquo; shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded
as its Phase 3 component, in accordance with the applicable protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B><I>Phase 3 Clinical Trial</I></B>&rdquo; means a human clinical
trial of a Product designed to: (i) establish that such Product is safe and efficacious for its intended use; (ii) define warnings, precautions
and adverse reactions that are associated with the Product in the dosage range to be prescribed; and (iii) support Regulatory Approval
of such Product, that would satisfy the requirements of 21 CFR &sect; 312.21 (or its successor regulation). A &ldquo;Phase 2/3 Clinical
Trial&rdquo; shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded as its
Phase 3 component, in accordance with the applicable protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Pipeline Technologies</I></B>&rdquo;
means, the set comprising all Company Products and Product candidates including, VCN-01, VCN-02, VCN-03, VCN-11, VCN-12, VCN-14 and derivatives
and variants thereof, and other products or technologies developed by the Company for commercial use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B><I>Pivotal Trial</I></B>&rdquo; means as to a particular
Product for a particular Indication, a controlled and lawful study in humans of the safety and efficacy of such Product for such Indication,
which is prospectively designed to demonstrate statistically whether such Product is safe and effective for use in such indication in
a manner sufficient to file a Marketing Approval Application for the Indication under investigation in such study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Privacy Laws</I></B>&rdquo; means
any national, provincial, territorial, state, local or foreign Law now in force or that may in the future come into force governing individual
privacy and/or access to Personal Information, or the collection, use, disclosure, access and management of Personal Information, including
without limitation, the Health Insurance Portability and Accountability Act of 1996, as amended, the Health Information Technology for
Economic and Clinical Health Act, state data breach notification Laws, state social security number protection Laws, the Federal Trade
Commission Act, the Financial Services Modernization Act of 1999, the Fair Credit Reporting Act, the Fair and Accurate Credit Transactions
Act, state consumer protection Laws, the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the
protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive
95/46/EC, and the Spanish Organic Act 3/2018, of 5 December, on Protection of Personal Data and guarantee of digital rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Purchaser Common Stock</I></B>&rdquo;
means the shares of common stock, par value $0.001 per share, of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Purchaser Indemnified Parties</I></B>&rdquo;
has the meaning given in Section 11.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Purchaser Material Adverse Effect</I></B>&rdquo;
means any state of facts, change, event, effect, occurrence or circumstance that, individually or in the aggregate (considered together
with all other state of facts, change, event, effect, occurrence or circumstance) has, has had or could reasonably be expected to have
or give rise to a material adverse effect on (a) the business, condition (financial or otherwise), results of operations, prospects, capitalization,
assets, liabilities, operations or financial performance of the Purchaser, (b) the ability of the Purchaser to consummate the transactions
contemplated by the Agreement or to perform any of its obligations under the Agreement prior to the Termination Date, or (c) the Shareholders&rsquo;
ability to vote, receive dividends with respect to or otherwise exercise ownership rights with respect to the shares of Purchaser Common
Stock issuable pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Product</I></B>&rdquo; means any
product related to oncolytic virus developed by VCN Biosciences, such as VCN-01 or VCN-11 but not limited to these two candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;RB&rdquo; </I></B>means Retinoblastoma<B><I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Registrations</I></B>&rdquo; means
authorizations, approvals, licenses, permits, certificates, or exemptions issued by the FDA, EMA or AEMPS (including, without limitation,
pre-market approval applications, pre-market notifications, investigational new drug applications, new drug applications, biologic license
applications, manufacturing approvals and authorizations, pricing and reimbursement approvals, labeling approvals or their foreign equivalent)
held by the Company that are required for, among other things, the research, development, manufacture, processing, labeling, distribution,
marketing, storage, transportation, use, sale and provision of the products and services of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Regulatory Approval</I></B>&rdquo;
means any approvals (including price and reimbursement approvals), licenses, registrations, or authorizations of a Regulatory Authority
that is necessary for the manufacture, distribution, marketing, importation, exportation, use, storage, import, transport and/or commercial
sale of a Product in a given country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Regulatory Authority</I></B>&rdquo;
means the FDA, EMA, AEMPS or a regulatory authority in other jurisdictions with equivalent authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Related Party</I></B>&rdquo; means
(a) each individual who is, or who has at any time been, an officer or director of the Company; (b) each member of the immediate family
of each of the individuals referred to in clause (a) above; and (c) any trust or other Entity (other than the Company) in which any one
of the individuals referred to in clauses (a) and (b) above holds (or in which more than one of such individuals collectively hold), beneficially
or otherwise, a material voting, proprietary, equity or other financial interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Release</I></B>&rdquo; or &ldquo;<B><I>Released</I></B>&rdquo;
means with respect to any Materials of Environmental Concern, any spilling, leaking, pumping, pouring, emitting, emptying, discharging,
injecting, escaping, leaching, migrating, dumping or disposing into any surface or ground water, drinking water supply, soil, surface
or subsurface strata or medium or the ambient air. For purposes of the Agreement, the term &ldquo;Release&rdquo; shall also mean any threatened
release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Remaining Shareholders</I></B>&rdquo;
means Ramon Alemany, Gabriel Capella, Manel Cascallo, BioCape Grup and BioVCN Patrimonial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Representatives</I></B>&rdquo; means,
with respect to a Person, the officers, directors, employees, agents, attorneys, accountants, advisors and representatives of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Securities Act</I></B>&rdquo; means
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Spanish GAAP</I></B>&rdquo; means
the accounting principles and standards generally accepted in Spain under current applicable law, including the Commercial Code and the
Spanish General Accounting Plan (<I>Plan General Contable</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Shareholder Entity</I></B>&rdquo;
means any Shareholder that is not a natural person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Shareholder Related Agreement</I></B>&rdquo;
means any certificate, agreement, document or other instrument, other than the Agreement, to be executed and delivered by the Company
or a Shareholder in connection with the transactions contemplated the Agreement, including without limitation the certificates, agreements,
documents and other instruments set forth in Section 6.6 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Shareholders Indemnified Parties</I></B>&rdquo;
has the meaning given in Section 1.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Specified Indebtedness</I></B>&rdquo;
means any liabilities of any nature outstanding as of the Closing Date set forth on Section 2.6(c) of the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Subsidiary</I></B>&rdquo; means,
with respect to any party, any corporation, partnership, trust, limited liability company or other non-corporate business enterprise
in which such party (or another Subsidiary of such party) holds stock or other ownership interests representing (a) 25% or more of the
voting power of all outstanding stock or ownership interests of such Entity, or (b) the right to receive 25% or more of the net assets
of such Entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution
of such Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Supplier</I></B>&rdquo; means any
supplier of goods or services to which the Company paid more than $25,000 in the aggregate during the 12-month period ended December 31,
2020 and since such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Taxes</I></B>&rdquo; means (a) any
and all taxes, charges, fees, levies or other similar assessments or liabilities in the nature of a tax, including income, gross receipts,
ad valorem, premium, value-added, net worth, share capital, capital gains, documentary, recapture, alternative or add-on minimum, disability,
estimated, registration, recording, excise, escheat, real property, personal property, sales, use, license, lease, service, service use,
transfer, withholding, employment, unemployment, insurance, employment insurance, social security, business license, business organization,
environmental, worker&rsquo;s compensation, pension, payroll, profits, severance, stamp, occupation, windfall profits, customs, franchise
and other taxes of any kind whatsoever imposed by the United States, or any state, provincial, local or foreign government, or any agency
or political subdivision thereof, (b) any interest, penalties or additions to tax imposed with respect to such items or any contest or
dispute thereof or in connection with the failure to timely or properly file any Tax Return; (c) any liability for payment of amounts
described in clause (a) or (b) whether as a result of transferee liability, of being a member of an affiliated, consolidated, combined
or unitary group for any period or otherwise through operation of law; and (d) any liability for the payment of amounts described in clauses
(a), (b) or (c) as a result of any tax sharing, tax indemnity or tax allocation agreement or any other express or implied agreement to
indemnify any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Tax Returns</I></B>&rdquo; means
any and all reports, returns, or declarations relating to Taxes filed or required to be filed with any Governmental Body, including any
schedule or attachment thereto, including any amendment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Termination Date</I></B>&rdquo; means
the date prior to the Closing on which the Agreement is terminated in accordance with <B>ARTICLE IX</B> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Third-Party Claim</I></B>&rdquo;
has the meaning given in Section 11.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>User Data</I></B>&rdquo; means any
Personal Information or other data or information collected by or on behalf of the Company from users of the Company&rsquo;s products
or of any website or service operated or maintained by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>US IND Safe To Proceed</I></B>&rdquo;
means notification from the FDA that it is safe to proceed with the planned clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF SPOUSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I, [____________________],
spouse of [______________], acknowledge that I have read the Share Purchase Agreement, dated as of December 14, 2021, to which this Consent
is attached as <U>Exhibit C</U> (the &ldquo;<U>Agreement</U>&rdquo;), and that I know the contents of the Agreement. I am aware that the
Agreement contains provisions regarding the transfer of shares of capital stock of the Company that my spouse may own, including any interest
I might have therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby agree that my interest,
if any, in any shares of capital stock of the Company subject to the Agreement shall be irrevocably bound by the Agreement and further
understand and agree that any community property interest I may have in such shares of capital stock of the Company shall be similarly
bound by the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I am aware that the legal,
financial and related matters contained in the Agreement are complex and that I am free to seek independent professional guidance or counsel
with respect to this Consent. I have either sought such guidance or counsel or determined after reviewing the Agreement carefully that
I will waive such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Name of Spouse, if any</I>]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Exhibit
D</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Accredited
Investor, Non-U.S. Person and Bad Actor Questionnaire</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACCREDITED INVESTOR AND BAD
ACTOR CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Certificate is delivered
in connection with the undersigned receipt of shares of common stock (the &ldquo;Shares&rdquo;) of Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby represents,
warrants and certifies to the Company, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Shares are being acquired for the undersigned&rsquo;s own account for investment, with no intention by the undersigned to distribute
or sell any portion thereof within the meaning of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and will
not be transferred by the undersigned in violation of the Securities Act or the then applicable rules or regulations thereunder. No one
other than the undersigned has any interest in or any right to acquire the Shares. The undersigned understands and acknowledges that the
Company will have no obligation to recognize the ownership, beneficial or otherwise, of the Shares by anyone but the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the undersigned is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) of Regulation D promulgated under the Securities Act </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the undersigned has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks
of acquiring the Shares and of making an informed investment decision with respect thereto. The undersigned acknowledges that an investment
in the Shares is highly speculative and involves a high degree of risk of loss of the entire investment. The undersigned&rsquo;s financial
condition is such that the undersigned is able to bear the risk of holding the Shares for an indefinite period of time, and the risk of
loss of the undersigned&rsquo;s entire investment in the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the undersigned has had an opportunity to ask questions of, and receive answers from, representatives of the Company concerning the terms
and conditions of this investment and all such questions have been answered to the full satisfaction of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the undersigned is aware that the undersigned&rsquo;s rights to transfer the Shares is restricted by the Securities Act and applicable
state securities laws, and the undersigned will not offer for sale, sell or otherwise transfer Shares without registration under the Securities
Act and qualification under the securities laws of all applicable states, unless such sale would be exempt therefrom. The undersigned
further understands and agrees that the Shares have not been registered under the Securities Act or any state securities act in reliance
on exemptions therefrom and that the Company has no obligation to register any of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the undersigned has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision
with respect to its investment in the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the undersigned understands that the certificates or other instruments representing the Shares shall bear a restrictive legend in substantially
the following form (and a stop transfer order may be placed against transfer of such stock certificates):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0.5in; text-align: justify">THE SECURITIES EVIDENCED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREUNDER AND UNDER APPLICABLE STATE LAW, THE AVAILABILITY OF WHICH
MUST BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
undersigned is not subject to any &ldquo;bad actor&rdquo; disqualification event in Rule 506(d)(1)(i)-(viii) of the Securities Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B>
the undersigned has executed this Certificate as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: December , 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Name</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">:</FONT></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT E</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate budget will be <FONT STYLE="font-family: Times New Roman, Times, Serif">~$27.81mm
through [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: white"><B>{{****2021</B></FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 89; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2135322d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2135322d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces Planned Transformative
Acquisition of VCN Biosciences;<BR>
Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Lead drug candidate VCN-01 demonstrated clinical
activity in multiple Phase 1 clinical trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Designed for systemic delivery, high selectivity,
and enhanced tumor access</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>VCN-01 granted Orphan Drug Designation in Pancreatic
Cancer by the EMA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Synthetic Biologics and VCN Biosciences to host
a conference call today,<BR>
December 14<SUP>th</SUP>, at 10:00 a.m. Eastern Time</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, December 14, 2021 &ndash;</B></FONT> Synthetic Biologics, Inc. <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a diversified
clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today
announced it has signed a definitive agreement to acquire VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus
(OV) platform designed for intravenous (IV) delivery to trigger tumor cell death and promote immune cell infiltration into tumors. Total
upfront consideration for the acquisition is $4.7 million in cash plus the assumption of $2.4 million of VCN liabilities. Additionally,
VCN will receive shares of Synthetic Biologics&rsquo; common stock representing 19.99% of the total shares outstanding of the Company&rsquo;s
common stock. The Company has also agreed to an additional $70.3 million of payments contingent upon the achievement of future milestones,
a majority of which are tied to late-stage clinical development and regulatory achievements. The transaction is expected to close during
the first quarter of 2022,</FONT> and <FONT STYLE="color: windowtext">is subject to, among other things, the approval by the Spanish government
of the Company&rsquo;s acquisition of VCN under Spain&rsquo;s Foreign Investment Act and other customary closing conditions. Additional
details regarding the transaction are available in the Company&rsquo;s Current Report on Form 8-K, which has been filed with the Securities
and Exchange Commission and is available on the Company&rsquo;s </FONT>website<FONT STYLE="color: windowtext">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VCN&rsquo;s technology platform is designed to
overcome critical challenges that restrict the development of the majority of OV therapies today. Unlike many OVs that can only be administered
by direct intratumoral injection, VCN&rsquo;s OVs are designed for systemic intravenous administration to target primary as well as metastatic
tumors. Once inside the tumor, VCN&rsquo;s OVs are designed to replicate selectively and aggressively, and to produce hyaluronidase (PH20),
an enzyme that digests hyaluronan, a key component of the dense tumor stroma that often plays a crucial role in tumor progression. Degradation
of tumor stroma has been shown to diminish a significant physical and immunosuppressive barrier to cancer treatment and thereby improve
access to the tumor by additional therapies such as chemo and immuno-therapies. Results from previously completed clinical trials demonstrate
that this process can occur for weeks or months following a single intravenous injection with a VCN OV. VCN is seeking to leverage these
unique capabilities to address cancers with a high unmet need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VCN OVs are also designed to be administered intratumorally
or intravitreally (in the eye), either as a monotherapy or in combination with standard of care, to treat a wide variety of cancer indications.
Combination treatment of VCN OVs with a variety of chemotherapies and immunotherapies such as checkpoint inhibitors and CAR-T cells are
in early clinical testing or planned. VCN has the rights to four exclusive patents for proprietary technologies, as well as technologies
developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional
patents pending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VCN&rsquo;s lead drug candidate, VCN-01, has been
evaluated in four Phase 1 clinical trials to date, including in patients with pancreatic cancer, head and neck squamous cell carcinoma,
and retinoblastoma (Rb). In a Phase 1 clinical trial, patients  with metastatic pancreatic ductal adenocarcinoma
(PDAC) received the combination therapy of intravenous VCN-01 with the standard of care chemotherapy Gemcitabine plus Abraxane&reg; (G/A).
Best results were observed when VCN-01 was administered one week before the first G/A dose. VCN-01 was well tolerated and when combined
with G/A demonstrated an improved median overall and progression free survival, as well as a high response rate compared to G/A alone.
These data compare favorably with current standard of care and are the basis of a planned Phase 2 clinical trial of the higher dosing
level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VCN-01 is also being studied as a monotherapy
in patients with retinoblastoma (RB) who previously failed chemotherapy. Intravitreal administration of VCN-01 produced a complete remission
and a reduction of tumors in several patients. These promising outcomes form the basis for an Orphan Drug application with the FDA and
are planned to be explored in a larger future clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VCN is also developing a next generation Albumin
Shield&trade; technology platform, VCN-11, which builds upon the pre-clinical and clinical results of VCN-01. VCN-11 incorporates an albumin
binding domain in the virus outer shell designed to enable the virus to coat itself with host serum albumin, potentially preventing its
inactivation by neutralizing antibodies in the bloodstream en route to the tumor. The addition of the Albumin Shield technology is not
expected to interfere with VCN-11&rsquo;s ability to target tumor cells and may allow for repeated administration to optimize tumor exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steven A. Shallcross, Chief Executive Officer
of Synthetic Biologics, commented, &ldquo;We are excited to announce this transformative acquisition, as VCN&rsquo;s platform represents
a potentially breakthrough approach to cancer treatment with oncolytic viruses by allowing for systemic delivery, high selectivity and
enhanced tumor access. In addition to triggering tumor cell death, these therapies have been shown to elicit a strong anti-tumor immune
response. The results of the Phase 1 clinical trial in PDAC, a highly aggressive and lethal malignancy, are very encouraging with respect
to tumor response and survival. Significantly, biopsies in these patients confirmed up regulation of tumor immune markers and induction
of a robust antitumor immune response, including increased tumor infiltration by cytotoxic T-cells. These results suggest VCN-01 holds
significant potential to increase the addressable market for checkpoint inhibitors and CAR-T therapies, as these therapies have historically
been less effective immunologically against &ldquo;cold&rdquo; tumors like PDAC.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<FONT STYLE="color: windowtext">Based on
encouraging results of prior preclinical and clinical trials of VCN-01, we plan to initiate a controlled Phase 2 clinical trial of VCN-01
at multiple centers across the US and EU. There is a significant unmet need for a safe and effective therapy for patients with pancreatic
cancer, a condition in which most people diagnosed do not survive more than a year following their initial diagnosis. Based on highly
encouraging early clinical results, we also plan to conduct a registrational trial in pediatric patients with advanced Rb. Importantly,
this is an underserved patient population and we believe VCN-01 holds tremendous promise to preserve the eyes of these patients, who are
typically less than two years old at diagnosis. We believe these trials can be conducted relatively quickly and efficiently. At the same
time, we are also evaluating investigator-sponsored studies combining VCN-01 with CAR-T therapies, as well as VCN-01 in other orphan indications
such as glioblastoma. We look forward to providing additional details on the timing and design of these trials in the near future.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;VCN was founded by internationally
recognized experts in oncolytic adenoviruses for cancer treatment and I will be delighted to welcome them to our team. VCN&rsquo;s
novel therapies allow for a robust and efficient manufacturing process, with an attractive cost structure. The platform is supported
by a growing intellectual property (IP) portfolio that provides it patent protection through at least 2030 with additional patents
underway that we believe would further strengthen our IP portfolio. Importantly, VCN-01 has been granted Orphan Drug Designation by
the European Medicines Agency (EMA), which may provide a number of benefits including up to ten years of market exclusivity.
Importantly, we have a strong balance sheet with over $72.1 million of cash as of September 30, 2021, which we believe will provide
us significant runway to both support our existing programs, as well as to able to advance VCN-01 and VCN-011 through important
milestones that we believe will drive significant shareholder value.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manel Cascall&oacute;, PhD, Chief Executive Officer
of VCN, noted, &ldquo;Joining together with Synthetic Biologics is a significant opportunity as it allows us to partner with an experienced
team, well-versed in drug development, manufacturing, and commercialization. We anticipate the combined company will have the financial
resources to fund our clinical programs to key value inflection points and we look forward to a successful future together.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference call
today, December 14, 2021, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">at 10:00 a.m. Eastern Time.</FONT>
The dial-in information for the call is as follows, U.S. toll free: 1-888-347-5280 or International: +1 412-902-4280. Participants are
asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/43946.
An archive of the call will be available for replay at the same URL, https://www.webcaster4.com/Webcast/Page/1096/43946, for 90 days after
the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company&rsquo;s
lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics
within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth
of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic
hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase
(IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About A.G.P./Alliance Global Partners</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A.G.P./Alliance Global Partners served as excusive
financial advisor to Synthetic Biologics in connection with the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A.G.P./Alliance Global Partners is a regional
investment banking and advisory firm that has been a member of FINRA and registered with the SEC since 1980. A.G.P. specializes in wealth
management and the middle-market institutional arena. With full-service capabilities, we possess a global ability to handle domestic as
well as international customers. In addition, A.G.P. provides capital markets and corporate services. We offer advanced market expertise
and deep industry knowledge to institutional clients and issuers alike. The core members of our team have been extremely active in the
small and mid-cap investment banking space, including, but not limited to, Follow-On Offerings, PIPEs and Registered Directs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Tungsten Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tungsten Advisors served as the exclusive financial
advisor to VCN Biosciences SL. Tungsten Advisors (www.tungstenadv.com) is an investment banking firm focused on strategic advisory and
corporate finance for healthcare and technology companies. Tungsten provides transactional services including financings (private placements/PIPEs),
corporate partnering and mergers and acquisitions (M&amp;A). Tungsten also focuses on company incubation and makes direct investments
alongside the creation of new companies in healthcare and technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Press Release is for informational purposes
only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, subscribe for, or issue any securities.
While the information provided herein is believed to be accurate and reliable, Tungsten Partners, LLC d/b/a Tungsten Advisors and Ashland
Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All
information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as
investment, legal, or tax advice and may not be reproduced or distributed to any person. Certain Principals of Tungsten Partners, LLC
are registered representatives of Ashland Securities, LLC Member FINRA, SIPC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tungsten Partners, LLC and Ashland Securities,
LLC are separate and unaffiliated entities. Securities and Investment Banking Services are offered through Ashland Securities, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can
be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
 &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions, and include statements regarding the proposed acquisition of VCN by Synthetic Biologics, closing the
transaction during the first quarter of 2022, VCN&rsquo;s platform representing a potentially breakthrough approach to cancer
treatment with oncolytic viruses by allowing for systemic delivery, high selectivity and enhanced tumor access, VCN-01 holding
significant potential to increase the addressable market for checkpoint inhibitors and CAR-T therapies, plans to initiate a
controlled Phase 2 clinical trial of VCN-01 at multiple centers across the US and EU, plans to conduct a registrational trial in
pediatric patients with advanced Rb, providing additional details on the timing and design of the trials in the near future and
Synthetic Biologics&rsquo; balance sheet providing significant runway to both support Synthetic Biologics&rsquo; existing programs,
as well as to able to advance VCN-01 and VCN-011 through important milestones that will drive significant shareholder value. These
forward-looking statements are based on management&rsquo;s expectations and assumptions as of the date of this press release and are
subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ
materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from current expectations include, among others, the risk associated
with Synthetic Biologics and VCN&rsquo;s ability to satisfy the conditions to consummate the proposed acquisition, including
obtaining necessary governmental approvals, the timing of the closing of the proposed acquisition, the occurrence of any event,
change or other circumstance or condition that could give rise to the termination of the Stock Purchase Agreement between VCN, the
shareholders of VCN and Synthetic Biologics, unanticipated difficulties or expenditures relating to the proposed acquisition or
development of VCN&rsquo;s drug candidates, the response of business partners and competitors to the announcement of the proposed
acquisition, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed
acquisition, whether the combined business of Synthetic Biologics and VCN will be successful, Synthetic Biologics&rsquo; and
VCN&rsquo;s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results,
the ability to initiate clinical trials and if initiated, the ability to complete them on time and achieve the desired results and
benefits continuing enrollment as expected, the ability to obtain regulatory approval for commercialization of product candidates or
to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics&rsquo; and VCN&rsquo;s
ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the
marketplace and the successful development, marketing or sale of Synthetic Biologics&rsquo; and VCN&rsquo;s products, developments
by competitors that render such products obsolete or non-competitive, Synthetic Biologics&rsquo; and VCN&rsquo;s ability to maintain
license agreements, the continued maintenance and growth of Synthetic Biologics&rsquo; and VCN&rsquo;s patent estate and other
factors described in Synthetic Biologics&rsquo; Annual Report on Form 10-K for the year ended December 31, 2020 and its other
filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only
as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained
in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Crescendo Communications, LLC (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Waldman / Natalya Rudman, (212) 671-1020, syn@crescendo-ir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>syn-20211214.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+LSbOdzZR+SYkxtmB3benabyguDyGr2SEJFlp2YcAN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20211214" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20211214">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20211214_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20211214_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>syn-20211214_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>syn-20211214_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20211214.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2135322d2_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135322d2_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 1T# 2(  A$! Q$!_\0
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M\FI([J2:2.&%)IIII(X8884:6:::5UCBAAB16>2661ECCC0%W=E506(%</\
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MP5U_;W_8X^%'Q%:\U&WT[P/\%_@MXFGBG>Y>#X-_ /P])J_Q'\3W+OM2"_\
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M^$-8^&]SHWAF#PIHMIJGCV31YKK3M9M[,>([B>*+P+:2QK>W4D327UQO3;'
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M(89T,'1H^]%T^2;5.G"G.,U*2234FN;X7\3;<F[:_E+_ ,&L'[*4C/\ 'O\
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M7:R:]J@?6=<C;J28M5U"\B!)Y5!C P!\C_$_X./^T1^WEX*O-3LS-\-?V;/
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M8U/95OJV.P]7#5_95>6?LZGLJL^2?)/DE:7+*UG[G#'$.8<)<29!Q5E'U?\
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2135322d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20211214.xsd" xlink:type="simple"/>
    <context id="From2021-12-14to2021-12-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-12-14to2021-12-14">0000894158</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-12-14to2021-12-14">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-12-14to2021-12-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-12-14to2021-12-14">2021-12-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-12-14to2021-12-14">SYNTHETIC BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-12-14to2021-12-14">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-12-14to2021-12-14">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-12-14to2021-12-14">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-12-14to2021-12-14">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-12-14to2021-12-14">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-12-14to2021-12-14">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-12-14to2021-12-14">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-12-14to2021-12-14">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-12-14to2021-12-14">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-12-14to2021-12-14">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-12-14to2021-12-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-12-14to2021-12-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-12-14to2021-12-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-12-14to2021-12-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-12-14to2021-12-14">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-12-14to2021-12-14">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-12-14to2021-12-14">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-12-14to2021-12-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046568422632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 14,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNTHETIC BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ L$".4Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ L$".4P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "P
M0(Y3:X-0GNX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "P0(Y3F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +! CE,(\T9D
M500  -X0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "P0(Y3GZ ;\+$"  #B#   #0
M@ &8#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +! CE.7BKL<P    !,"
M   +              "  70/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +!
MCE.JQ"(6,P$  "("   /              "  5T0  !X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " "P0(Y3)!Z;HJT   #X 0  &@              @ &]
M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "P0(Y3
M99!YDAD!  #/ P  $P              @ &B$@  6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     "0 ) #X"  #L$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2135322d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2135322d2_8k.htm">tm2135322d2_8k.htm</File>
    <File>syn-20211214.xsd</File>
    <File>syn-20211214_lab.xml</File>
    <File>syn-20211214_pre.xml</File>
    <File>tm2135322d2_ex2-1.htm</File>
    <File>tm2135322d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2135322d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2135322d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20211214_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20211214_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20211214.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20211214",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2135322d2_8k.htm",
      "contextRef": "From2021-12-14to2021-12-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://syntheticbiologics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2135322d2_8k.htm",
      "contextRef": "From2021-12-14to2021-12-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-21-149412-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-149412-xbrl.zip
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MYBIAF$4)IE5Z1-L5\?X09[0,-%^!TZ,/@Z%A)ELX%6$ZEV$5>$AUZ?I2>O$
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M;6S-G%USVC@4AN]W9O^#E[T& NE^)$VVD]#089HVV9"VNWO3$;8 362)D>0
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M[IOV?KQ,SYLWL'Z>P<(,0A6'IOA12@<M-'=7H3_\Q?_N>EK0CKD_M)P=5BF
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MOQ]2-8%I:V1^_>I9ZY/G; >]D?O]N>+I)"$*G=G\8!Y,A;W33]TV:]!\W'G
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MX_$)^VNMN%FI%"N52D:SJM; ;<&(-=-+2P]P"$AT0>IU'. 6R<'(UHCN7EH
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M?/RH3_E7+:U4GM3U9?)4RA"&46VPJ(TX8^L:1N194E-8=!GOC2!="9,F=83
M6('PK^7]0 F?ID252D=1L01L52E>FQ8!JF8(I21>[H><N[PT !0_:!N1NH8^
M'P?I H)^%-*6V3)AI*@)_3,T<KVT<UQ43\#"\Y3S)AT-DG6.0'6(S'OX+S[V
M7C9T0IS#'.90A/C(0YT_DV^J;9:WJIC#L %-OPFC-\J'Y?/5!BR)V._0=ON
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MN8"#U8_ %!+HG<F)@Y$;8=4$DA17A6W.E\@QLF5MIA6@,Q'YLF)N5G/*TQU
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M*K!.5%:*I]T\C%"F_<&9:G55VCQ%Q]-[D4+;'%1)Z\4@.6QP/$(GA3SB "N
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M+ _<FD)*R\-;5(I["DYGW-4OI[9+L0*E]]'?-EYY1#6;\KY9O(SSN"MO8YK
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M [Y-X1[4Z*U,A FT9A?>L?FE%484X,X>7FH70_-STO>&;<FAD'#B!1(R7*E
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M?V393*B8B3:0]/KTPFFCI;TA&Q@QK$&1=*>#G^I 1DCE/MWAC)L=+DU0M%1
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M5N:%3S5:'B4ZM%7S>6&U*&'RW=+C-+JF9@\S?:(8 >N.*F,05MJ^P@K!K;*
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MO^=)UV=L2/(='9A.-_#&]1\-$*<DI (;)32<FX R2R@=^T;DOR_W/A3XZ88
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MDKPN[<?Q-LG5 ZCBN%&ZT++@M>4%35#O(:# :1/&<D$R=P.XA1$KUJ;K]^[
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MP2X2/XT4VC2-E"0Z%5G%/5+<S[T\)-\:K)V)BC&;Q*"WD7*0*!I*98!GNF"
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M?MBD#<+B;A\Y>W1W>\0/:!E=L4U0*1CI(JW8*"AJ,-(JW.1,I'^\!>CP+LU
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M&>-D!SC6./[*W'=[$5H0C8]AHIN8K7ZV#TO4 TN337+X!$Z_?'[.)6>,8L9
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M,TC-C[ZQU3 M,$@I+AK&LV(]<LC2,CP(*ZEYT\; 'S08VL8X,I2'Q&8UY\[
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M]5PD<[Q@;J(7E9;7=8TXIE&[CAP@\[<$&.5?0UX&>[FQS4F+PQ!/#/CG'"M
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M:5+3Y/>[A.%T7Y-PO%)B\:BHGKY [./J&FK88_26A'HW^<:EUN9;H0"]"*S
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MN$4%)D6"%47)Z(+1@ C $W^=R#H-DC(OXG#&5038JQM2VS? #S_"-JH&FI1
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M5P\N-<^ICC+XF#.$S%6&R9\<+H>?CAMA^R8; !;TXS9B>''O#%Y&XT4^JKB
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MJ*&7T66QF(P<Q8GW)?(&)KG&([+K=S/ZX<Z6W=KCX^$)<R-_I?=[[U.L^;U
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M# 3O[&MOS>NLL5RJZ23V>)D:.YM75$)JAZ-I;+S2I //W*@DOG-2Z!%&_VR
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M(&,[I>WAG9EXL-=&-?N*X-\=U:EABM&2ZL$X*96^],'42?-JVWV[O_/J@N4
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MC&'VS# U1JMJ+FN-I(1JP(K]3\+-PMM<BK:RYLG"0&HG3B9Q)'_Z<5U2M,
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MZHH=I'A'##*H2 %HH^ \*L3B^!,XEYQ:8Y8%33S]_Y!W1!:10DTO&"9E5%8
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M60Q@LN:'I!OE9YQUWQA#-*DQS:&9&5R(Z:W3R *KI1,6SBVV[GE>?&:S)F*
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MKF5/6NFXSRN1<0.029P>[\VU6/>^'+%V3B/H7X"VO8@K*P=F=KWW[E<SC5G
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M*9HMK>7Y=FW0LY09.IG&*AY%9.,K-:N 2EFVN>*1O'>TA(^Z]J3=6$'C+HW
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MY5<YZ$[>J@X;-O.U=&J8PPTO48*:S(+D0>=6X)V35"$HXS&M&R5](UVH-IR
M0_8/\NW@QD$<%,0W"#@ XU6G<8,F#M_HIM0%(7YY30V,LVC @9MHF$\J]MIX
MZ3',M9/R';$#$3%@;%)70L2D:2%?GSBXE"L.D>IA<!A?7"),=C6HI;1FJ!]0
MF =.%S84!J5+#J]!J)OP8F"CBZ/DBZ!@V:CQTZ8D^) MI7OX'5/%?$*@*H:
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M:4R8%Z]ISY!1]W34Y=QF G7.9>?BDI/U%LHE0O%03(GM3=-?]N.<7PC0IY5
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M$XUF**J>UQ!M[Z,?A%X;KNXT:EY;Y![FN(0-9A^G Y_W/;BL5A'-N4OKSN<
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M=X]$+5<8[MUS/9N_'FY&=$G<[7@@1<T0D8">9M05JV?Z2G"U/UX96,D>K:S
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M?XOK?P!02P$"% ,4    " "P0(Y3?;^CYS<#   (#   $
M@ $     <WEN+3(P,C$Q,C$T+GAS9%!+ 0(4 Q0    ( +! CE/9QZ?J_0H
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M,S(R9#)?97@R+3$N:'1M4$L! A0#%     @ L$".4YE=?3D%'@  E&L  !8
M             ( !9J\! '1M,C$S-3,R,F0R7V5X.3DM,2YH=&U02P4&
/  8 !@") 0  G\T!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
